Miruvor
Sign up
The short answer

What studies of COVID vaccination found

160papers on COVID vaccination
30,935people in 29 studies testing COVID vaccination alone, and 4,516,243 patients in 13 health-record studies, counted apart
0randomised trials, the strongest kind of study

At a glance, by condition

Long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised and studies with no comparison group (very low certainty): 9 of 14 findings are D.

10 outcomes rated · see each below

Both together: C Might help, very uncertain

Based on the strongest evidence, compared with another group, not randomised and studies with no comparison group (very low certainty): 5 of 8 findings are C.

6 outcomes rated · see each below

Preventing long COVID: C Might help, very uncertain

Based on the strongest evidence, compared with another group, not randomised (very low certainty): 10 of 11 findings are C.

11 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: For long COVID, studies found little or no difference with COVID vaccination. For long COVID and ME/CFS studied together, COVID vaccination might help some people, but research can’t show it yet. For preventing long COVID, COVID vaccination might help some people, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 160 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. COVID vaccination · Both together is hereCOVID vaccination · Preventing long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. COVID vaccination · Long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Low mood or anxiety2 studies · 119 people received COVID vaccination Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised2 studies · 149 people with results

Studies disagree about low mood or anxiety.

Studies disagree about whether COVID vaccination helps low mood or anxiety. Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 2 studies
  1. Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses. (2023)

    People in the study
    83 in the study
    Dose
    one or two doses
    Outcome
    WHO-5 Well-Being Index scores and scores ≤50 World Health Organization (WHO)-5 Well-Being Index
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; vaccination not controlled It was not possible to sample all participants pre-vaccination as we did not control vaccine administration.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: available-case analysis; no imputation We included all participants for whom the variables of interest were available in the final analysis, without imputing missing data.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Are vaccines safe in patients with Long COVID? A prospective observational study (2021) preprint

    People in the study
    66 in the study
    Dose
    at least one dose
    Outcome
    WEMWBS Warwick and Edinburgh Mental Wellbeing scores (WEMWBS)
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched 2:1 (in terms of 8-month symptoms) using baseline symptoms, age, and gender in linear regression
    Selection of participants
    Moderate. comparison group: matched 2:1 (in terms of 8-month symptoms) matched 2:1 (in terms of 8-month symptoms)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Cognition (brain fog)1 study · 14 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (14 in all); not all results were tested against chance.

Studies with no comparison group16 in the study · 14 with outcome data · first dose of the primary series; nine of 13 recommended a second dose reported receiving it · first dose of the primary series, single first dose; second dose in the primary series if recommended

Cognition (brain fog) improved.

The evidence is very uncertain about the effect of COVID vaccination on cognition (brain fog) in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (14 in all)
  • Not all results were tested against chance
See the 1 study
  1. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. (2024)

    People in the study
    16 in the study · 14 with outcome data
    Dose
    first dose of the primary series, single first dose; second dose in the primary series if recommended
    Outcome
    difficulty concentrating or focusing at 12 weeks compared with before vaccination
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Anxiety2 studies · 88 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); the change wasn't shown to be more than chance.

Compared with another group, not randomised193 in the study · 174 started · 148 with outcome data · 3 to 6 months between visits; vaccination to follow-up 144 ± 86 days · one additional dose between baseline and follow-up

No clear difference in anxiety.

The evidence is very uncertain about the effect of COVID vaccination on anxiety in long COVID. Little or no difference · very low certainty D

  • Risk of bias couldn't be judged for most results (ROBINS-I: no information)
  • The change wasn't shown to be more than chance

Studies with no comparison group16 in the study · 14 with outcome data · first dose of the primary series; nine of 13 recommended a second dose reported receiving it · first dose of the primary series, single first dose; second dose in the primary series if recommended

No clear change in anxiety.

The evidence is very uncertain about the effect of COVID vaccination on anxiety in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (14 in all)
See the 2 studies
  1. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    Suspected GAD Generalized Anxiety Disorder Scale-2
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. (2024)

    People in the study
    16 in the study · 14 with outcome data
    Dose
    first dose of the primary series, single first dose; second dose in the primary series if recommended
    Outcome
    anxiety
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue2 studies · 88 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised193 in the study · 174 started · 148 with outcome data · 3 to 6 months between visits; vaccination to follow-up 144 ± 86 days · one additional dose between baseline and follow-up

No clear difference in fatigue.

The evidence is very uncertain about the effect of COVID vaccination on fatigue in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance

Studies with no comparison group16 in the study · 14 with outcome data · first dose of the primary series; nine of 13 recommended a second dose reported receiving it · first dose of the primary series, single first dose; second dose in the primary series if recommended

No clear change in fatigue.

The evidence is very uncertain about the effect of COVID vaccination on fatigue in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (14 in all)
See the 2 studies
  1. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    FAS score Fatigue Assessment Scale
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. (2024)

    People in the study
    16 in the study · 14 with outcome data
    Dose
    first dose of the primary series, single first dose; second dose in the primary series if recommended
    Outcome
    fatigue
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain2 studies · 75 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised193 in the study · 174 started · 148 with outcome data · 3 to 6 months between visits; vaccination to follow-up 144 ± 86 days · one additional dose between baseline and follow-up

No clear difference in pain.

The evidence is very uncertain about the effect of COVID vaccination on pain in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance

Studies with no comparison group1 in the study · three-year arc · two-dose (few people)

Pain improved.

The evidence is very uncertain about the effect of COVID vaccination on pain in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 2 studies
  1. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    Arthritis
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Corona With Lyme: A Long COVID Case Study. (2023)

    People in the study
    1 in the study
    Dose
    two-dose
    Outcome
    severity and frequency of associated myalgias, headaches, and scalp allodynia
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Depression1 study · 74 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); the change wasn't shown to be more than chance.

Compared with another group, not randomised193 in the study · 174 started · 148 with outcome data · 3 to 6 months between visits; vaccination to follow-up 144 ± 86 days · one additional dose between baseline and follow-up

No clear difference in depression.

The evidence is very uncertain about the effect of COVID vaccination on depression in long COVID. Little or no difference · very low certainty D

  • Risk of bias couldn't be judged for most results (ROBINS-I: no information)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    Suspected MDD Patient Health Questionnaire-2
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Autonomic symptoms1 study · 14 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (14 in all).

Studies with no comparison group16 in the study · 14 with outcome data · first dose of the primary series; nine of 13 recommended a second dose reported receiving it · first dose of the primary series, single first dose; second dose in the primary series if recommended

No clear change in autonomic symptoms.

The evidence is very uncertain about the effect of COVID vaccination on autonomic symptoms in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (14 in all)
See the 1 study
  1. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID. (2024)

    People in the study
    16 in the study · 14 with outcome data
    Dose
    first dose of the primary series, single first dose; second dose in the primary series if recommended
    Outcome
    heart palpitations
    Effect
    no clear difference
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms6 studies · 698 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree.

Compared with another group, not randomised5 studies · 1,266 people with results

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on overall symptoms in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree

Studies with no comparison group42 in the study · before and 14–21 days after first vaccination · single vaccination (first dose)

Overall symptoms improved.

The evidence is very uncertain about the effect of COVID vaccination on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (42 in all)
  • Not all results were tested against chance
See the 6 studies
  1. Long COVID symptom trajectories according to post-COVID-19 vaccination status: a prospective longitudinal study. (2026)

    People in the study
    59 in the study
    Dose
    full dose, initiate vaccination after the 1-month visit and complete the vaccination schedule before the 3-month visit
    Outcome
    Symptom Tool (ST) score trajectory according to post-COVID-19 vaccination status Symptom Tool (ST)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Serious. the comparison isn't adjusted for differences between the groups adjustment for multiple confounding variables (including age, sex, comorbidities, and disease severity) was not performed
    Selection of participants
    Moderate. comparison group: Non-randomised; participants who received vaccination during follow-up were the vaccinated group, and those remaining unvaccinated were controls Participants who received vaccination during follow-up were classified as the vaccinated group, while those who remained unvaccinated constituted the control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Serious. only people who finished were analysed Only participants who completed all follow-up visits were included in the final analysis.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    Condition – Improved
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses. (2023)

    People in the study
    83 in the study
    Dose
    one or two doses
    Outcome
    PCC symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; vaccination not controlled It was not possible to sample all participants pre-vaccination as we did not control vaccine administration.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: available-case analysis; no imputation We included all participants for whom the variables of interest were available in the final analysis, without imputing missing data.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France (2022) preprint

    People in the study
    910 in the study
    Dose
    between baseline and 60 days
    Outcome
    Long COVID ST score at 120 days long COVID symptom tool (ST)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score-matched all variables included in the propensity score models had standardized differences below 10%
    Selection of participants
    Moderate. comparison group: propensity score-matched The 455 vaccinated patients were propensity score-matched to 455 patients who did not receive the vaccine in the same period
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Outcome data were missing for 37 (8.1%) and 32 (7.0%) patients; missing outcome data were handled by multiple imputations with chained equations Outcome data were missing for 37 (8.1%) and 32 (7.0%) patients in the vaccination and control groups, respectively.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Are vaccines safe in patients with Long COVID? A prospective observational study (2021) preprint

    People in the study
    66 in the study
    Dose
    at least one dose
    Outcome
    Long Covid symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched 2:1 (in terms of 8-month symptoms) using baseline symptoms, age, and gender in linear regression
    Selection of participants
    Moderate. comparison group: matched 2:1 (in terms of 8-month symptoms) matched 2:1 (in terms of 8-month symptoms)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  6. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. (2022)

    People in the study
    42 in the study
    Dose
    single vaccination (first dose)
    Outcome
    Postvaccination symptoms
    Effect
    better (not tested)
    Risk of bias
    before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life3 studies · 573 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; the studies disagree; effect size 0.47 (small).

Compared with another group, not randomised3 studies · 1,124 people with results

No clear difference in quality of life.

The evidence is very uncertain about the effect of COVID vaccination on quality of life in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • The studies disagree
  • Effect size 0.47 (small)

How big was the difference?

0.47, small. The effect size compares COVID vaccination with no vaccination.

See the 3 studies
  1. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    Quality of Life visual analog scale (VAS)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France (2022) preprint

    People in the study
    910 in the study
    Dose
    between baseline and 60 days
    Outcome
    Long COVID IT score at 120 days impact tool (IT)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: propensity score-matched all variables included in the propensity score models had standardized differences below 10%
    Selection of participants
    Moderate. comparison group: propensity score-matched The 455 vaccinated patients were propensity score-matched to 455 patients who did not receive the vaccine in the same period
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Outcome data were missing for 37 (8.1%) and 32 (7.0%) patients; missing outcome data were handled by multiple imputations with chained equations Outcome data were missing for 37 (8.1%) and 32 (7.0%) patients in the vaccination and control groups, respectively.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Are vaccines safe in patients with Long COVID? A prospective observational study (2021) preprint

    People in the study
    66 in the study
    Dose
    at least one dose
    Outcome
    PCS Short Form-36 (SF-36)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched 2:1 (in terms of 8-month symptoms) using baseline symptoms, age, and gender in linear regression
    Selection of participants
    Moderate. comparison group: matched 2:1 (in terms of 8-month symptoms) matched 2:1 (in terms of 8-month symptoms)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Daily functioning2 studies · 82 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); the change wasn't shown to be more than chance.

Compared with another group, not randomised2 studies · 207 people with results

No clear difference in daily functioning.

The evidence is very uncertain about the effect of COVID vaccination on daily functioning in long COVID. Little or no difference · very low certainty D

  • Risk of bias couldn't be judged for most results (ROBINS-I: no information)
  • The change wasn't shown to be more than chance
See the 2 studies
  1. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC). (2026)

    People in the study
    193 in the study · 174 started · 148 with outcome data
    Dose
    one additional dose between baseline and follow-up
    Outcome
    6MWD 6-minute walk distance
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) sex, body mass index, smoking status, cardiovascular disease, depression, Charlson Comorbidity Index, obstructive lung disease, FAS score and number of prior SARS-CoV-2 infections and vaccinations
    Selection of participants
    Moderate. comparison group: propensity score matching (1:1 nearest neighbor, ATT, caliper 0.2 SD) We estimated propensity scores with a logistic regression model and performed 1:1 nearest neighbor matching targeting the average treatment effect among the treated.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 19 patients excluded due to SARS-CoV-2 re-infection during the observation period n = 19 were excluded due to a SARS-CoV-2 re-infection during the observation period
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Long COVID symptom trajectories according to post-COVID-19 vaccination status: a prospective longitudinal study. (2026)

    People in the study
    59 in the study
    Dose
    full dose, initiate vaccination after the 1-month visit and complete the vaccination schedule before the 3-month visit
    Outcome
    Impact Tool (IT) score trajectory according to post-COVID-19 vaccination status Impact Tool (IT)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Serious. the comparison isn't adjusted for differences between the groups adjustment for multiple confounding variables (including age, sex, comorbidities, and disease severity) was not performed
    Selection of participants
    Moderate. comparison group: Non-randomised; participants who received vaccination during follow-up were the vaccinated group, and those remaining unvaccinated were controls Participants who received vaccination during follow-up were classified as the vaccinated group, while those who remained unvaccinated constituted the control group.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Serious. only people who finished were analysed Only participants who completed all follow-up visits were included in the final analysis.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Both together

Symptoms

Breathlessness1 study · 1,596 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised6,987 in the study · 2,094 started · 1,596 with outcome data · one or two doses · one or two doses

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on breathlessness in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2. (2022)

    People in the study
    6,987 in the study · 2,094 started · 1,596 with outcome data
    Dose
    one or two doses
    Outcome
    prevalence of dyspnea
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue. time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue.
    Selection of participants
    Moderate. comparison group: self-selected vaccination status with a potential indication bias if more symptomatic individuals preferred to withhold vaccination.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8). Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8).
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Smell and taste loss1 study · 1,596 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised6,987 in the study · 2,094 started · 1,596 with outcome data · one or two doses · one or two doses

Smell and taste loss improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on smell and taste loss in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2. (2022)

    People in the study
    6,987 in the study · 2,094 started · 1,596 with outcome data
    Dose
    one or two doses
    Outcome
    change in taste
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue. time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue.
    Selection of participants
    Moderate. comparison group: self-selected vaccination status with a potential indication bias if more symptomatic individuals preferred to withhold vaccination.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8). Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8).
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Fatigue1 study · 155 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised305 in the study · 252 started · 252 with outcome data · 106 ± 77 days between baseline and follow-up blood sampling times · mean number of vaccines received was 1.8 ± 0.7

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on fatigue in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 1 study
  1. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome. (2023)

    Same trial, also reported in: Interruption of viral interference by anti-SARS-CoV-2 vaccination (2023) (fatigue)

    People in the study
    305 in the study · 252 started · 252 with outcome data
    Dose
    mean number of vaccines received was 1.8 ± 0.7
    Outcome
    fatigue
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised: vaccinated and non-vaccinated at presentation 155 had been vaccinated either before or after their SARS-CoV-2 infection (vaccinated), and 97 were non-vaccinated, for any reason before presenting
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 53 patients excluded after registry entry; 252 included in analysis After exclusion of 53 patients, 252 patients were included in the current analysis
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Low mood or anxiety1 study · 36 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (36 in all).

Studies with no comparison group36 in the study · approximately 1 month after vaccination · 1 dose, first vaccine dose

No clear change in low mood or anxiety.

The evidence is very uncertain about the effect of COVID vaccination on low mood or anxiety in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 1 study
  1. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. (2021)

    People in the study
    36 in the study
    Dose
    1 dose, first vaccine dose
    Outcome
    Mental well-being (as measured by the WEMWBS) Warwick–Edinburgh Mental Wellbeing Scale
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Daily life and health overall

Overall symptoms4 studies · 1,958 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree.

Compared with another group, not randomised3 studies · 2,070 people with results

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on overall symptoms in long COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree

Studies with no comparison group36 in the study · approximately 1 month after vaccination · 1 dose, first vaccine dose

Overall symptoms improved.

The evidence is very uncertain about the effect of COVID vaccination on overall symptoms in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
  • Not all results were tested against chance
See the 4 studies
  1. Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2. (2022)

    People in the study
    6,987 in the study · 2,094 started · 1,596 with outcome data
    Dose
    one or two doses
    Outcome
    prevalence of the six cardinal post-SARS-CoV-2 symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue. time for infection, age, sex, smoking, and the following comorbidities present prior to the infection: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, migraine, tension headache, sleeping disorder, anxiety, depression, hypothyroidism, anemia, and chronic fatigue.
    Selection of participants
    Moderate. comparison group: self-selected vaccination status with a potential indication bias if more symptomatic individuals preferred to withhold vaccination.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8). Participants answering (“Prefer not to answer”) were not included in this analysis (n = 8).
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome. (2023)

    Same trial, also reported in: Interruption of viral interference by anti-SARS-CoV-2 vaccination (2023) (combination of several (≥ 3) multiorgan symptoms)

    People in the study
    305 in the study · 252 started · 252 with outcome data
    Dose
    mean number of vaccines received was 1.8 ± 0.7
    Outcome
    combination of several (≥3) multiorgan symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised: vaccinated and non-vaccinated at presentation 155 had been vaccinated either before or after their SARS-CoV-2 infection (vaccinated), and 97 were non-vaccinated, for any reason before presenting
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 53 patients excluded after registry entry; 252 included in analysis After exclusion of 53 patients, 252 patients were included in the current analysis
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. 15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study. (2023)

    People in the study
    958 in the study · 222 started · 222 with outcome data
    Dose
    "59.6% (102/171) and 40.4% (69/171) of vaccinated patients received single and double vaccination, respectively.", "Vaccinations were administered at a median of 60 days (IQR 31-84) prior to 15 months visit."
    Outcome
    PCS at T4
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: Unadjusted models only The unadjusted odds ratio (OR) with 95% confidence interval (CI) for the probability to develop PCS at T3 (10 months) and T4 (15 months) were reported for defined variables as follows
    Selection of participants
    Moderate. comparison group: Non-randomised: groups defined by patients' own vaccination status following the national vaccination programme Depending on guidelines of national authorities and the local availability of vaccines either a vector-based, or a messenger ribonucleic acid (mRNA)-based, or a heterologous regimen was administered
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. (2021)

    People in the study
    36 in the study
    Dose
    1 dose, first vaccine dose
    Outcome
    Changes in symptoms 1 month after SARS-CoV-2 vaccination
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Quality of life2 studies · 360 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised453 in the study · 6-month follow-up · at least one dose

No clear difference in quality of life.

The evidence is very uncertain about the effect of COVID vaccination on quality of life in long COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance

Studies with no comparison group36 in the study · approximately 1 month after vaccination · 1 dose, first vaccine dose

No clear change in quality of life.

The evidence is very uncertain about the effect of COVID vaccination on quality of life in long COVID. Little or no difference · very low certainty D

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (36 in all)
See the 2 studies
  1. Association of Vaccination with the Persistence of Post-COVID Symptoms. (2022)

    People in the study
    453 in the study
    Dose
    at least one dose
    Outcome
    quality of life Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.0 Scale
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, gender, race, ethnicity, marital status, income, smoking history, comorbidities, and severity of acute COVID-19 age, gender, race, ethnicity, marital status, income, smoking history, comorbidities, and severity of acute COVID-19
    Selection of participants
    Moderate. comparison group: vaccinated defined as at least one dose at least 2 weeks before the 6-month follow-up; compared with unvaccinated individuals who had received at least one dose of the vaccine at least 2 weeks prior to the 6-month follow-up interview were coded as vaccinated
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 11 excluded due to missing data regarding vaccination status 11 were excluded due to missing data regarding vaccination status leaving a cohort of 453 study participants
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series. (2021)

    People in the study
    36 in the study
    Dose
    1 dose, first vaccine dose
    Outcome
    quality-of-life metrics Short Form-36 Health Survey
    Effect
    no clear difference
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Preventing long COVID

Symptoms

Sleep3 studies · 13,332 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree.

Compared with another group, not randomised3 studies · 23,142 people with results

Sleep improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on sleep later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 3 studies
  1. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. (2022)

    People in the study
    10,024 in the study · 9,479 with outcome data
    Dose
    at least one COVID-19 vaccine dose, at least 14 days before SARS-CoV-2 infection
    Outcome
    sleep disorders
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched age, sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance misuse
    Selection of participants
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Evidence for positive long- and short-term effects of vaccinations against COVID-19 in wearable sensor metrics -- Insights from the German Corona Data Donation Project (2022) preprint

    People in the study
    8,134 with outcome data
    Dose
    at least two doses
    Outcome
    sleep duration
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Serious. the comparison isn't adjusted for differences between the groups Due to the limited sample size, we refrained from performing any further discrimin- ation along these potentially confounding factors
    Selection of participants
    Moderate. comparison group: unvaccinated mostly because vaccines were not yet available at the time of infection individuals that were designated as unvaccinated were primarily assigned to this cohort because, at the time of infection, vaccine availability was limited
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: users with less than 3 weeks of baseline data dropped Users with less than 3 weeks of sufficient data preceding their test were dropped since no reli- able baseline could be computed
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Insomnia (reported)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Breathlessness8 studies · 11,717 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; effect size 0.98 (large).

Compared with another group, not randomised8 studies · 17,301 people with results

Breathlessness improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on breathlessness later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
  • Effect size 0.98 (large)

How big was the difference?

0.98, large. The effect size compares COVID vaccination with no vaccination.

See the 8 studies
  1. Impact of COVID-19 Vaccination on Post-COVID Syndrome Across Clinical Definitions and Phenotypes: A Prospective Multicenter Cohort Study. (2026)

    People in the study
    787 in the study · 756 with outcome data
    Dose
    1 dose, given at least 6 weeks before baseline
    Outcome
    respiratory cluster
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, body mass index (BMI), hospitalization status, and comorbidities controlling for age, sex, body mass index (BMI), hospitalization status, and comorbidities
    Selection of participants
    Moderate. comparison group: Vaccinated vs unvaccinated patients within the NAPKON-SUEP cohort; all adult patients with known vaccination status before infection and at least 3 months follow-up were included we included all adult patients (≥18 years) with follow-up information available for at least 3 months and known COVID-19 vaccination status before infection.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 75 to 109 patients (13% to 18%) excluded because of missing covariates, most frequently missing BMI; patients with missing symptom data were also excluded depending on PCS definition Depending on the model, 75 to 109 patients (13% to 18%) were excluded because of missing covariates, most frequently because of missing BMI values.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. SC-31 SARS-CoV-2 vaccination influence in development of Long-COVID clinical phenotypes (2024)

    People in the study
    593 in the study · 582 with outcome data
    Dose
    at least one anti- SARS-CoV-2 vaccine dose
    Outcome
    respiratory support
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: retrospective study of unvaccinated and vaccinated COVID-19 patients A retrospective study of unvaccinated and vaccinated COVID-19 patients was performed at a post-COVID-19 clinic.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Information on vaccination status was available for 582 patients Information on vaccination status was available for 582 patients
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Clinical Features and Vaccination Effects among Children with Post-Acute Sequelae of COVID-19 in Taiwan. (2024)

    People in the study
    500 in the study
    Dose
    —
    Outcome
    rhinorrhea/ nasal congestion
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age and sex Logistic regression models with age and sex adjustment were applied
    Selection of participants
    Moderate. comparison group: divided into two groups based on vaccination status The study participants were divided into two groups based on vaccination status (vaccinated and unvaccinated)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Protective Effects of BNT162b2 Vaccination on Aerobic Capacity Following Mild to Moderate SARS-CoV-2 Infection: A Cross-Sectional Study Israel. (2022)

    People in the study
    50 in the study
    Dose
    at least two doses, with the exception of two patients
    Outcome
    VE at peak (% of predicted) cardiopulmonary exercise test (CPET)
    Effect
    better
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. adjusted for: predicted values based on age, sex and height For each individual, we compared the observed values to predicted values based on age, sex and height
    Selection of participants
    Moderate. comparison group: advertised through hospital clinics and among staff and students based at the hospital The study was advertised through hospital clinics and among staff and students based at the hospital.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study. (2025)

    People in the study
    25,911 in the study · 9,668 started · 7,936 with outcome data
    Dose
    1 or 2 doses, before the infection
    Outcome
    neurological and respiratory symptoms according to vaccination dose
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, BMI, pre-existing medical conditions, household income, educational level, and severity of acute COVID-19 age (continuous variable), sex, BMI (continuous variable), pre-existing medical conditions (dummy variables for each condition), household income, educational level, and severity of acute COVID-19
    Selection of participants
    Moderate. comparison group: Vaccination status was extracted from the municipal Vaccination Record System Information on vaccination status (i.e. vaccination date and manufacturer) was extracted from the Vaccination Record System
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: multiple imputations using chained equations to account for missing data from the questionnaire we conducted multiple imputations using chained equations to account for missing data from the questionnaire
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  6. Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study. (2024)

    People in the study
    1,367 in the study · 1,012 with outcome data
    Dose
    —
    Outcome
    respiratory conditions
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: male sex; age ≥65 years; Italian nationality; asymptomatic at admission; vaccination against COVID-19; ICU admission; Omicron variant; Delta variant; Alpha variant; time of follow-up a multivariable logistic binary regression analysis that included all the factors reported in the Table and time of follow-up, as covariate.
    Selection of participants
    Moderate. comparison group: vaccination status yes vs no in the same cohort vaccination against COVID-19 (categorized as yes vs. no)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 355 patients excluded because they died during follow-up or did not answer phone calls; 1012 analysed we excluded 355 patients since they died during the follow-up or since they did not answer the phone calls, finally leaving 1012 people.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  7. Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers. (2025)

    People in the study
    2,584 in the study · 936 with outcome data
    Dose
    2 doses, ≥14 days prior to initial infection
    Outcome
    PCC cardiovascular/respiratory symptoms
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: gender, age, presence of chronic conditions, number of symptoms during acute infection, interval between infection and survey completion, and variant type gender, age, presence of chronic conditions, number of symptoms during acute infection, interval between infection and survey completion, and variant type
    Selection of participants
    Moderate. comparison group: Nested case-control; participants grouped by vaccination status relative to initial infection date. Vaccination status was defined in relation to initial infection date
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants excluded for early survey response, incomplete survey response, or survey nonresponse. 305 (11.8%) for early survey response (defined as survey received <60 days from date of acute infection), incomplete survey response, or survey nonresponse
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  8. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Dyspnoea (reported)
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Pain5 studies · 11,562 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree.

Compared with another group, not randomised5 studies · 16,067 people with results

Pain improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on pain later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 5 studies
  1. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. (2022)

    People in the study
    10,024 in the study · 9,479 with outcome data
    Dose
    at least one COVID-19 vaccine dose, at least 14 days before SARS-CoV-2 infection
    Outcome
    pain
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched age, sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance misuse
    Selection of participants
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar. (2023)

    People in the study
    250 in the study
    Dose
    minimum of two doses, before contracting COVID-19
    Outcome
    Chest pain
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; convenient nonprobability sampling A convenient nonprobability sampling technique was used to select cases from various population settings such as schools, colleges, and workplaces.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Clinical Features and Vaccination Effects among Children with Post-Acute Sequelae of COVID-19 in Taiwan. (2024)

    People in the study
    500 in the study
    Dose
    —
    Outcome
    abdominal pain
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age and sex Logistic regression models with age and sex adjustment were applied
    Selection of participants
    Moderate. comparison group: divided into two groups based on vaccination status The study participants were divided into two groups based on vaccination status (vaccinated and unvaccinated)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. COVID-19 Vaccination Modifies COVID-19-Related Headache Phenotype: Evidence from Case-Control Study on 309 Participants. (2025)

    People in the study
    309 in the study
    Dose
    —
    Outcome
    Headache duration
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: matched controls matched for age, sex, and prior history of headache
    Selection of participants
    Moderate. comparison group: matched controls Each case was matched with two controls that were paired by age, sex, and prior history of headache.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: complete case analysis Missing data were managed with complete case analysis.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Chest pain (reported)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Fatigue3 studies · 11,167 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree.

Compared with another group, not randomised3 studies · 15,258 people with results

Fatigue improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on fatigue later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 3 studies
  1. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. (2022)

    People in the study
    10,024 in the study · 9,479 with outcome data
    Dose
    at least one COVID-19 vaccine dose, at least 14 days before SARS-CoV-2 infection
    Outcome
    fatigue
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched age, sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance misuse
    Selection of participants
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar. (2023)

    People in the study
    250 in the study
    Dose
    minimum of two doses, before contracting COVID-19
    Outcome
    Fatigue
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; convenient nonprobability sampling A convenient nonprobability sampling technique was used to select cases from various population settings such as schools, colleges, and workplaces.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Fatigue (reported)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Anxiety2 studies · 11,060 people received COVID vaccination Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised2 studies · 15,008 people with results

Studies disagree about anxiety.

Studies disagree about whether COVID vaccination helps anxiety. Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 2 studies
  1. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. (2022)

    People in the study
    10,024 in the study · 9,479 with outcome data
    Dose
    at least one COVID-19 vaccine dose, at least 14 days before SARS-CoV-2 infection
    Outcome
    anxiety disorder
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched age, sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance misuse
    Selection of participants
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Anxiety (reported)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Autonomic symptoms3 studies · 2,401 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; the studies disagree.

Compared with another group, not randomised3 studies · 8,434 people with results

Autonomic symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on autonomic symptoms later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
  • The studies disagree
See the 3 studies
  1. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar. (2023)

    People in the study
    250 in the study
    Dose
    minimum of two doses, before contracting COVID-19
    Outcome
    Palpitation
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; convenient nonprobability sampling A convenient nonprobability sampling technique was used to select cases from various population settings such as schools, colleges, and workplaces.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Protective Effects of BNT162b2 Vaccination on Aerobic Capacity Following Mild to Moderate SARS-CoV-2 Infection: A Cross-Sectional Study Israel. (2022)

    People in the study
    50 in the study
    Dose
    at least two doses, with the exception of two patients
    Outcome
    maximum HR cardiopulmonary exercise test (CPET)
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. adjusted for: predicted values based on age, sex and height For each individual, we compared the observed values to predicted values based on age, sex and height
    Selection of participants
    Moderate. comparison group: advertised through hospital clinics and among staff and students based at the hospital The study was advertised through hospital clinics and among staff and students based at the hospital.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Evidence for positive long- and short-term effects of vaccinations against COVID-19 in wearable sensor metrics -- Insights from the German Corona Data Donation Project (2022) preprint

    People in the study
    8,134 with outcome data
    Dose
    at least two doses
    Outcome
    more than 5 bpm/day RHR change
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Serious. the comparison isn't adjusted for differences between the groups Due to the limited sample size, we refrained from performing any further discrimin- ation along these potentially confounding factors
    Selection of participants
    Moderate. comparison group: unvaccinated mostly because vaccines were not yet available at the time of infection individuals that were designated as unvaccinated were primarily assigned to this cohort because, at the time of infection, vaccine availability was limited
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: users with less than 3 weeks of baseline data dropped Users with less than 3 weeks of sufficient data preceding their test were dropped since no reli- able baseline could be computed
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Cognition (brain fog)3 studies · 1,927 people received COVID vaccination Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised3 studies · 6,535 people with results

Studies disagree about cognition (brain fog).

Studies disagree about whether COVID vaccination helps cognition (brain fog). Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 3 studies
  1. Impact of COVID-19 Vaccination on Post-COVID Syndrome Across Clinical Definitions and Phenotypes: A Prospective Multicenter Cohort Study. (2026)

    People in the study
    787 in the study · 756 with outcome data
    Dose
    1 dose, given at least 6 weeks before baseline
    Outcome
    cognitive cluster
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, body mass index (BMI), hospitalization status, and comorbidities controlling for age, sex, body mass index (BMI), hospitalization status, and comorbidities
    Selection of participants
    Moderate. comparison group: Vaccinated vs unvaccinated patients within the NAPKON-SUEP cohort; all adult patients with known vaccination status before infection and at least 3 months follow-up were included we included all adult patients (≥18 years) with follow-up information available for at least 3 months and known COVID-19 vaccination status before infection.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 75 to 109 patients (13% to 18%) excluded because of missing covariates, most frequently missing BMI; patients with missing symptom data were also excluded depending on PCS definition Depending on the model, 75 to 109 patients (13% to 18%) were excluded because of missing covariates, most frequently because of missing BMI values.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar. (2023)

    People in the study
    250 in the study
    Dose
    minimum of two doses, before contracting COVID-19
    Outcome
    Cognitive impairment
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; convenient nonprobability sampling A convenient nonprobability sampling technique was used to select cases from various population settings such as schools, colleges, and workplaces.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Memory loss (reported)
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Smell and taste loss2 studies · 1,688 people received COVID vaccination Mixed results C
Very low certainty

Why this grade: Mixed results, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the studies disagree; controlled studies found mixed results.

Compared with another group, not randomised2 studies · 5,779 people with results

Studies disagree about smell and taste loss.

Studies disagree about whether COVID vaccination helps smell and taste loss. Mixed results · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • The studies disagree
See the 2 studies
  1. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar. (2023)

    People in the study
    250 in the study
    Dose
    minimum of two doses, before contracting COVID-19
    Outcome
    Anosmia/loss of taste
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; convenient nonprobability sampling A convenient nonprobability sampling technique was used to select cases from various population settings such as schools, colleges, and workplaces.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Loss of taste (reported)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Low mood or anxiety5 studies · 173,710 people received COVID vaccination Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; the studies disagree.

Compared with another group, not randomised5 studies · 339,332 people with results

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of COVID vaccination on low mood or anxiety later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
  • The studies disagree
See the 5 studies
  1. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. (2022)

    People in the study
    10,024 in the study · 9,479 with outcome data
    Dose
    at least one COVID-19 vaccine dose, at least 14 days before SARS-CoV-2 infection
    Outcome
    mood disorder
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched age, sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance misuse
    Selection of participants
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection. (2024)

    People in the study
    323,062 in the study
    Dose
    at least 14 days prior to the documented SARS-CoV-2 positive test
    Outcome
    mental health disorders
    Effect
    worse
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Vaccinated and unvaccinated COVID-19 cases were matched on location, test date, severity of acute infection, age, and sex. adjusted for matched variables and prior SARS-CoV-2 infection, race and ethnicity, Charlson comorbidity score, Medicaid status, influenza vaccination, and healthcare utilization in the year prior.
    Selection of participants
    Moderate. comparison group: Vaccinated and unvaccinated COVID-19 cases were matched on location, test date, severity of acute infection, age, and sex. Vaccinated and unvaccinated COVID-19 cases were matched on location, test date, severity of acute infection, age, and sex.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients were excluded if missing information on age or sex; no per-arm missing outcome data reported. Patients were also excluded if they were missing information on age or sex since these were important adjustment variables.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  3. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar. (2023)

    People in the study
    250 in the study
    Dose
    minimum of two doses, before contracting COVID-19
    Outcome
    Mood changes
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: non-randomised; convenient nonprobability sampling A convenient nonprobability sampling technique was used to select cases from various population settings such as schools, colleges, and workplaces.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  4. Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study. (2024)

    People in the study
    1,367 in the study · 1,012 with outcome data
    Dose
    —
    Outcome
    Psychiatric
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: male sex; age ≥65 years; Italian nationality; asymptomatic at admission; vaccination against COVID-19; ICU admission; Omicron variant; Delta variant; Alpha variant; time of follow-up a multivariable logistic binary regression analysis that included all the factors reported in the Table and time of follow-up, as covariate.
    Selection of participants
    Moderate. comparison group: vaccination status yes vs no in the same cohort vaccination against COVID-19 (categorized as yes vs. no)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 355 patients excluded because they died during follow-up or did not answer phone calls; 1012 analysed we excluded 355 patients since they died during the follow-up or since they did not answer the phone calls, finally leaving 1012 people.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  5. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    Low mood (reported)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Daily life and health overall

Overall symptoms23 studies · 4,541,230 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance; the studies disagree.

Compared with another group, not randomised23 studies · 20,957,440 people with results

Overall symptoms improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on overall symptoms later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
  • Not all results were tested against chance
  • The studies disagree
See the 23 studies
  1. The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19. (2026)

    People in the study
    293 in the study · 288 with outcome data
    Dose
    at least one dose
    Outcome
    post-COVID conditions (PCC)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  2. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection. (2024)

    People in the study
    323,062 in the study
    Dose
    at least 14 days prior to the documented SARS-CoV-2 positive test
    Outcome
    PCC outcomes (9 of the 13 PCC outcomes studied)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Vaccinated and unvaccinated COVID-19 cases were matched on location, test date, severity of acute infection, age, and sex. adjusted for matched variables and prior SARS-CoV-2 infection, race and ethnicity, Charlson comorbidity score, Medicaid status, influenza vaccination, and healthcare utilization in the year prior.
    Selection of participants
    Moderate. comparison group: Vaccinated and unvaccinated COVID-19 cases were matched on location, test date, severity of acute infection, age, and sex. Vaccinated and unvaccinated COVID-19 cases were matched on location, test date, severity of acute infection, age, and sex.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients were excluded if missing information on age or sex; no per-arm missing outcome data reported. Patients were also excluded if they were missing information on age or sex since these were important adjustment variables.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  3. Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study. (2024)

    People in the study
    1,367 in the study · 1,012 with outcome data
    Dose
    —
    Outcome
    any long COVID symptomatology
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: male sex; age ≥65 years; Italian nationality; asymptomatic at admission; vaccination against COVID-19; ICU admission; Omicron variant; Delta variant; Alpha variant; time of follow-up a multivariable logistic binary regression analysis that included all the factors reported in the Table and time of follow-up, as covariate.
    Selection of participants
    Moderate. comparison group: vaccination status yes vs no in the same cohort vaccination against COVID-19 (categorized as yes vs. no)
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 355 patients excluded because they died during follow-up or did not answer phone calls; 1012 analysed we excluded 355 patients since they died during the follow-up or since they did not answer the phone calls, finally leaving 1012 people.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  4. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. (2022)

    People in the study
    10,024 in the study · 9,479 with outcome data
    Dose
    at least one COVID-19 vaccine dose, at least 14 days before SARS-CoV-2 infection
    Outcome
    long-COVID features
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched age, sex, race, ethnicity, obesity, hypertension, diabetes, chronic kidney disease, asthma, chronic lower respiratory diseases, nicotine dependence, substance misuse
    Selection of participants
    Moderate. comparison group: Unvaccinated for COVID-19 but had received an influenza vaccine; propensity score-matched propensity score-matched individuals unvaccinated for COVID-19 but who had received an influenza vaccine
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  5. Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study. (2024)

    People in the study
    1,319 in the study · 1,296 with outcome data
    Dose
    1 dose
    Outcome
    Long Covid at 3-6-12-18 months (Vaccine)
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, vaccination, SARS-CoV-2 variant, female sex and presence of comorbidities including age, vaccination, SARS-CoV-2 variant, female sex and presence of comorbidities
    Selection of participants
    Moderate. comparison group: non-randomised; children referred by emergency department, admission ward or family pediatricians Patients were referred to the public post-COVID outpatient unit by the hospital Emergency Department, Admission Ward, or external family pediatricians
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Missing data addressed with Inverse Probability Weighting (IPW); per-arm not-analysed counts not reported Missing data were addressed using Inverse Probability Weighting (IPW)
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  6. Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study. (2024)

    People in the study
    1,067 in the study · 914 with outcome data
    Dose
    primary vaccination series (two doses of CoronaVac, ChAdOx1 nCov-19, or BNT162b2 vaccines or the single-dose Ad26.Cov2.S vaccine) with or without one or more booster doses
    Outcome
    Individual persistent COVID-19-related symptoms across different vaccine groups
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, history of anxiety or depression, Charlson comorbidity index, and the proxy period for SARS-CoV-2 variants adjusted for age, sex, history of anxiety or depression, Charlson comorbidity index, and SARS-CoV-2 variant proxy period
    Selection of participants
    Moderate. comparison group: Groups defined by vaccination status documented or plausibly reported at enrollment; consecutive outpatients enrolled. COVID-19 vaccination status was based on source documentation or plausible reporting by the patient or their proxies at the time of enrollment.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1 patient died, 32 withdrew consent before outcome assessment, 120 missed the 3-month follow-up assessment One patient died and 32 withdrew consent before outcome assessment, and 120 patients missed the 3-month follow-up assessment.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  7. Impact of COVID-19 Vaccination on Post-COVID Syndrome Across Clinical Definitions and Phenotypes: A Prospective Multicenter Cohort Study. (2026)

    People in the study
    787 in the study · 756 with outcome data
    Dose
    1 dose, given at least 6 weeks before baseline
    Outcome
    WHO definition of PCS
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, body mass index (BMI), hospitalization status, and comorbidities controlling for age, sex, body mass index (BMI), hospitalization status, and comorbidities
    Selection of participants
    Moderate. comparison group: Vaccinated vs unvaccinated patients within the NAPKON-SUEP cohort; all adult patients with known vaccination status before infection and at least 3 months follow-up were included we included all adult patients (≥18 years) with follow-up information available for at least 3 months and known COVID-19 vaccination status before infection.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 75 to 109 patients (13% to 18%) excluded because of missing covariates, most frequently missing BMI; patients with missing symptom data were also excluded depending on PCS definition Depending on the model, 75 to 109 patients (13% to 18%) were excluded because of missing covariates, most frequently because of missing BMI values.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  8. The Effect of COVID-19 Vaccination on the Risk of Persistent Post-COVID-19 Condition: Cohort Study. (2025)

    People in the study
    331,042 in the study
    Dose
    1 dose, 14 days before the SARS-CoV-2–positive PCR test
    Outcome
    persistent PCC
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, region of birth, education level, comorbidities, previous infection, SARS-CoV-2 variant period, and days since 9 January 2021 adjusting for age, sex, region of birth, education level, comorbidities, previous infection, SARS-CoV-2 variant period, and days since 9 January 2021
    Selection of participants
    Moderate. comparison group: Exposure defined by COVID-19 vaccination status 14 days before the SARS-CoV-2–positive PCR test The exposure was COVID-19 vaccination status 14 days before the SARS-CoV-2–positive PCR test (unvaccinated, 1 dose, 2 doses, or 3 doses).
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Individuals with less than 365 days of follow-up after the positive test were excluded; per-arm missing data not reported Individuals with less than 365 days of follow-up after the positive test were excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  9. Impact of Pre-Infection COVID-19 Vaccination on the Incidence and Severity of Long COVID: A Retrospective Case-Control Study. (2025)

    People in the study
    1,175 in the study · 421 started · 421 with outcome data
    Dose
    —
    Outcome
    Risk of developing long COVID
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: sex, age, university studies, body mass index, physical activity, race, tobacco use, alcohol intake, adherence to Mediterranean diet, previous illness, flu vaccination, health care worker, high risk of COVID worker, sleep hours and sedentarism Adjusted by sex, age, university studies, body mass index, physical activity, race, tobacco use, alcohol intake, adherence to Mediterranean diet, previous illness, flu vaccination, health care worker, high risk of COVID worker, sleep hours and sedentarism.
    Selection of participants
    Moderate. comparison group: Cases self-reported long COVID diagnosis; controls had acute COVID-19 without long COVID symptoms. Controls were those participants who had experienced an acute COVID- 19 infection without presenting symptoms of long COVID. Cases were participants who reported a long COVID diagnosis.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Exclusions described; per-arm missing not reported. Participants who had not provided informed consent, had completed the survey but had not had at least one diagnosis of COVID- 19 or did not provide sufficient information to diagnose the presence of long COVID were excluded.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  10. Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged ≥ 60 years in Germany: a population-based cohort study. (2026)

    People in the study
    19,121,674 with outcome data
    Dose
    single dose, received between Quarter 3 (Q3)/2023 – Q1/2024
    Outcome
    PCC diagnosis (adjusted Risk Ratio)
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, prior PCC status, and number of chronic disease groups adjusted for age, sex, prior PCC status, and number of chronic diseases groups
    Selection of participants
    Moderate. comparison group: Non-randomised; all adults aged ≥60 years with ≥1 documented doctor’s visit in 2021 initially included all adults aged ≥ 60 years with ≥1 documented doctor’s visit in 2021 were initially included
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Patients excluded if neither a PCC outcome during follow-up nor a documented doctor’s visit in the last two quarters of 2024 patients were excluded if they had neither a PCC outcome during follow-up nor a documented doctor’s visit in the last two quarters of 2024
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  11. Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study. (2025)

    People in the study
    25,911 in the study · 9,668 started · 7,936 with outcome data
    Dose
    1 or 2 doses, before the infection
    Outcome
    post-COVID-19 condition (PCC) according to vaccination dose
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, BMI, pre-existing medical conditions, household income, educational level, and severity of acute COVID-19 age (continuous variable), sex, BMI (continuous variable), pre-existing medical conditions (dummy variables for each condition), household income, educational level, and severity of acute COVID-19
    Selection of participants
    Moderate. comparison group: Vaccination status was extracted from the municipal Vaccination Record System Information on vaccination status (i.e. vaccination date and manufacturer) was extracted from the Vaccination Record System
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: multiple imputations using chained equations to account for missing data from the questionnaire we conducted multiple imputations using chained equations to account for missing data from the questionnaire
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  12. Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras. (2024)

    People in the study
    59 in the study · 41 with outcome data
    Dose
    2 doses, at least 2 weeks prior to the initial COVID-19 infection
    Outcome
    medically attended and diagnosed PASC
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: vaccination status at time of infection; no matching reported age, sex, race, hospitalization during the initial infection, variant period (ancestral, Alpha, Delta, Omicron), severity-weighted Charlson Comorbidity Index, and smoking status.
    Selection of participants
    Moderate. comparison group: vaccination status at time of infection; no matching reported Vaccination status was the primary exposure of interest and was defined as unvaccinated or vaccinated (at least 2 weeks prior to the initial COVID-19 infection) with 2 mRNA vaccines or >2 mRNA vaccines.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: complete case analysis; smoking status not documented for 70% of patients The final model presented utilized a complete case analysis, whereby patients with missing values were not included.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  13. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population. (2023)

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    > 14 days after two doses of mRNA vaccines or a single dose of the Ad26.COV2.S vaccine
    Outcome
    PASC
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age; sex; race; ethnicity; Charlson Comorbidity Index (CCI); COVID-19 illness severity; state (Texas) area deprivation index (ADI); Models were adjusted for age (18–39, 40–64, 65+ years), sex, race, ethnicity, Charlson Comorbidity Index (CCI; 0–1, 2–4, 5+), and COVID-19 illness severity categorised as mild/ambulatory disease; Models were also adjusted for state (Texas) area deprivation index (ADI; 0–3, 4–6, 7+), a composite measure of socioeconomic disadvantage
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1953 (3.5%) were excluded due to missing or unverifiable data 1953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  14. Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers. (2025)

    People in the study
    2,584 in the study · 936 with outcome data
    Dose
    2 doses, ≥14 days prior to initial infection
    Outcome
    PCC number of symptoms
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: gender, age, presence of chronic conditions, number of symptoms during acute infection, interval between infection and survey completion, and variant type gender, age, presence of chronic conditions, number of symptoms during acute infection, interval between infection and survey completion, and variant type
    Selection of participants
    Moderate. comparison group: Nested case-control; participants grouped by vaccination status relative to initial infection date. Vaccination status was defined in relation to initial infection date
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants excluded for early survey response, incomplete survey response, or survey nonresponse. 305 (11.8%) for early survey response (defined as survey received <60 days from date of acute infection), incomplete survey response, or survey nonresponse
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  15. The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020-2022. (2024)

    People in the study
    —
    Dose
    initial vaccination series prior to COVID-19 onset
    Outcome
    30-day long COVID
    Effect
    better (not tested)
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: stated in the result we considered multiple unvaccinated comparison groups as counterfactuals for the vaccinated group
    Selection of participants
    Moderate. comparison group: multiple unvaccinated comparison groups as counterfactuals for the vaccinated group we considered multiple unvaccinated comparison groups as counterfactuals for the vaccinated group
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  16. Effect of a Third COVID-19 Vaccine Dose on the Incidence of Long COVID Among Adults Who Completed a Primary Vaccine Series: a Target Trial Emulation in a Community-Based Cohort. (2025)

    People in the study
    4,044 in the study
    Dose
    —
    Outcome
    Cumulative incidence curves for long COVID
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: time-fixed and time-varying confounders (IPTW) and censoring factors (IPCW): age, gender, race/ethnicity, education, household income, comorbidities, prior SARS-CoV-2 infection history, obesity status, smoking status, health insurance status, access to a primary care provider, region of residence, food insecurity, housing instability, calendar month of censoring We employed an IPTW approach to adjust for time-fixed and time-varying confounding
    Selection of participants
    Moderate. comparison group: non-randomised: in each month, individuals who had not received a third dose by the end of the month were assigned the last day of that month as time zero In the same month, unexposed individuals—those who had not received a third dose by the end of the month—were identified, and the last day of that month was assigned as their time zero.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: participants artificially censored at deviation from assigned strategy or loss to follow-up, with inverse-probability weights participants were artificially censored upon deviating from their assigned strategy or lost-to-follow-up, with inverse-probability weights to address selection due to censoring and time-varying confounding
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  17. Do COVID-19 Vaccinations Affect the Most Common Post-COVID Symptoms? Initial Data from the STOP-COVID Register-12-Month Follow-Up. (2023)

    People in the study
    1,050 in the study · 900 started · 801 with outcome data
    Dose
    2 doses of Comirnaty (Pfizer/BioNTech), 2 doses of Spikevax (Moderna), 2 doses of Vaxzevria (AstraZeneca), or 1 dose of Johnson & Johnson, at least the basic vaccination schedule
    Outcome
    post-COVID syndrome diagnosis
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    NI. adjustment for confounding isn't reported
    Selection of participants
    Moderate. comparison group: by vaccination status information from patients on vaccination status was also collected
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 150 did not attend; 99 did not provide vaccination status of which 150 did not attend. Of the data obtained from 900 patients, 99 did not provide
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  18. Real World Evidence of Effectiveness of COVID-19 Vaccines and Anti SARS-CoV-2 Monoclonal Antibodies Against Post-Acute Sequelae of SARS-CoV-2 Infection (2022) preprint

    People in the study
    55,192 in the study · 53,239 started · 53,239 with outcome data
    Dose
    2-doses of mRNA vaccines or a single dose of the Ad26.COV2.S vaccine, > 14 days after
    Outcome
    PASC
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, race, ethnicity, area deprivation index, Charlson Comorbidity Index, COVID-19 illness severity adjusted for age (18 to 39, 40 to 64, 65+ years), sex, race, ethnicity, area deprivation index (ADI: 0 to 3, 4 to 6, 7+),6 Charlson Comorbidity Index (CCI: 0 to 1, 2 to 4, 5+),7 and COVID-19 illness severity
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 1,953 (3.5%) were excluded due to missing or unverifiable data 1,953 (3.5%) were excluded due to missing or unverifiable data
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  19. Vaccine Effectiveness Against Long COVID in Children: A Report from the RECOVER EHR Cohort. (2023) preprint

    People in the study
    1,037,936 in the study
    Dose
    at least one dose
    Outcome
    probable long COVID
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: sex, ethnicity, health system, comorbidity burden, and pre-exposure health care utilization adjustment for sex, ethnicity, health system, comorbidity burden, and pre-exposure health care utilization.
    Selection of participants
    Moderate. comparison group: unvaccinated patients had a random in-person visit date after vaccine eligibility For vaccinated patients, cohort entry was the date of their first vaccine dose, while for unvaccinated patients, the date of an in-person visit after vaccine eligibility was selected randomly
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 27% of unvaccinated and 64% of vaccinated patients lost to one-to-one matching One-to-one matching resulted in loss of 27% of unvaccinated and 64% of vaccinated patients due to the high overall vaccination rate.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Moderate. a pre-specified primary outcome
  20. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study (2022) preprint

    People in the study
    3,090 with outcome data
    Dose
    at least two doses, ≥ 14 days before the first test-confirmed infection
    Outcome
    Long Covid of any severity
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Propensity-score matched unvaccinated controls socio-demographic characteristics (age, sex, white or non-white ethnicity, country/region of residence, area deprivation quintile group, and self-reported, pre-existing health/disability status) and time from infection to follow-up for Long Covid
    Selection of participants
    Moderate. comparison group: Propensity-score matched unvaccinated controls control participants who were unvaccinated when infected and remained so at their first follow-up visit ≥ 12 weeks later
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants excluded before analysis; 3,090 (92.7%) of 3,333 eligible double-vaccinated were matched Of 3,333 eligible participants who were double-vaccinated before their first test-confirmed SARS-CoV-2 infection, 3,090 (92.7%) were 1:1 matched
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Low. a pre-specified primary outcome in a registered study
  21. Vaccination and Patient Status of Long COVID-19 Hospitalized Patients: A Cohort Observational Study (2024)

    People in the study
    503 in the study
    Dose
    —
    Outcome
    Influence of patient status during hospitalisation on the onset of long COVID-19
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. adjusted for: Age, BMI, Gender, stay in ICU, steroids, number of complications and number of comorbidities Logistic regression was employed first to analyze odds of association of various patient status variables (Age, BMI, Gender, stay in ICU, steroids, number of complications and number of comorbidities) on long COVID-19 onset
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: no missing values; complete cases only They were no missing values, because only participants with complete data were selected to be included in the study.
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  22. Impact of COVID 19 Vaccination on Long COVID Symptoms in Ecuador a Nationwide Cross Sectional Study (2025) preprint

    People in the study
    202 with outcome data
    Dose
    at least one dose, at the time of their acute infection
    Outcome
    Long COVID symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age group, sex, comorbidity presence, ethnicity, COVID-19 treatment status, smoking status Independent variables included long COVID timing (vaccinated vs. unvaccinated), age group, sex, comorbidity presence, ethnicity, COVID-19 treatment status, and smoking status.
    Selection of participants
    NI. how the comparison group was chosen isn't reported
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Incomplete responses excluded; no imputation Incomplete responses were excluded due to missing key variables (e.g., symptom duration, vaccination status), and no imputation was conducted.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  23. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India (2022) preprint

    People in the study
    6,676 in the study · 5,529 with outcome data
    Dose
    —
    Outcome
    no long-COVID symptom
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. adjusted for: age, sex, length of stay, disease severity, and comorbidities (and wave in the logistic regression) after adjusting for covariates such as age, sex, length of stay, disease severity, and comorbidities
    Selection of participants
    Moderate. comparison group: hospitalised patients unvaccinated at admission (including those vaccinated after discharge), from the same hospitals; follow-up longer for the unvaccinated A larger proportion of the unvaccinated cases were from those who were discharged in 2020 and early 2021 and thus their follow-up period was longer.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: 6056 of 6676 responded; 133 deaths and 394 partly vaccinated excluded Of these, 6056 (90.7%) responded after clearly understanding the purpose of the survey.
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
Daily functioning3 studies · 5,384 people received COVID vaccination Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I).

Compared with another group, not randomised3 studies · 11,274 people with results

Daily functioning improved more than in the comparison group.

The evidence is very uncertain about the effect of COVID vaccination on daily functioning later, when given during acute COVID. Improvement · very low certainty C

  • Serious risk of bias (ROBINS-I)
See the 3 studies
  1. Protective Effects of BNT162b2 Vaccination on Aerobic Capacity Following Mild to Moderate SARS-CoV-2 Infection: A Cross-Sectional Study Israel. (2022)

    People in the study
    50 in the study
    Dose
    at least two doses, with the exception of two patients
    Outcome
    V’O2/kg peak % of predicted cardiopulmonary exercise test (CPET)
    Effect
    better
    Risk of bias
    ROBINS-I: No information
    Confounding
    Moderate. adjusted for: predicted values based on age, sex and height For each individual, we compared the observed values to predicted values based on age, sex and height
    Selection of participants
    Moderate. comparison group: advertised through hospital clinics and among staff and students based at the hospital The study was advertised through hospital clinics and among staff and students based at the hospital.
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Moderate. administered or clinician-rated; assessors blinded: NI
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  2. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study (2022) preprint

    People in the study
    3,090 with outcome data
    Dose
    at least two doses, ≥ 14 days before the first test-confirmed infection
    Outcome
    activity-limiting symptoms
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Propensity-score matched unvaccinated controls socio-demographic characteristics (age, sex, white or non-white ethnicity, country/region of residence, area deprivation quintile group, and self-reported, pre-existing health/disability status) and time from infection to follow-up for Long Covid
    Selection of participants
    Moderate. comparison group: Propensity-score matched unvaccinated controls control participants who were unvaccinated when infected and remained so at their first follow-up visit ≥ 12 weeks later
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: Participants excluded before analysis; 3,090 (92.7%) of 3,333 eligible double-vaccinated were matched Of 3,333 eligible participants who were double-vaccinated before their first test-confirmed SARS-CoV-2 infection, 3,090 (92.7%) were 1:1 matched
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported
  3. Evidence for positive long- and short-term effects of vaccinations against COVID-19 in wearable sensor metrics -- Insights from the German Corona Data Donation Project (2022) preprint

    People in the study
    8,134 with outcome data
    Dose
    at least two doses
    Outcome
    drastic reduction in activity
    Effect
    better
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Serious. the comparison isn't adjusted for differences between the groups Due to the limited sample size, we refrained from performing any further discrimin- ation along these potentially confounding factors
    Selection of participants
    Moderate. comparison group: unvaccinated mostly because vaccines were not yet available at the time of infection individuals that were designated as unvaccinated were primarily assigned to this cohort because, at the time of infection, vaccine availability was limited
    Classification of interventions
    Low. assigned and recorded at the start
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    Moderate. missing data: users with less than 3 weeks of baseline data dropped Users with less than 3 weeks of sufficient data preceding their test were dropped since no reli- able baseline could be computed
    Measurement of outcomes
    Low. an objective measure
    Selection of the reported result
    NI. whether this outcome was pre-specified isn't reported

Side effects

Side effects studies reported7 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Worse symptoms or a flare10 studies
Fatigue6 studies
Headache5 studies
Nausea or stomach upset4 studies
Anxiety or irritability1 study
Dizziness1 study
Trouble sleeping1 study

Systematic reviews

Reviews pool earlier studies. Each shows when it was published and how far its search went.

Systematic reviewPublished 2025Searched to January 1, 2020 and July 18, 2023

Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review. (2025)

“there is consistent evidence suggesting that pre-infection COVID-19 vaccination reduces the risk of ≥1 PCC.”
“Collectively, our findings suggest that COVID-19 vaccination received prior to SARS-CoV-2 infection reduces the subsequent risk of developing PCC regardless of the predominant variant circulating.”

Systematic reviewPublished 2023Searched to 1 January 2020 to 3 August 2022

Effect of covid-19 vaccination on long covid: systematic review. (2023)

“Current studies suggest that covid-19 vaccines might have protective and therapeutic effects on long covid.”
“Vaccination after infection and in those with long covid has been more controversial, but the studies we identified are reassuringly consistent in being protective.”

All papers

  1. Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study.2026 · randomised trial · 450 randomised
    Summary

    This prospective cohort study enrolled 450 adults aged ≥60 years in Zhejiang Province, China, with no history of SARS-CoV-2 infection at baseline. Participants were randomized to three vaccination schedules (S1–S3, n=150/group) and received CoronaVac or Covilo, forming six subgroups of 75; follow-up was 12 months. S1 received two doses one month apart, S2 three doses one month apart, and S3 three doses with 4–6 months between the second and third. The study measured neutralizing antibody titers, SARS-CoV-2-specific IgG, variant neutralization, adverse reactions within 7 days after each dose, and later COVID-19 and long COVID symptoms. Adverse reaction incidence was 0.0%–8.0%; CoronaVac-S3 local reactions were 8.0% versus 0.0% with Covilo-S3 (P = 0.0124). Systemic reactions were limited to Covilo-S2 allergy (1.3%) and CoronaVac-S3 fever (1.3%). At 1 month, GMTs were highest in S3 groups (Covilo 57.2; CoronaVac 59.4; P<0.001 versus respective S1/S2); CoronaVac-S1 GMT was 21.8 versus Covilo-S1 15.4 (P = 0.009). At 12 months, Covilo-S3 GMT was 9.9, and CoronaVac-S2 was 8.0 versus Covilo-S2 5.1 (P = 0.021). COVID-19 symptoms were reported by 60/74 (81.1%) in S1, 57/72 (79.2%) in S2, and 55/74 (74.3%) in S3 (P = 0.606). Long COVID symptoms were reported by 11 (14.9%), 23 (31.9%), and 21 (28.4%), respectively (P = 0.022). Withdrawals for harms were not reported.

  2. The association between COVID-19 vaccination with the prevalence of post-COVID conditions in Thai patients with mild COVID-19.2026 · compared with another group · 293 in the study · 288 with outcome data
    Summary

    This prospective cohort study at Maharaj Nakorn Chiang Mai Hospital enrolled 293 patients with mild COVID-19 between February 1 and December 30, 2023; 288 were included in the final analysis after five were excluded due to loss to follow-up at the 4–6-week assessment. Participants were categorized by mRNA vaccination status: 49 received no mRNA vaccine and 239 received at least one mRNA vaccine dose. Symptoms of post-COVID conditions (PCC) were assessed by structured telephone interviews at weeks 4–6 and weeks 12–14 post-diagnosis. PCC prevalence was 47.6%. PCC was reported in 33 (67.3%) of the no-mRNA group versus 104 (43.5%) of the ≥1 mRNA dose group (OR 0.37, 95% CI 0.20–0.71; p=0.003). For 1–2 mRNA doses the OR was 0.40 (0.21–0.78; p=0.007) and for ≥3 doses 0.27 (0.12–0.64; p=0.003), but the difference between the 1–2-dose and ≥3-dose groups was not statistically significant. In participants aged ≥35 years, the OR was 0.39 (0.16–0.92; p=0.031). Multivariate analysis gave an OR of 0.42 (p=0.023). Timing of the last mRNA vaccine was not significantly associated with PCC (OR 0.86, 0.40–1.86; p=0.710). No harms were reported. The authors state limitations including telephone interviews, an older non-mRNA group, and Omicron-dominant circulation.

  3. Association Between COVID-19 Vaccination and Long COVID Symptoms in Hospitalised Survivors: Distinguishing Prevention from Reverse Causality.2026 · compared with another group · 627 in the study
    Summary

    This retrospective observational cohort study asked whether COVID-19 vaccination relates to long COVID in adults hospitalised for COVID-19 at a single university hospital in London. The study cohort consisted of 627 adult participants hospitalised with acute COVID-19. Participants were divided by vaccination timing: a prevention cohort vaccinated at least 14 days before infection (167 individuals), a post-acute cohort vaccinated after acute infection (226 individuals), compared with 234 unvaccinated participants. The outcome was long COVID, defined as symptoms beyond 12 weeks post-infection. In the prevention cohort, prior vaccination showed a protective but non-statistically significant trend against long COVID (aOR 0.81; 95% CI 0.45–1.42; p = 0.45). Homologous (aOR 0.76; 95% CI 0.37–1.47; p = 0.41) and heterologous (aOR 0.88; 95% CI 0.41–1.80; p = 0.73) regimens both showed non-statistically significant protective trends compared with unvaccinated participants, with no significant difference observed between homologous and heterologous regimens. In the post-acute cohort, receiving the first vaccine dose after infection was strongly and statistically significantly associated with reporting long COVID symptoms (aOR 3.41; 95% CI 2.23–5.52; p < 0.001). The raw prevalence of long COVID was 58.7% in the post-acute cohort compared with 28.3% in the prevention cohort. Harms were not reported in the recorded data.

  4. Effects of HIV status and vaccination on long COVID conditions within an integrated health care system.2026 · compared with another group · 103,581 in the study · 72,376 with outcome data
    Summary

    This observational study asked whether COVID vaccination was associated with post-COVID conditions (PCC) and examined PCC in people with and without HIV. It included 103,581 adult patients in Kaiser Permanente Mid-Atlantic States with a positive SARS-CoV-2 PCR test between January 1, 2020 and January 31, 2022. A matched analysis compared 749 people with HIV with 2,236 people without HIV. The vaccination analysis included 72,376 patients with first positive tests during the Delta and Omicron periods: 40,620 vaccinated (two or more Pfizer/Moderna doses at least 14 days apart or one Janssen dose before infection) and 31,756 unvaccinated. Follow-up for PCC was 30–120 days after the positive test. Among vaccinated patients who developed COVID, 13% developed PCC, and 13% of unvaccinated patients developed PCC. The study did not find a higher overall risk of PCC in the incident interval for unvaccinated compared with vaccinated patients (RR=1.05; 95% CI 1.00-1.10; p=.05). The overall risk of PCC in the persistent interval was higher in unvaccinated patients (RR=1.90; 95% CI 1.69-2.15; p=<0001). Multiple individual incident conditions were elevated in unvaccinated patients, while dizziness or vertigo showed decreased risk. In the persistent interval, all individual conditions except anosmia, anxiety, malaise and fatigue, and vertigo were higher and statistically significant for unvaccinated patients. The interaction between HIV and vaccination on overall PCC was not significant (p=.97). Harms and withdrawals were not reported. The authors state limitations including observational design and no adjustments for multiple testing.

  5. Determinants and long-term outcomes of COVID-19 undervaccination: a cohort study of 6.8 million individuals in Lombardy, Italy2026 · compared with another group · 6,836,566 in the study · preprint
    Summary

    This population-based cohort study used linked administrative data from Lombardy, Italy, to examine COVID-19 undervaccination — receiving fewer doses than age-specific recommendations — modelled as a time-varying exposure. All 6,836,566 residents aged 30-105 years alive and registered on June 1, 2022 were included and followed until Dec 31, 2024; 1,668,014 (24·4%) were not up to date. During follow-up there were 265,383 deaths, 52,121 severe COVID-19 events and 23,780 long COVID events. Outcome analyses included 2,899,447 people aged 60 years or older and 3,842,799 younger than 60 (2,677,004 and 3,635,531 in the long COVID analysis). Compared with no vaccine deficit, in people younger than 60 a one-dose deficit was associated with long COVID (HR 1·13, 95% CI 1·07–1·19) and a two-dose deficit with HR 1·31 (1·21–1·43), whereas a three-dose deficit did not differ significantly (HR 1·04, 0·97–1·12). In people aged 60 years or older, all deficit categories were associated with long COVID, with adjusted HRs of 1·30 (1·24–1·35), 1·31 (1·23–1·40), 1·40 (1·24–1·57) and 1·25 (1·15–1·35). Severe COVID-19 HRs in this group ranged from 1·21 to 2·16 and mortality HRs reached 1·63. The text and Table 2 disagree for the one-dose severe COVID-19 HR in younger adults (1·16 vs 1·08).

  6. Association of mRNA SARS-CoV-2 vaccination with fatigue and functional recovery in patients with post-acute sequelae of COVID-19 (PASC).2026 · compared with another group · 193 in the study · 174 started · 148 with outcome data
    Summary

    This retrospective analysis of a prospectively established observational cohort at a post-COVID outpatient clinic at Hannover Medical School, Germany, examined whether an additional SARS-CoV-2 vaccine dose was associated with fatigue and functional recovery in adults with confirmed SARS-CoV-2 infection and post-acute sequelae of COVID-19 (PASC). Of 193 included patients, 174 were evaluated and 148 remained after propensity score matching (74 per group). Participants received an additional SARS-CoV-2 vaccine dose between visits (BNT162b2, mRNA-1273, ChAdOx1-S) or no vaccination, with visits 3 to 6 months apart. Fatigue (Fatigue Assessment Scale, FAS) and exercise capacity (6-minute walk distance, 6MWD) were measured at baseline and follow-up. The authors report no statistically significant differences between groups after adjustment for multiple comparisons. FAS decreased in the no vaccination group (−3.62 points over 365 days, p < 0.001) and in the vaccination group (−1.10 points, p = 0.305); the slope difference was 2.52 points (p = 0.091). 6MWD changed by 17.61 m (p = 0.189) and 8.33 m (p = 0.710), with a slope difference of −9.28 m (p = 0.718). Self-rated condition worsened in 15 (22%) no vaccination and 14 (19%) vaccination participants, and improved in 23 (34%) and 29 (40%). Nineteen patients were excluded due to SARS-CoV-2 re-infection. The authors state that the observational design and possible residual confounding preclude causal conclusions.

  7. Long COVID symptom trajectories according to post-COVID-19 vaccination status: a prospective longitudinal study.2026 · compared with another group · 59 in the study
    Summary

    The relationship between post-COVID-19 vaccination and symptom persistence was uncertain. This prospective longitudinal observational study included 59 adults with PCR-confirmed SARS-CoV-2 who were unvaccinated at diagnosis and had persistent symptoms, at Istanbul Faculty of Medicine Hospital. Eight patients received a full-dose SARS-CoV-2 vaccine after the 1-month visit and were to complete the schedule before the 3-month visit; 51 remained unvaccinated. Symptom Tool (ST) and Impact Tool (IT) scores were measured at 1, 3, 6, and 9 months. The study found no statistically significant interaction between vaccination status and time for ST scores (p=0.406) or IT scores (p=0.434). At 3 months, at least one symptom was reported by 6/7 (85.7%) vaccinated and 28/35 (80%) unvaccinated patients (p=1). The paper did not report harms or adverse events of vaccination. The authors state the study is limited by the small number of patients, especially n=8 vaccinated participants, by self-selected vaccination status rather than random assignment, and by inability to adjust for confounders; they call the findings exploratory and underpowered.

  8. Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods.2026 · compared with another group · 22,496 in the study
    Summary

    Why: The authors estimated vaccine effectiveness against COVID-19 and long COVID during pre-Omicron and Omicron periods, by number of doses and prior infection history. Who: 22 496 healthcare workers in Quebec, Canada responded to a survey. What was given: mRNA vaccines (BNT-162b2 or mRNA-1273), 1 to 5 doses; follow-up allowed 12-week follow-up for long COVID case ascertainment. Compared with what: vaccinated participants were compared with unvaccinated participants during the pre-Omicron period or with those twice vaccinated ≥6 months before laboratory testing during the Omicron period. Measured: symptomatic laboratory-confirmed COVID-19 and self-reported symptoms persisting ≥12 weeks. Found: during the pre-Omicron period, 1-dose vaccine effectiveness was 91% (95% CI: 79–96) against long COVID, with a risk reduction of 77% (95% CI: 38–82) among COVID-19 infected HCWs; 2-dose vaccine effectiveness was 87% (95% CI: 27–98) against long COVID, with no RCD evidence of long COVID risk reduction among infected 2-dose vaccinated HCWs (−122% [−2119–78]). During the Omicron period, booster-dose vaccine effectiveness was 57% (95% CI: 46–63) against long COVID and 41% (95% CI: 34–47) against COVID-19; it was 72% (95% CI: 62–79) against long COVID within 2 months and 29% (95% CI: −1 to 50) at 6 months post-vaccination. Hybrid VE against long COVID for prior Omicron infection was 87% (95% CI: 72–94) for 2-dose recipients and 85% (95% CI: 73–91) to 92% (95% CI: 87–95) for booster-dose recipients. Risk reduction of long COVID post-reinfection varied between 65% and 79%. No harms, side effects, or withdrawals were reported. The authors state limitations including insufficient unvaccinated participants to measure absolute VE during the Omicron period.

  9. Booster dose of COVID-19 vaccine and its effectiveness against post COVID-19 condition in individuals with pre-existing immunity: a sequential propensity score-matched cohort study.2026 · compared with another group · 1,385,497 with outcome data
    Summary

    The study asked whether a fourth COVID-19 vaccine dose was linked with fewer diagnoses of post COVID-19 condition than three doses in people who already had immunity. It was a sequential propensity score-matched cohort study in adults aged 18 years or older in Stockholm or Västra Götaland county, Sweden, who had received a third dose. In total, 801,869 people who received a fourth dose were matched with 801,869 people with three doses; the study population included 1,385,497 unique individuals. Median follow-up was 120 days in the three-dose group and 121 days in the four-dose group. The outcome was a clinical diagnosis of post COVID-19 condition from primary or specialist care. The incidence rate was 1.67 per 1000 person-years with three doses and 1.14 per 1000 person-years with four doses, an incidence rate difference of −0.52 per 1000 person-years. The hazard ratio was 0.69 (95% CI 0.62–0.78), with a reported vaccine effectiveness of 31% (95% CI 22–38). In people with risk factors for severe acute COVID-19, vaccine effectiveness was 38% (95% CI 29–47); in those without, it was 18% (95% CI 2–31), and the incidence rate difference in the no-risk group was −0.21 (95% CI −0.45 to 0.04). The paper did not report harms or side effects. The authors state that residual confounding cannot be excluded and that the diagnosis code is not yet formally validated.

  10. Factors Associated with the Deterioration of Post-COVID-19 Condition Symptoms Following a Dose of SARS-CoV-2 Vaccine2026 · compared with another group · 533 in the study · 476 with outcome data · preprint
    Summary

    This multicentre cohort study asked whether a SARS-CoV-2 vaccine dose given at least 90 days after infection was associated with worsening post-COVID-19 condition (PCC) symptoms. It recruited consecutive adults who visited 33 emergency departments across Canada between October 18, 2020, and February 28, 2022, tested positive for SARS-CoV-2, and later met WHO PCC criteria. Of 533 who received a vaccine dose ≥90 days after the index emergency department visit, 476 were analysed. Participants reported whether their persistent symptoms changed after vaccination. Overall, 28.8% (137/476, 95% CI 24.7-32.9) reported deterioration, while 71.2% (339/476, 95% CI 67.1-75.3) reported improvement or no change. Deterioration was reported by 38.9% (95% CI 30.6-47.3) of participants who received the Moderna vaccine and 25.5% (95% CI 20.8-30.2) of those who received combined AstraZeneca and Pfizer vaccines. In multivariable modelling, the adjusted odds ratio for deterioration with Moderna versus other vaccines was 1.81 (95% CI 1.15-2.84). A new persistent cough was also associated with deterioration (adjusted odds ratio 1.87, 95% CI 1.06-3.26). Age and sex were not identified as risk factors. Withdrawals attributed to harms were not reported. The authors state limitations including modest effect sizes with wide confidence intervals, no formal psychometric evaluation of the questionnaire, self-reported vaccine data, and inability to determine how long deterioration lasted.

  11. Effectiveness of seasonal mRNA COVID-19 vaccination against post COVID-19 condition between July 2023 and September 2024 among adults aged ≥ 60 years in Germany: a population-based cohort study.2026 · compared with another group · 19,121,674 with outcome data
    Summary

    This retrospective cohort study in Germany asked whether one mRNA COVID-19 vaccine dose in the 2023/2024 season was associated with fewer post COVID-19 condition (PCC) diagnoses in adults aged ≥ 60 years. The final cohort included 19,121,674 patients; 3,437,701 (18.0%) received one dose and 15,683,973 were non-vaccinated. Vaccinated patients were followed for six months after vaccination; non-vaccinated patients were followed from Q4/2023 to Q3/2024. The outcome was a first PCC diagnosis. During follow-up, PCC was diagnosed in 0.08% of vaccinated patients compared with 0.22% of non-vaccinated patients. The adjusted Risk Ratio was 0.37 (95% CI 0.36–0.39), with a vaccine effectiveness of 63% (95% CI 61–64) and a number needed to vaccinate of 7.2 (95% CI 7.1–7.5). In a sensitivity analysis restricted to patients with a preceding COVID-19 diagnosis, 2,366 non-vaccinated patients received a PCC diagnosis compared with 42 vaccinated patients; the adjusted Risk Ratio was 0.09 (95% CI 0.07–0.12), vaccine effectiveness was 91% (95% CI 88–93), and the number needed to vaccinate was 55.0 (95% CI 53.8–56.8). Stratified analyses reported a Risk Ratio of 0.42 (95% CI 0.37–0.47) among patients with prior PCC and 0.37 (95% CI 0.35–0.38) among those without. Harms and withdrawals were not reported. The authors note reliance on secondary data with possible coding errors and misclassifications.

  12. Impact of COVID-19 Vaccination on Post-COVID Syndrome Across Clinical Definitions and Phenotypes: A Prospective Multicenter Cohort Study.2026 · compared with another group · 787 in the study · 756 with outcome data
    Summary

    This prospective multicenter cohort study in Germany (NAPKON-SUEP) asked whether COVID-19 vaccination before infection was associated with less post-COVID syndrome (PCS). The cohort comprised 787 adults with COVID-19; 756 had valid information on vaccination status before infection and were included in the analysis. Of these, 517 were unvaccinated, 43 had received 1 dose, and 196 had received 2 or more doses before infection. Patients were followed at 3 months and 12 months after enrollment, and PCS was assessed by the WHO definition, symptom clusters (fatigue, respiratory, cognitive), and the PCS score. In the multivariable models, vaccination with 2 or more doses was associated with a lower risk of PCS according to the WHO definition (OR, 0.555; 95% CI, 0.339 to 0.906), the PCS score (OR, 0.536; 95% CI, 0.335 to 0.856), the respiratory cluster (OR, 0.508; 95% CI, 0.295 to 0.875), and the cognitive cluster (OR, 0.443; 95% CI, 0.213 to 0.923). No protective association was observed for the fatigue cluster (OR, 0.917; 95% CI, 0.554 to 1.519), and at 12 months the fatigue cluster result remained not statistically significant (OR, 0.971; 95% CI, 0.512 to 1.843). The paper reports no side effects or harms of vaccination.

  13. Clinical and economic benefits of seasonal COVID-19 vaccination in Germany: results from the ROUTINE-COV19 Study, September 2022 to March 2024.2026 · compared with another group · 146,132 started · 146,132 with outcome data
    Summary

    ROUTINE-COV19 was a retrospective cohort study using statutory health insurance data from Saxony and Thuringia to assess clinical and economic outcomes of seasonal COVID-19 vaccination in adults aged ≥18 years. Vaccinated individuals received COVID-19 vaccination during 1 September to 30 November 2023, regardless of vaccine product, and were matched 1:1 with unvaccinated individuals using propensity scores. Before matching, 73,067 vaccinated and 3,145,952 unvaccinated individuals met eligibility criteria; after matching, 146,132 individuals (73,066 per group) were analysed, with one individual excluded due to matching constraints. Follow-up was 4 months (1 December 2023–31 March 2024). Outcomes included SARS-CoV-2 infection, long COVID, respiratory infections, hospitalisations, mortality, healthcare costs and sick leave. Documented SARS-CoV-2 infection did not differ significantly (RR 0.86, 95% CI 0.72–1.02; p = 0.079). Vaccinated individuals had lower rates of long COVID (RR 0.43, 95% CI 0.26–0.70; p < 0.001), respiratory infections (RR 0.91, 95% CI 0.87–0.95), COVID-19-related hospitalisations (RR 0.41, 95% CI 0.31–0.54), CVD-related hospitalisations (RR 0.80, 95% CI 0.75–0.84), all-cause mortality (HR 0.756, 95% CI 0.70–0.82) and mortality during COVID-19-related hospitalisation (HR 0.29, 95% CI 0.14–0.58). COVID-19-related hospitalisation costs were EUR 21.13 vs EUR 64.43 per person-year, with a total reduction of EUR 1,035,191.39. Indirect cost reductions were EUR 248,045.00 for COVID-19 sick leave and EUR 1,034,474.00 for respiratory infection sick leave. Harms and withdrawals due to harms were not reported. The authors state residual confounding and healthy vaccinee bias may have contributed.

  14. Beneficial Effect of COVID-19 Vaccination on Decreased Pulmonary Vascular and Airway Volumes of Patients with Long-COVID Syndrome.2026 · compared with another group · 60 in the study
    Summary

    Thirty patients with long COVID (mean 221 ± 128 days after confirmed SARS-CoV-2 infection) and 30 matched healthy controls were included. This was a retrospective analysis of a prospective cohort; patients attended a long COVID cardiac outpatient clinic. At lung CT, nine patients were fully vaccinated (two primary doses plus one updated booster), ten partially vaccinated (one or two primary doses), and eleven non-vaccinated. The first COVID-19 vaccination was given a mean 163 ± 150 days after infection. CT datasets were analysed with functional respiratory imaging. Compared with partially and non-vaccinated patients, fully vaccinated patients had significantly greater small-vessel pulmonary blood volume (<5 mm2) and greater cumulative IVLOBE. IVAW was higher in fully vaccinated patients but not significantly. No significant differences were found for large pulmonary artery/vein volumes; medium-sized vessels showed only minor differences. BV5 RUL, BV5 RLL and IVLOBE TOTAL were not significantly associated with vaccination subgroup (p = 0.142, p = 0.079, p = 0.078). Non-vaccinated patients had lower BV5 TOTAL than fully vaccinated patients (β = −19.6 mL, 95% CI −36.2 to −3.0; p = 0.023); sensitivity analysis β = −34.4 mL (95% CI −63.2 to −5.5). VAS health score was significantly higher and exercise-induced dyspnea significantly lower in fully vaccinated than non-vaccinated patients. Harms were not reported. The authors state limitations including retrospective design and small sample.

  15. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.2026 · compared with another group · 2,234 in the study · 2,033 with outcome data
    Summary

    This multicenter, cross-sectional observational study asked why long COVID occurred among people previously infected with SARS-CoV-2 in five medical centers in São Paulo and Rio de Janeiro, Brazil. Of 2234 participants enrolled, 2033 questionnaires were analyzed. Immunization status was classified by vaccine doses received at least 14 days or more before acute infection: unvaccinated (270), 1 dose (62), 2 doses (315), 2 doses +1 booster (1070), and 2 doses +2 boosters (316). Long COVID was identified in 1370 individuals (67%). Compared with unvaccinated participants, the odds of long COVID were OR 0.18 (95% CI 0.07–0.46; p < 0.001) for 2 doses +2 boosters, OR 0.36 (95% CI 0.15–0.86; p = 0.02) for 1 dose, and OR 0.34 (95% CI 0.14–0.83; p = 0.02) for 2 doses. In the Omicron-period sub-analysis, 2 doses +2 boosters versus 2 doses gave OR 0.50 (95% CI 0.34–0.74; p < 0.001); 2 doses +1 booster versus 2 doses gave OR 0.97 (95% CI 0.70–1.35; p = 0.87), reported as no significant effect. No harms or withdrawals were reported. The authors state limits including self-reported survey data and possible overestimation because participation was voluntary.

  16. Optimizing the schedule of BNT162b2 COVID-19 against long COVID and associated quality of life losses.2025 · compared with another group · 4,809 in the study · 3,946 with outcome data
    Summary

    This longitudinal cohort in Northern Israel invited adults aged 18 years and older who had SARS-CoV-2 RT-PCR testing at three government hospitals, regardless of result. A total of 4809 individuals were enrolled and responded to up to five follow-up surveys; 3946 unique individuals were included in the analysis. Infected participants were grouped by vaccination status at infection: 380 unvaccinated, 348 vaccinated after infection, 123 with 1 dose before infection, 215 with 2 doses, and 311 with 3 or more doses. Median follow-up was 300 (interquartile range 328) days. The study compared long COVID symptom clusters and quality of life (EQ-5D-5L utility index) across these groups. Receiving 3 doses before infection was associated with lower odds of reporting long COVID (adjusted odds ratio 0.66, 95% CI 0.47–0.94, p=0.022); 1 or 2 doses were not significantly associated, and post-infection vaccination showed no difference (aOR 1.05, 95% CI 0.75–1.47, p=0.776). Vaccine effectiveness of 3 pre-infection doses against long COVID was 26.50% (95% CI 10.8–39.4). Quality of life increased with 2 doses (0.06 points, p=0.008) and 3 doses (0.07 points, p<0.001), but not with post-infection vaccination. Among participants reporting long COVID, pre-infection vaccination was associated with QoL increases of 0.25, 0.16, and 0.22 (p=0.001 or less). Harms were not reported.

  17. Symptom evolution in individuals with ongoing symptomatic COVID-19 and post-COVID-19 syndrome after SARS-CoV-2 vaccination versus influenza vaccination.2025 · compared with another group
    Summary

    This matched cohort study used ZOE COVID Symptom Study app data from UK adults aged ≥18 years with ongoing symptomatic COVID-19 or post-COVID syndrome. It compared symptoms in people receiving a first SARS-CoV-2 vaccination with unvaccinated matched controls (1679 individuals in each group), and people receiving influenza vaccination with unvaccinated matched controls (n=692 in each group). Symptoms were measured in the second week before and second week after vaccination. After SARS-CoV-2 vaccination, the odds of experiencing a particular symptom were reduced for thirteen symptoms; fatigue symptom burden changed with β=-−0.9 [95% CI: −1.86; −0.67], p < 0.0001, and myalgia with β=−0.3 [95% CI: −0.50; −0.12], p < 0.001. Symptom improvement was systematically more common in the vaccinated group than in the control group, and symptom remission was more rapid in SARS-CoV-2-vaccinated individuals compared with controls (p < 0.005 by log-rank testing). The paper reports no symptom worsened after vaccination and does not report withdrawal counts. For influenza vaccination, no differences were evident for any symptoms, and there was no improvement beyond natural history resolution.

  18. COVID-19 Vaccination Modifies COVID-19-Related Headache Phenotype: Evidence from Case-Control Study on 309 Participants.2025 · compared with another group · 309 in the study
    Summary

    This case–control study asked whether COVID-19 vaccination changes the duration and phenotype of COVID-19-associated headache. It included 309 participants: 103 vaccinated cases and 206 non-vaccinated controls, matched for age, sex, and prior headache history, managed in outpatient primary care. Cases had received a COVID-19 vaccine (Pfizer BioNTech BNT162b2, Moderna mRNA-1273, Johnssons & Johnssons Janssen Ad26.COV2.S, or AstraZeneca ChAdOx-1s); controls had received no COVID-19 vaccine dose. Follow-up was at least three months. Headache duration was shorter in vaccinated patients: 4 (IQR 2–8) vs. 8 (IQR 4–16.5) days, p < 0.001. At month 3, 2 (1.9%) vaccinated and 14 (6.8%) unvaccinated patients still had headache. Headache as the first symptom did not differ: 35% vs. 32.5%, p = 0.670. Treatment resistance was reported by 37 (35.9%) vaccinated and 44 (21.4%) non-vaccinated patients (p = 0.006–0.009). NSAIDs were more frequently used in vaccinated patients (p < 0.001), and the need for acute medication was comparable between groups. Vaccinated patients more often had holocranial topography, pressing quality, phonophobia, and cranial autonomic symptoms. Harms were not reported. The authors note that cases and controls were recruited at different times, the variant was not microbiologically determined, and hospitalized patients were absent.

  19. Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection.2025 · compared with another group · 2,353 in the study · 1,231 with outcome data
    Summary

    This observational cohort study asked whether COVID-19 vaccination before SARS-CoV-2 infection prevents long COVID (LC) in adolescents aged 12–17 years. Participants were recruited from over 60 US healthcare and community settings. The exposure was any COVID-19 vaccine dose within 6 months and 14 days before first reported infection; unvaccinated participants had never been vaccinated. Of 2353 eligible participants, 1231 were selected in the matched cohort: 507 unvaccinated and 724 vaccinated. LC was assessed at enrollment at least 90 days after infection using the LC research index for adolescents; severe LC was a secondary endpoint. LC risk was 20.7 % in unvaccinated participants and 13.3 % in vaccinated participants, with RR 0.64 (95 % CI 0.50, 0.83). Severe LC risks were 6.1 % and 4.7 % in unvaccinated and vaccinated participants, respectively, with RR 0.77 (95 % CI 0.48, 1.26); no statistically significant difference was reported for severe LC. Side effects, harms, and withdrawals were not reported. The authors state limitations including caregiver-reported vaccination with possible recall bias, exclusion of participants infected during pre-Delta and Delta waves because they were generally not vaccine-eligible, assessment only of vaccination before first infection without prospective follow-up from first vaccination, no assessment of specific dose effects, and likely underpowering for severe LC.

  20. Coronavirus Disease 2019 Case Series in China: Sequelae and Effectiveness of Vaccination and Antiviral Drugs.2025 · compared with another group · 869 in the study
    Summary

    Researchers retrospectively analysed 869 patients who visited the Emergency Department of Beijing Shijitan Hospital between December 7, 2022 and January 31, 2024, and who had a positive nucleic acid or antigen test. The paper compared COVID-19 vaccination status (0 doses, 1 doses, 2 doses, 3 doses; 320, 46, 162 and 341 patients respectively) and antiviral medication use (used, 514; not used, 355; drugs listed as namatevir/ritonavir, azvudine and molnupiravir) against post-COVID-19 sequelae and mortality. Follow-up for sequelae was reported as 2 to 13 months. The paper reports that individuals who received a higher number of COVID-19 vaccine doses were significantly less likely to experience sequelae (P < 0.01), and that mortality differed among patients who received a higher number of vaccine doses versus those who did not (P<0.01). It reports that the difference in incidence of sequelae between the group that took antiviral drugs and the group that did was statistically significant (P < 0.01), and that mortality rate differed between the antiviral and no-antiviral groups (P < 0.01). Harms and withdrawals were not reported. The authors state limitations involving time and sample size and state that validation by large-scale research is needed.

  21. Association between COVID-19 vaccination, SARS-CoV-2 variants, and post COVID-19 condition: A cross-sectional study.2025 · compared with another group · 1,587 in the study
    Summary

    This cross-sectional study included 1,587 participants seen at Post-COVID-19 Clinics across British Columbia, Canada between March 2020 and Oct 2022, with post COVID-19 condition (PCC) and a baseline questionnaire within 6 months of infection. Vaccination status was grouped as unvaccinated (n = 739), partially vaccinated (n = 126), fully vaccinated (n = 178), or vaccinated after infection (n = 544). Participants completed patient-reported outcome measures for fatigue, dyspnea, PTSD, anxiety, and depression. After adjustment for age, sex and comorbidities, partial or full vaccination was not associated with any abnormal PROMs. In non-hospitalized patients, those fully vaccinated were less likely to report PTSD (OR 0.57; 95% CI 0.33–0.97; p-value 0.04) than unvaccinated patients. In unadjusted analysis, non-hospitalized patients partially vaccinated (OR 2.51; 95% CI 1.21–5.90; p-value 0.02) or fully vaccinated (OR 2.10; 95% CI 1.15–4.10; p-value 0.02) were more likely to report fatigue than unvaccinated patients. Side effects and withdrawals were not reported. The authors state the study is limited by absence of PROM data before infection and lack of a control cohort.

  22. Effect of a Third COVID-19 Vaccine Dose on the Incidence of Long COVID Among Adults Who Completed a Primary Vaccine Series: a Target Trial Emulation in a Community-Based Cohort.2025 · compared with another group · 4,044 in the study
    Summary

    This target trial emulation used the U.S. CHASING COVID Cohort, a national community-based prospective cohort, to ask whether a third COVID-19 vaccine dose prevents long COVID. Across 16 sequential trials, there were 18,930 person-trials and 4,044 unique individuals. Participants had completed a two-dose primary series; 3,321 person-trials received a third dose at time zero and 15,609 did not. Follow-up was 6 and 12 months. Long COVID was defined as at least one new symptom at or beyond 3 months post-infection with concurrent activity limitation, absent in the prior year. At 6 months, weighted long COVID incidence was 0.9% (95% CI: 0.5%, 1.3%) with a third dose versus 1.0% (95% CI: 0.8%, 1.1%) without; the incidence difference was −0.1% (95% CI: −0.5%, 0.4%). At 12 months, incidence was 4.9% (95% CI: 4.1%, 5.9%) versus 4.5% (95% CI: 4.1%, 4.8%), with an incidence difference of 0.4% (95% CI: −0.5%, 1.4%). Cumulative incidence curves showed overlapping trends. Harms and withdrawals due to harms were not reported. The authors state limitations including self-reported long COVID outcomes, exclusion of prior SARS-CoV-2 infection within three months of time zero, possible unmeasured confounding, and possible misclassification in infection imputation.

  23. Pre-infection COVID-19 vaccination and long-COVID mental fatigue severity: Findings from the Johns Hopkins COVID Long Study2025 · compared with another group · 22,811 in the study · 2,634 with outcome data · preprint
    Summary

    This preprint reports a nationwide, virtual cohort study, the Johns Hopkins COVID Long Study. The analysis included 2,634 participants; among 1,320 with long-COVID, 543 were boosted, 408 fully vaccinated, and 321 unvaccinated. Vaccination status was defined before SARS-CoV-2 infection, and follow-up was every 3 or 6 months. The outcome was mental fatigue on the Wood Mental Fatigue Inventory (WMFI; range 0-36, lower scores indicating less fatigue). Boosted participants with long-COVID had WMFI scores 1.5 points lower at the 25th percentile (p = 0.02), 2.6 points lower at the median (p = 0.01), and 3.8 points lower at the 75th percentile (p = 0.002) than unvaccinated participants. In mixed-effects models, boosted participants scored 4 points lower (p < 0.0001) and fully vaccinated participants 1.9 points lower (p < 0.05). Quantile differences for fully vaccinated participants did not reach statistical significance. No significant difference was observed for never-infected participants (-2.2, p = 0.15) or recovered-COVID participants (-0.1, p = 0.92). In an Omicron sensitivity analysis, boosted participants scored 2.4 points lower (p < 0.05) in the mixed-effects model. Side effects were not described. The authors state the sample over-represents women, white participants, and those with higher educational backgrounds, limiting generalizability.

  24. The Effect of COVID-19 Vaccination on the Risk of Persistent Post-COVID-19 Condition: Cohort Study.2025 · compared with another group · 331,042 in the study
    Summary

    This retrospective population-based cohort study in Stockholm County, Sweden, asked whether COVID-19 vaccination was associated with a reduced risk of persistent post–COVID–19 condition (PCC) among people surviving a SARS-CoV-2 infection. The study included 331 042 individuals aged ≥18 years with a polymerase chain reaction (PCR)-verified infection. Vaccination status was assessed 14 days before the SARS-CoV-2–positive PCR test and grouped as unvaccinated, 1 dose, 2 doses, or 3 doses. Persistent PCC was defined as a PCC diagnosis code registered at least once 90 to 364 days and once 365 to 660 days after the PCR test. The comparison was vaccinated groups versus unvaccinated individuals. The adjusted risk ratio for developing persistent PCC was 0.81 (95% CI, .59–1.10) for 1 dose, 0.42 (95% CI, .35–.52) for 2 doses, and 0.37 (95% CI, .27–.52) for 3 doses compared with unvaccinated individuals. The incidence of persistent PCC was 0.4% (575/136 840) for unvaccinated, 0.3% (32/11 484) for 1 dose, 0.1% (212/157 287) for 2 doses, and 0.1% (33/25 431) for 3 doses. A reduced risk of persistent PCC was also observed for individuals having received 2 or 3 doses compared with unvaccinated individuals across all 8 subgroup analyses. Side effects and withdrawals were not reported. The authors state that an important limitation includes potential outcome misclassification depending on the clinical use of the PCC diagnosis code.

  25. SARS-CoV-2 vaccination influence in the development of long-COVID clinical phenotypes.2025 · compared with another group · 582 in the study
    Summary

    This single-centre retrospective study enrolled 582 COVID-19 patients at Policlinico Umberto I, Sapienza University of Rome, and compared 425 unvaccinated with 157 vaccinated before SARS-CoV-2 infection; follow-up was at least 3 months after the acute phase. Long-COVID symptoms were self-reported and grouped into clinical phenotypes, with pulmonary and cardiovascular assessments. At least one Long-COVID symptom was reported by 364/425 (86%) unvaccinated and 142/157 (90%) vaccinated patients, with no statistical significance. Cardiorespiratory symptoms were mostly observed in vaccinated patients (96/142 [67.6%] vs 209/364 [57.4%], p = 0.0430), while neuropsychiatric disorders were more frequent in unvaccinated patients (222/364 [61%] vs 69/142 [48.6%], p = 0.0124). Cardiovascular alterations were more frequent in the unvaccinated group (52/74 [70.3%] vs 62/112 [55.4%], p = 0.0464). Spirometry alterations were 168/211 (79.6%) in unvaccinated vs 47/150 (31.3%) in vaccinated, p < 0.0001; chest CT alterations were 208/299 (69.6%) vs 25/73 (34.2%), p < 0.0001; CTSS was 3 (0–8) vs 0 (0–1), p < 0.0001. Harms and withdrawals were not reported. The authors state limitations include the single-centre retrospective design, a small vaccinated sample, self-referred symptoms, and missing assessment data.

  26. COVID-19 Vaccination and Odds of Post-COVID-19 Condition Symptoms in Children Aged 5 to 17 Years.2025 · compared with another group · 622 in the study
    Summary

    This nested case-control study asked whether COVID-19 mRNA vaccination before SARS-CoV-2 infection was associated with decreased odds of post–COVID-19 condition (PCC) symptoms in children aged 5 to 17 years. It included 622 children from a US multisite pediatric cohort enrolled from July 27, 2021, to September 1, 2022, and followed through May 2023; 28 (5%) were case participants and 594 (95%) were controls. Vaccination was defined as 2 or more monovalent mRNA doses at least 14 days before infection; 474 children were vaccinated and 148 were unvaccinated, with 468 and 147 analysed. PCC was surveyed at least 60 days after infection. Adjusted odds ratios compared vaccinated with unvaccinated children: 1 or more PCC symptoms, 0.43 (95% CI, 0.19-0.98); 2 or more PCC symptoms, 0.27 (0.10-0.69); respiratory PCC symptoms, 0.28 (0.10-0.75); nonrespiratory PCC symptoms, 0.49 (0.20-1.21); and PCC impact on function, 0.25 (0.08-0.74). The nonrespiratory confidence interval included 1. Harms and withdrawals were not reported. Slightly more than 10% of participants were lost to follow-up. The authors state limits including small sample size, a largely non-Hispanic White population, and findings limited to the BNT162b2 vaccine.

  27. Impact of Pre-Infection COVID-19 Vaccination on the Incidence and Severity of Long COVID: A Retrospective Case-Control Study.2025 · compared with another group · 1,175 in the study · 421 started · 421 with outcome data
    Summary

    This retrospective case–control study enrolled participants through an outpatient population over 5 years old and long COVID associations in Spain; data came from a self-reported survey. Of 421 participants analysed, 212 had long COVID and 209 did not have long COVID but had a history of COVID-19 infection. The study compared complete COVID-19 vaccination before SARS-CoV-2 infection (147 participants) with no pre-infection vaccination (274 participants). For long COVID risk, the multivariable-adjusted OR was 0.49 (CI 0.28–0.87, p = 0.013) with pre-infection vaccination. Among participants with long COVID, the mean number of symptoms was 8.18 (SD 4.21) in vaccinated participants and 10.06 (SD 4.53) in unvaccinated participants; the adjusted B coefficient was −1.79 (CI −3.15 to −0.43; table p = 0.006; text p = 0.010). Symptom analyses reported lower odds for taste/smell disorders (OR 0.21, CI 0.10–0.47), myalgias or arthralgias (OR 0.42, CI 0.21–0.82), concentration problems (OR 0.43, CI 0.21–0.88), ophthalmological problems (OR 0.45, CI 0.23–0.86), gastrointestinal problems (OR 0.47, CI 0.25–0.88) and amnesia (OR 0.51, CI 0.26–0.99). A single post-infection vaccine dose versus no vaccination showed no significant association with long COVID outcomes (multivariable-adjusted OR 1.20, CI 0.56–2.57; 159 vs 115). The paper does not report harms or side effects for this study. The authors state limitations including a small sample, recall bias, lack of sample representativeness and a specific target population.

  28. Differences in Long COVID severity by duration of illness, symptom evolution, and vaccination: a longitudinal cohort study from the INSPIRE group.2025 · compared with another group · 6,044 in the study · 4,119 started · 3,663 with outcome data
    Summary

    This prospective, multisite study enrolled U.S. adults with COVID-like symptoms at eight major healthcare institutions and analyzed people with prior SARS-CoV-2 infection who completed a long-term survey 18–40 months after infection. The initial cohort included 6044 adults; 4119 consented to the long-term survey, 4009 completed it, and 3663 (91%) qualified for analysis. By self-report, 2604 (71.1%) never had Long COVID, 994 (27.1%) had current Long COVID, and 65 (1.8%) had resolved Long COVID. The study compared participants vaccinated before Long COVID onset with those not vaccinated before onset, and compared total vaccination dose groups (0, 1–2, 3–5, ≥6 doses). Among participants with current Long COVID, those vaccinated before Long COVID onset had higher (better) PROMIS physical health scores by +2.3 (95% CI 0.8–3.7) and PROMIS mental health scores by +1.7 (95% CI 0.1–3.2). Across all participants, the paper reports better PROMs, including PROMIS physical and mental health, FSS, SNAP, EVS, PSS, and UCLA Loneliness scores, for those who received more vaccine doses. Harms were not reported. The authors state limitations including self-reported Long COVID status and a cross-sectional analysis that could not account for baseline differences.

  29. Vaccination and food consumption: association with Post-Acute COVID-19 Syndrome in Brazilian adults (CUME Study).2025 · compared with another group · 3,666 in the study · 2,065 with outcome data
    Summary

    This open prospective cohort study examined Post-Acute COVID-19 Syndrome (PACS) after SARS-CoV-2 infection in Brazilian adults from the Cohort of Universities of Minas Gerais, graduates of seven public federal higher education institutions in Minas Gerais, Brazil. Of 3,666 who completed the baseline and COVID-19/PACS-specific questionnaires, 2,065 were analysed. The exposures examined were COVID-19 vaccination status and dietary intake. After a median of 5.5 years of follow-up (approximately 10,752 person-years), 1,124 participants reported PACS (54.4%). PACS was self-reported by questionnaire. The study compared pre-infection with post-infection COVID-19 vaccination and quartiles of nutrient and food-group intake. In the nutrient model, pre-infection vaccination (HR: 0.69; 95% CI: 0.56–0.85), vitamin C (HR: 0.78; 95% CI: 0.64–0.94-4th quartile), vitamin D (HR: 0.81; 95% CI: 0.67–0.99-4th quartile), and zinc (HR: 0.78; 95% CI: 0.64–0.97-3rd quartile; HR: 0.66; 95% CI: 0.52–0.83-4th quartile) were reported. In the food-group model, pre-infection vaccination (HR: 0.68; 95% CI: 0.55–0.84) and vegetables (HR: 0.82; 95% CI: 0.69–0.97-2nd quartile; HR: 0.81; 95% CI: 0.68–0.96-3rd quartile) were reported, while eggs (HR: 1.59; 95% CI: 1.34–1.89-4th quartile) were a risk factor. Side effects and withdrawals were not reported. Limitations include self-reported PACS, a non-representative high-education sample, mild COVID-19 cases, modifiable exposures, and symptom overlap with menopause.

  30. P-2060. Effectiveness of BNT162b2 COVID-19 Vaccination Against Long COVID Among Older Adults: A Nationwide Study2025 · compared with another group · 277 in the study
    Summary

    This nationwide study asked whether receiving BNT162b2 bivalent before SARS-CoV-2 infection was associated with fewer long COVID symptoms among older adults. Symptomatic US adults ≥50 years old testing positive at CVS Health were recruited between 03/02-05/18/2023. Of 277 older adults, 172 received BNT162b2 and 105 did not. Mean time since last bivalent dose was 168 days. Participants reported presence or absence of 30 long COVID symptoms at 4 weeks, months 3 and 6 after testing; CDC-defined long COVID was operationalized as ≥2 or ≥3 new or persistent symptoms from week 4 to month 6. At month 6, prevalence of ≥2 and ≥3 symptoms was 33.1% and 23%. Those who received BNT162b2 were less likely than those who did not to report ≥2 symptoms (27.0% vs 44.4%; adjusted OR 0.50, 95% CI 0.28-0.88) and ≥3 symptoms (16.5% vs 34.9%; adjusted OR 0.43, 95% CI 0.24-0.79) from 4 weeks to 6 months. Absolute VE ranged 50-57%. Harms and withdrawals were not reported. The authors state no limitations.

  31. Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.2025 · compared with another group · 81 in the study · 74 with outcome data
    Summary

    This open-label, non-randomised study enrolled ambulatory adults who had previously received at least two, but up to four, doses of different COVID-19 vaccines. Of 81 participants who consented and received a single intramuscular SpikoGen® 25 μg booster formulated with Advax-CpG55.2™ adjuvant, 74 had follow-up blood results for analysis. Participants were grouped by primary vaccine course: mRNA-prime (22 analysed), adenoviral-prime (16), and SpikoGen®-prime (36). Blood samples were taken at baseline and at 1 month (+/− 1 week) and 3 months post-booster. Outcomes included anti-spike antibody seroconversion and neutralising antibody fold rise, breakthrough SARS-CoV-2 infections, and long COVID symptoms. One month post-booster, all groups showed a significant rise in serum spike-binding IgG, sVNTw and pVNTw levels; at 3 months, spike-binding IgG and pVNTw levels did not differ significantly between groups, while sVNTw levels were significantly higher in the mRNA-prime group than in the adenoviral-prime and SpikoGen®-prime groups. Nine participants (9/74, 12.2%) had a breakthrough SARS-CoV-2 infection between 2 weeks and 3 months post-booster; the results text states one infection occurred sooner than 14 days and was excluded, leaving eight. No long COVID was observed after breakthrough infections. Reported adverse events were mild to moderate and transient, with no vaccine-associated serious adverse events and no cases of myocarditis or pericarditis observed. Reactions were mild and short-lived with full recovery. Withdrawal counts were not reported for harms. The authors state it was not practicable to run the trial as blinded or randomised.

  32. COVID-19 Vaccination Timing, Relative to Acute COVID-19, and Subsequent Risk of Long COVID.2025 · compared with another group · 1,558,018 in the study · 1,702,308 with outcome data
    Summary

    This retrospective cohort used electronic health record data from N3C (84 health institutions; more than 22 million total patients) to study whether COVID-19 vaccination before acute COVID-19 was associated with later Long COVID (ICD-10 code U09.9). The abstract reports 1,558,018 patients; results describe 1,702,308 unique patients across longitudinal and binary cohorts, and a binary cohort of 670,452 patients (the abstract gives n = 519,980). Vaccinated patients (2 or more doses) were compared with unvaccinated patients (0 doses); separate analyses compared people diagnosed with acute COVID-19 1–3, 3–5, or 5–7 months after vaccination/booster. Long COVID was assessed 1 to 12 months after acute COVID-19. In the binary cohort, vaccinated patients had a lower risk of Long COVID (adjusted marginal risk ratio 0.843 (0.811, 0.876)). In the longitudinal cohort, the authors did not find a significant relationship between vaccination timing and Long COVID: 3–5 vs 1–3 months risk ratio 0.933 (0.617, 1.412); 5–7 vs 1–3 months risk ratio 1.058 (0.716, 1.564). Marginal adjusted 12-month risks were 0.005, 0.005, and 0.006. Harms were not reported. The authors state limitations including incomplete EHR reporting, high missingness of vaccination data, and wide confidence intervals in the longitudinal cohort.

  33. Association of COVID vaccinations and treatments with long COVID beyond 6 months: a case-control study on the adult population in a large integrated healthcare system in the United States from 2020 to 2023.2025 · compared with another group · 840 with outcome data
    Summary

    This case-control study used electronic medical records from Kaiser Permanente Southern California to examine whether COVID vaccination or acute COVID treatments were associated with Long COVID at least 6 months after infection. Adults with Long COVID diagnosed by ICD-10 code were matched to controls without Long COVID by age, sex, race/ethnicity, body mass index, and date of acute COVID infection. The January 2022 to June 2023 analysis included 840 cases and 4200 controls; the October 2020 to June 2023 analysis included 2632 cases and 13,160 controls. Patients with a history of ME/CFS or fibromyalgia fulfilling ME/CFS criteria were excluded. Compared with no vaccination, one dose was associated with lower odds of Long COVID (OR 0.77; 95 % CI 0.63–0.96), two doses (OR 0.73; 95 % CI 0.59–0.92), three doses (OR 0.66; 95 % CI 0.44–1.00), and four doses (OR 0.29; 95 % CI 0.06–1.49). Nirmatrelvir/ritonavir was associated with lower odds (OR 0.05; 95 % CI 0.04–0.07), as was remdesivir (OR 0.31; 95 % CI 0.19–0.49). No interaction was found between nirmatrelvir/ritonavir and one, two, or three vaccinations (p = 0.38, p = 0.24, p = 0.08); an interaction was found with four doses (p = 0.002). No interaction was found between remdesivir and one to four vaccinations (p = 0.74, p = 0.92, p = 0.96, p = 0.98). No harms or withdrawals were reported. The authors state the case-control design cannot establish causality and note possible misclassification of the index infection and limited power.

  34. Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study.2025 · compared with another group · 25,911 in the study · 9,668 started · 7,936 with outcome data
    Summary

    This population-based study in Shinagawa City, Tokyo, Japan, asked community-dwelling adults aged 20–69 years with confirmed SARS-CoV-2 infection between 1 July and 31 August 2022 about post-COVID-19 condition (PCC). Among 29,276 identified infected residents, 3,365 who died or moved out were excluded and 25,911 were selected; 9,668 responded to the questionnaire (response rate 37.3%), and 7,936 were eligible for analysis (mean age 42.9 years; 4,553 women). Vaccination status came from the municipal Vaccination Record System and was grouped as unvaccinated, 1 or 2 doses, or three or more doses before infection. At approximately 6 months after infection, 940 (11.8%) had at least 1 PCC. Compared with unvaccinated participants, those vaccinated three or more times had lower odds of PCC (OR 0.69, 95% CI 0.53–0.90, p=0.01); 1 or 2 doses were not significantly associated (OR 0.91, 95% CI 0.68–1.22, p=0.53). The association was present in women (OR 0.70, 95% CI 0.51–0.95, p=0.02) but not clear in men (OR 0.83, 95% CI 0.50–1.37, p=0.46). Three or more doses were associated with fewer neurological symptoms (OR 0.61, 95% CI 0.45–0.83, p=0.002), with no clear association for respiratory symptoms (OR 1.24, 95% CI 0.79–1.97, p=0.35). When adjusted for vaccine doses, timing since the last vaccination did not significantly impact risk reduction. Harms of vaccination and withdrawals were not reported. The authors state limitations including possible overestimation of PCC from selection bias, residual confounding, and limited generalizability of a single-city analysis.

  35. Incidence of Long COVID Diagnoses in 3.6 Million U.S. Medicare Beneficiaries With COVID-19.2025 · compared with another group · 3,588,671 in the study
    Summary

    This descriptive, observational cohort study used the COVVAXAGE database of CVS Health and Walgreens customers linked to Medicare claims. It identified 3 588 671 Medicare beneficiaries aged 66 years or older diagnosed with COVID-19 between October 1, 2021, and March 31, 2023, followed from the index date for 1 year. Beneficiaries were grouped by the number of COVID-19 vaccine doses administered prior to the index date (0 to 4 or more), and Long COVID was identified from Medicare Part A-B claims using ICD-10 code U09.9. Overall, 3.89% of beneficiaries were diagnosed with Long COVID over 1 year. One-year Kaplan–Meier cumulative incidence was 5.62% with no vaccine, 3.59% with 1 vaccine, 3.82% with 2 vaccines, 3.26% with 3 vaccines, and 2.73% with 4+ vaccines. Beneficiaries with 4 or more COVID-19 vaccine doses had a 39% lower adjusted rate of Long COVID relative to beneficiaries without a prior dose (adjusted hazard ratio = 0.61, 95% CI = 0.60–0.62). Beneficiaries with no COVID-19 vaccine doses showed a 59% greater relative risk and 1.58% greater absolute risk of a Long COVID diagnosis relative to those with 4 or more vaccine doses (4.23% vs 2.65%). The relative reduction was 42% among beneficiaries without a prior COVID diagnosis and 16% among those with prior COVID-19 diagnoses. Harms were not reported. The authors note that all measures rely on administrative claims, and that the estimates do not have causal interpretations.

  36. Impact of COVID 19 Vaccination on Long COVID Symptoms in Ecuador a Nationwide Cross Sectional Study2025 · compared with another group · 202 with outcome data · preprint
    Summary

    This cross-sectional online survey in Ecuador examined whether COVID-19 vaccination at the time of acute infection was associated with long COVID symptoms among adults with prior COVID-19. A total of 202 individuals completed the survey; 91 participants (45.1%) had received at least one dose of a COVID-19 vaccine at the time of their acute infection. Vaccination status was compared with unvaccinated participants. The main outcome was long COVID symptoms. In a Firth logistic regression adjusted for age group, sex, comorbidity, ethnicity, COVID-19 treatment and smoking, vaccination was associated with lower odds of reporting long COVID symptoms (aOR = 0.362, 95% CI: 0.14 – 0.87, p = 0.02). Individuals aged 40–49 had higher odds (aOR = 5.951, 95% CI: 1.46 – 18.5, p = 0.01), and inpatient care during acute COVID-19 was associated with increased odds (aOR = 9.153, 95% CI: 1.42 – 17.6, p = 0.038). Symptom prevalence tables reported differences for some symptoms, including coughing (18 vaccinated vs 10 unvaccinated, p = 0.039) and hyperhidrosis (0 vaccinated vs 21 unvaccinated, p = 0.000002). Harms and withdrawals were not reported. Authors note reliance on self-reported symptoms and small sample size may introduce reporting bias.

  37. Association of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination and Reductions in Post COVID Conditions Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection in a US Prospective Cohort of Essential Workers.2025 · compared with another group · 2,584 in the study · 936 with outcome data
    Summary

    This retrospective nested case-control analysis within the HEROES-RECOVER cohort asked whether monovalent mRNA COVID-19 vaccination was associated with post COVID conditions (PCCs) after SARS-CoV-2 infection among US frontline and essential workers. Of 2584 participants who received the PCC survey, 936 comprised the final analytic sample; 23.6% reported PCCs and 83.2% were vaccinated. Vaccination status was defined relative to initial infection: 2 doses if received ≥14 days before infection, 3 doses if received ≥7 days before infection, or unvaccinated; 478 (51.1%) received a third monovalent mRNA vaccine dose ≥7 days before infection. Surveys were distributed at least 60 days after illness start, and PCCs were self-reported symptoms persisting ≥4 weeks after acute infection. Compared with unvaccinated participants, receipt of 3 doses was associated with lower odds of PCC gastrointestinal symptoms (aOR 0.37 [95% CI, .16–.85]), neurological symptoms (aOR 0.56 [.32–.97]), and other symptoms (aOR 0.48 [.25–.91]). No significant associations were found between 3 doses and number of symptoms, cardiovascular/respiratory symptoms, or general symptoms. For 2 doses versus unvaccinated, the odds of PCCs with at least 1 symptom was 0.84 (95% CI, .53–1.32); the paper states this was not statistically significant. Category aORs for 2 doses were reported, including gastrointestinal 0.69 (.31–1.53) and neurological 0.80 (.46–1.40). Harms were not reported. The authors state limitations including inability to calculate PCC incidence, recall bias, unmeasured confounding, possible nonresponse bias, and limited generalizability.

  38. Symptoms Six Weeks After COVID-19 Are Reduced Among US Health Care Personnel Receiving Additional Vaccine Doses During the Omicron Period, December 2021-April 2022.2024 · compared with another group · 2,478 in the study
    Summary

    This case–control analysis in US health care personnel examined whether a COVID-19 vaccine dose after the primary mRNA series was associated with symptoms 6 weeks after COVID-19-like illness. Project PREVENT was a 16-site study. The study included 2478 participants; 1422 had COVID-19. Participants were compared as primary series only versus primary series plus an additional vaccine dose, separately among SARS-CoV-2-positive and SARS-CoV-2-negative participants. The outcome was self-reported symptoms at 6 weeks after symptom onset. Among participants with COVID-19, those with an additional dose had lower odds of any symptoms at 6 weeks (aOR, 0.55; 95% CI, 0.43–0.70). Among SARS-CoV-2-negative participants, no statistical association was found (aOR, 0.87; 95% CI, 0.59–1.29). The paper reports that no participants were hospitalized for acute COVID-19, and no participants died; withdrawals for harms were not reported. A total of 269 (6.5%) did not complete the follow-up survey within 10 weeks and were excluded. The authors note limitations including self-reported symptoms, lack of blinding, possible unrecognized SARS-CoV-2 infection, and a smaller SARS-CoV-2-negative group.

  39. Receiving three doses of inactivated or mRNA COVID-19 vaccines was associated with lower odds of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China: a cross-sectional survey study.2024 · compared with another group · 1,542 in the study
    Summary

    This secondary analysis of a cross-sectional online survey conducted between June and August 2022 in Hong Kong included 1,542 adult residents with confirmed SARS-CoV-2 infection during the fifth wave. It examined COVID-19 vaccination status before that wave, grouped as 2 doses (888), 3–4 doses (491), and 0–1 dose (163), and compared three doses of Pfizer-BioNTech (345) or SinoVac CoronaVac (98) with two doses of Pfizer-BioNTech. Outcomes were self-reported long COVID symptoms, defined with reference to WHO, as any long COVID symptoms or ≥3 types. Overall, 40.9% reported any long COVID symptoms and 16.1% reported ≥3 types. Compared with 2 doses, 3–4 doses were associated with lower odds of any long COVID symptoms (AOR 0.69, 95% CI 0.54, 0.87, P = .002); for ≥3 types the association was not statistically significant (AOR 0.72, 95% CI 0.51, 1.00, P = .051). Compared with two doses of Pfizer-BioNTech, three doses of Pfizer-BioNTech (AOR 0.68, 95% CI 0.52, 0.90, P = .006) and three doses of SinoVac CoronaVac (AOR 0.57, 95% CI 0.35, 0.90, P = .02) had lower odds of any long COVID symptoms. Three doses of SinoVac CoronaVac versus three doses of Pfizer-BioNTech had similar odds for any long COVID symptoms (AOR 0.74, 95% CI 0.44, 1.23, P = .25) and ≥3 types (AOR 0.82, 95% CI 0.40, 1.68, P = .59). No harms, side effects, adverse events, or withdrawals for harms were reported. The authors state causal relationship could not be established because the study was cross-sectional.

  40. The impact of COVID-19 vaccination prior to SARS-CoV-2 infection on prevalence of long COVID among a population-based probability sample of Michiganders, 2020-2022.2024 · compared with another group
    Summary

    This study used a population-based probability sample of adults with PCR-confirmed COVID-19 in Michigan, identified through the Michigan Disease Surveillance System and sampled with a stratified probabilistic sampling methodology. It compared people who completed an initial COVID-19 vaccination series prior to COVID-19 onset with unvaccinated comparison groups; the authors considered multiple unvaccinated comparison groups as counterfactuals for the vaccinated group. The outcomes were prevalence of 30-day long COVID and 90-day long COVID, incorporating CDC and WHO definitions. The number of participants enrolled or analysed is not reported in the provided text. The authors report that completing an initial vaccination series prior to COVID-19 onset was associated with a 40–50% reduction in the prevalence of 30-day long COVID and a 50–60% reduction in the prevalence of 90-day long COVID. In the conclusion they state a 40–60% reduction in the prevalence of 30-day and 90-day long COVID. Harms, side effects, and withdrawals were not reported. The authors state that the estimates were similar regardless of which unvaccinated comparison group was used, despite potential bias.

  41. A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID-19 patients.2024 · compared with another group · 211 in the study
    Summary

    This retrospective cohort study asked whether early antibiotics affect recovery from COVID-19 and long COVID in patients from southern Italy during October 2020 to October 2022. A total of 211 COVID-19 patients with mild to moderate symptoms were included; five vaccinated individuals who did not receive antibiotics for home treatment were excluded. The main therapy was amoxicillin with clavulanic acid or azithromycin, given for a minimum duration of 5 days or longer; rifaximin was used in the later-start group. The study compared patients who started antibiotics within 3 days with those who started after 3 days. It measured recovery time, COVID-19 consequences, and blood oxygen saturation. Early starters had a median illness duration of 7 days versus 11.5 days for later starters (crude HR 4.74, p < 0.001; adjusted HR 5.25, p < 0.001). COVID-19 consequences were not significantly associated with antibiotic timing (crude OR 0.530, p = 0.251; adjusted OR 0.35, p = 0.096). Blood oxygen saturation was 95.4% with early treatment versus 92.6% later (p < 0.001). NSAID use showed the same median recovery time of 7 days (crude HR 0.88, p = 0.388) but prolonged disease in multivariate analysis (HR 0.73, p = 0.041); corticosteroids were associated with longer recovery (median 9 vs 7 days, p < 0.001). Harms were not reported.

  42. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia.2024 · compared with another group
    Summary

    Researchers conducted a staggered cohort study using primary care records from the UK (CPRD GOLD and AURUM), Catalonia, Spain (SIDIAP), and national health insurance claims from Estonia (CORIVA). They aimed to evaluate the overall effect of vaccination to prevent long COVID and compare ChAdOx1 and BNT162b2. A total of 1 618 395 (CPRD GOLD), 5 729 800 (CPRD AURUM), 2 744 821 (SIDIAP), and 77 603 (CORIVA) vaccinated people and 1 640 371 (CPRD GOLD), 5 860 564 (CPRD AURUM), 2 588 518 (SIDIAP), and 302 267 (CORIVA) unvaccinated people were included. Long COVID was defined as at least one of 25 WHO-listed symptoms between 90 and 365 days after a PCR-positive test or clinical diagnosis of COVID-19. Compared with unvaccinated people, overall HRs for long COVID symptoms in people vaccinated with a first dose of any COVID-19 vaccine were 0·54 (95% CI 0·44–0·67) in CPRD GOLD, 0·48 (0·34–0·68) in CPRD AURUM, 0·71 (0·55–0·91) in SIDIAP, and 0·59 (0·40–0·87) in CORIVA. For BNT162b2 versus ChAdOx1, meta-analytic calibrated sHRs were 0·84 (0·74–0·94) in CPRD AURUM and 0·85 (0·60–1·20) in CPRD GOLD. The paper reports no harms data for the arms.

  43. Characteristics and predictors of Long Covid in children: a 3-year prospective cohort study.2024 · compared with another group · 1,319 in the study · 1,296 with outcome data
    Summary

    This prospective study in Rome followed children aged 0–18 years with confirmed SARS-CoV-2 infection to describe Long Covid and assess COVID-19 vaccination. A total of 1319 patients were included, and 1296 reached the 3-month follow-up or more; assessments were scheduled at 3, 6, 12, 18, 24 and 36 months after infection. Vaccination status before infection was compared: 1049 children had no vaccine, 82 had one dose, 166 had two doses and 20 had three doses. The paper reports adjusted models for Long Covid at 3, 6, 12 and 18 months. The vaccine estimate was not significant at 3 months (OR 1.34, 95% CI 0.93–1.93; P 0.11), 6 months (OR 1.51, 95% CI 0.81–2.78; P 0.184), 12 months (OR 1.62, 95% CI 0.76–3.44; P 0.21) or 18 months (OR 1.35, 95% CI 0.58–3.11; P 0.476). In age subgroups, three doses were reported as significant for reduction of Long Covid at 3, 6 and 12 months in children aged 5–11 years; one dose was significant from age 14 upwards at 3 months and from age 13 upwards at 6 months. For new infection, one dose showed no significant effect compared with no vaccine, two doses showed a significant reduction at any age, and three doses after age 14. Steroid use during acute infection was associated with persisting muscle pains and post-exertional malaise at three and six months. No harms or withdrawals for the vaccination groups were reported. The authors state as a limitation that this is a single-center study.

  44. The impact of vaccination status on post-acute sequelae in hospitalized COVID-19 survivors using a multi-disciplinary approach: An observational single center study.2024 · compared with another group · 458 in the study
    Summary

    This prospective observational follow-up study compared 229 vaccinated and 229 unvaccinated hospitalized COVID-19 survivors (458 total) at a single academic hospital in Rome, with a two-month follow-up visit and a one-year telephone follow-up. Vaccinated patients received BNT162b2, mRNA-1273, or ChAdOx1-S; doses, routes, schedules, and duration were not reported. The unvaccinated group was the comparator. During hospitalization, vaccinated patients had fewer CPAP events, 3 (1.3%) vs 46 (20.1%), p<0.001; fewer high-flow nasal oxygen therapy events, 4 (1.7%) vs 18 (7.9%), p=0.02; and lower low-flow oxygen therapy rates, 3.5% vs 63.3%, p<0.001. In a 1:1 case-control matched analysis of 72 survivors (36 per group), vaccinated patients had fewer CPAP events, 0% vs 25%, p<0.001, and fewer high-flow nasal oxygen therapy events, 0% vs 11.1%, p=0.04. 33 patients disagreed to participate and 69 were lost at follow-up. Side effects and withdrawals for harms were not reported. Limitations stated include single-center design and an enrolled population that does not reflect all COVID-19 survivors but only those who agreed to participate.

  45. Vaccination and Patient Status of Long COVID-19 Hospitalized Patients: A Cohort Observational Study2024 · compared with another group · 503 in the study
    Summary

    This observational cohort study examined COVID-19 vaccination and long COVID-19 in 503 people hospitalized for COVID-19 pneumonia at the Community Healthcare Center dr. Adolf Drolc Maribor, Slovenia, from October 2020 to July 2022. Vaccination against COVID-19 was compared with non-vaccination. Participants were checked every 3 months until long COVID-19 symptoms disappeared or for the duration of one year. The study measured long COVID-19, long COVID symptoms, and percentages with dyspnoea, chest pain, cough, tiredness, UCI, stroke, embolism, thrombosis, myopathy, secondary infection, and hypertrichosis. The paper reports that more non-vaccinated patients acquired long COVID-19 than vaccinated and that vaccinated patients experienced less symptoms than unvaccinated. In the table, dyspnoea was 62.6% in vaccinated and 69.6% in non-vaccinated; chest pain 20.2% vs 21.6%; cough 46.1% vs 55.9%; tiredness 42.2% vs 44.1%. In logistic regression for long COVID-19 onset, the vaccination row had Exp(B) 0.511, 95% CI 0.372 to 0.3824, p=0.071. Harms and withdrawals were not reported. The authors state limits: a relative small number of patients, vaccination not available at the beginning, possible prevented COVID-19 pneumonia hospitalizations, and patients from northeast Slovenia, so results cannot be generalized.

  46. Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.2024 · compared with another group · 36,109 with outcome data
    Summary

    This nationwide Danish questionnaire study (EFTER-COVID) examined postacute symptoms and new-onset health problems 4 months after SARS-CoV-2 infection. The final cohort was 36,109 people aged 15 years or more in Denmark: 28,128 from the Omicron period (13,274 cases and 14,854 controls) and 7,981 Delta cases. For the treatment comparison, Omicron cases vaccinated with 3 doses were compared with Omicron cases vaccinated with 2 doses (n = 12,713); follow-up was 4 months after infection. Among 24 postacute symptoms, 11 had significantly decreased risk differences and none had significantly increased risk differences with 3 doses versus 2 doses. PEM had RD = –6.6% (95% CI, –10.6 to −2.4), substantial fatigue RD = –6.2% (95% CI: –10.8 to −1.8), and reduced strength in the legs/arms RD = –4.2% (95% CI: –6.5 to −1.9). New-onset mental exhaustion RD = –4.2% (95% CI, –6.6 to −1.8), memory issues RD = –2.5% (95% CI, –4.5 to −0.4), and difficulties concentrating RD = –2.3% (95% CI, –4.1 to −0.4). Cases vaccinated with 3 doses had 8% fewer postacute physical symptoms than those vaccinated with 2 doses (RR = 0.92; 95% CI, 0.89-0.95). No harms events were recorded.

  47. Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study.2024 · compared with another group · 1,067 in the study · 914 with outcome data
    Summary

    The study asked whether complete COVID-19 vaccination reduces persistent symptoms 3 months after mild Omicron infection. In a prospective multicenter cohort in Brazil (January 2022–June 2023), 1,067 adults with symptomatic laboratory-confirmed COVID-19 not requiring hospitalization were enrolled across 14 centers; 914 were included in the primary outcome analysis (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). Complete vaccination meant full primary series with or without booster; the comparator was no vaccine or an incomplete primary series. Vaccination status was assessed at enrollment, and no treatment duration was reported. Outcomes were assessed by telephone 3 months after enrollment. Overall persistent COVID-19-related symptoms occurred in 362/871 (41.6%) completely vaccinated vs 19/43 (44.2%) unvaccinated or incompletely vaccinated patients (aRR 0.87; 95% CI 0.61–1.23; p = 0.43). Mental health symptoms were lower with complete vaccination (9.6% vs 20.9%; aRR 0.44; 95% CI 0.24–0.81; p = 0.01). The paper reports no significant differences in general, neurological, or respiratory symptoms, mean organ systems affected in the primary comparison, or EQ-5D-3L scores. In the booster comparison, no significant overall difference was found; mental health symptoms were 9.1% vs 13.7% (aRR 0.57; 95% CI 0.33–0.98; p = 0.04), and mean organ systems affected were 0.64 vs 0.67 (p = 0.03). Side effects were not described; one patient died, 32 withdrew consent before outcome assessment, and 120 missed the 3-month follow-up assessment.

  48. SC-31 SARS-CoV-2 vaccination influence in development of Long-COVID clinical phenotypes2024 · compared with another group · 593 in the study · 582 with outcome data
    Summary

    This retrospective study at a post-COVID-19 clinic compared Long-COVID clinical phenotypes in vaccinated and unvaccinated COVID-19 patients. Of 593 patients enrolled, vaccination status was available for 582; 157 were in the vaccinated group (at least one anti-SARS-CoV-2 vaccine dose) and 425 in the unvaccinated group. Duration and follow-up were not reported. The study assessed self-reported Long-COVID symptoms, clinical phenotypes, pulmonary and cardiologic evaluations, and CT scans. Vaccination status was associated with avoidance of hospital admission (OR=14.26, CI:91.116 to 22.31, p<0.0001), and fully vaccinated patients (3 or more doses) had OR=0.3491 (CI:0.1543 to 0.7584, p=0.0108). Vaccinated patients needed less invasive respiratory support (OR=8.345, CI:5.276 to 13.41, p<0.0001). No statistical significance was found for onset of symptoms in Long-COVID (OR=0.6303, CI:0.3430 to 1.117, p=0.1650). Neuropsychiatric disorders (OR=1.548, CI:1.038 to 2.328, p=0.0430) and cardiorespiratory symptoms (OR=0.3067, CI:0.2034 to 0.4579, p<0.0001) were most likely observed in the unvaccinated group. The vaccinated group showed a higher disposition to cardiological alterations (OR=3.458, CI:2.294 to 5.212, p<0.0001). CT severity score was lower in vaccinated patients (median 0 [0–1] vs 3 [0–8], p<0.0001). Hospitalized vaccinated patients had cardiological alterations OR=0.3210 (CI:0.1467 to 0.6977, p=0.0053); unvaccinated OR=1.360 (CI:0.7513 to 2.517, p=0.3279). Side effects were not reported.

  49. Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study.2024 · compared with another group · 3,029,340 in the study
    Summary

    This cohort study used the TriNetX health research database (69 US health care organizations) to identify adults aged ≥18 years with confirmed SARS-CoV-2 between January 1, 2020 and July 20, 2023. Of 3,029,340 people with confirmed SARS-CoV-2 infection, 13,214 were people with HIV (PWH), and 989 (7.5%) of PWH had documented at least 1 dose of any COVID-19 vaccine. The vaccination analysis compared vaccinated with unvaccinated PWH; vaccine type, number of doses, and duration were not reported, and outcomes were assessed at least 28 days following the first COVID-19 diagnosis. In Table 4, vaccinated PWH had lower odds than unvaccinated PWH for mortality (OR 0.29, 95% CI 0.19-0.46), diabetes (0.65, 0.43-0.99), heart disease (0.58, 0.4-0.85), mental disorders (0.66, 0.43-1.00), respiratory symptoms (0.82, 0.7-0.95), gastrointestinal symptoms (0.78, 0.67-0.9), fatigue (0.81, 0.67-0.98), chest pain (0.73, 0.61-0.87), and disturbances to smell and taste (0.47, 0.22-1.01). No significant differences were reported for hypertension, thyroid disorders, malignancy, thrombosis, rheumatoid arthritis, headache, bodyache, cognitive impairment, chronic cough, brain fog, palpitations, dizziness, hair loss, abnormal movements, or sexual desire or capacity. Harms and withdrawals were not reported. The abstract reported mortality OR 0.63 (95% CI 0.42-0.93) and fatigue OR 0.82 (95% CI 0.67-0.98), differing from the results/Table 4 values above.

  50. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection.2024 · compared with another group · 323,062 in the study
    Summary

    This retrospective matched cohort study used electronic health records from eight US integrated healthcare systems in the Vaccine Safety Datalink network. It included patients with SARS-CoV-2 positive tests from March 2021 to February 2022. Vaccinated cases (N = 161,531) had a documented Pfizer-BioNTech or Moderna mRNA COVID-19 vaccine at least 14 days before the positive test; unvaccinated cases (N = 161,531) had no documented vaccination at least 14 days before the test. The total was 323,062, and follow-up was during a median follow-up period of 151 days. PCC was a new diagnosis in one of 13 PCC categories 30 days to 6 months after the positive test. In adjusted analyses, risk of PCC was significantly lower for vaccinated vs unvaccinated patients for 9 of the 13 PCC outcomes studied. Relative risks included 0.53 (95% CI 0.51–0.56) for non-specific COVID-19 related outcomes, 0.69 (0.66–0.72) for skin and subcutaneous tissue disorders, 0.79 (0.71–0.89) for blood and hematologic disorders, 0.88 (0.83–0.94) for circulatory disorders, and 0.90 (0.86–0.95) for sensory disorders. Mental health disorders had RR 1.06 (1.02–1.10); in adolescents aged 12–17 years the RR was 1.12 (1.00–1.24), reported as not statistically significant. The paper does not report side effects or withdrawals for harms.

  51. Clinical Features and Vaccination Effects among Children with Post-Acute Sequelae of COVID-19 in Taiwan.2024 · compared with another group · 500 in the study
    Summary

    This cross-sectional study from a prospective cohort at a single tertiary center in central Taiwan included 500 children with post-acute sequelae of SARS-CoV-2 infection (PASC). Of these, 292 (58.4%) were vaccinated; the study compared vaccinated and unvaccinated children. Symptoms in the acute and post-COVID-19 phases were assessed, with logistic regression models adjusted for age and sex. In the acute phase, vaccination was associated with higher odds of cough (AOR 1.57; 95% CI 1.02–2.42), rhinorrhea/nasal congestion (AOR 1.74; 95% CI 1.13–2.67), sneezing (AOR 1.68; 95% CI 1.02–2.76), sputum (AOR 1.91; 95% CI 1.15–3.19), headache/dizziness (AOR 1.73; 95% CI 1.04–2.87), and muscle soreness (AOR 2.33; 95% CI 1.13–4.80). In the post-COVID-19 phase, vaccination was associated with lower odds of abdominal pain (AOR 0.49; 95% CI 0.25–0.94) and diarrhea (AOR 0.37; 95% CI 0.17–0.78). The authors state that vaccination may reduce certain gastrointestinal symptoms in the post-COVID-19 phase. They note limitations including self-reported symptoms and possible recall bias, no comparison of different vaccine types, unmeasured confounding, and data collected only at the first PASC outpatient visit.

  52. Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates.2024 · compared with another group · 28,375 in the study
    Summary

    This cohort study asked which patient-specific factors were associated with long COVID and whether pre-COVID vaccination or treatments received during acute COVID-19 were associated with long COVID risk. It included 28,375 non-hospitalized adult patients diagnosed with mild to moderate COVID-19 in Dubai between January 1, 2021, and September 31, 2022, who were followed up for 90 days. The presence of long COVID symptoms was documented by physicians during patient visits to the family medicine department. The abstract reports that pre-COVID vaccination was associated with a reduced risk of long COVID in all patient subgroups. It also reports that treatment with favipiravir or sotrovimab during the acute phase of COVID-19 was linked to a decreased risk of long COVID, although the abstract notes a limit for favipiravir in the high-risk group. Doses and treatment duration are not reported. The abstract reports no side effects, harms, or withdrawals due to harms for any arm. The authors conclude that the study identifies risk factors for long COVID among non-hospitalized patients and emphasizes the potential benefits of pre-COVID vaccination and timely treatment. The abstract does not state limitations.

  53. SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition.2024 · compared with another group · 540 in the study
    Summary

    This cohort study used 540 individuals from the DigiHero cohort, recruited between August 2021 and February 2022 via mailed invitation, plus vaccination cohorts at the University Hospital Halle. The post-COVID-19 condition (PCC) analysis included 162 people with ongoing PCC, 146 with resolved PCC, 136 who never reported PCC and 96 without COVID-19. COVID-19 vaccination was given after SARS-CoV-2 infection; the study compared ongoing-PCC patients who were not vaccinated (n = 30), vaccinated once post-infection (n = 86) or vaccinated twice post-infection (n = 52). Blood sampling occurred at a median of 100 days (range 10-330) after the last vaccination. The study measured plasma cytokines, SARS-CoV-2 S1/NCP IgG antibodies and self-reported symptoms. In ongoing PCC, plasma IL-1β was lower in those who received one or two vaccine doses after infection; IL-18 showed a step-wise reduction after post-infection vaccination, with two vaccinations reducing mean IL-18 to levels seen in individuals without COVID-19. Vaccination status had no impact on most symptoms, but less frequent reporting of abdominal pain and gastrointestinal complaints was noted after post-infection vaccination, after one and two doses. TNF and IL-6 levels were not affected by post-infection vaccination, and no vaccination-associated differences were found for several other cytokines. The authors report none developed persisting adverse sequelae four weeks or later after vaccine administration and that they did not observe any vaccination-associated adverse events.

  54. How does COVID-19 vaccination affect long-COVID symptoms?2024 · compared with another group · 1,988 in the study · 1,236 started · 1,236 with outcome data
    Summary

    This retrospective follow-up study asked whether COVID-19 vaccination is associated with prolonged post-COVID symptoms in adults who already reported long-COVID. Participants came from a previous cohort of adult patients with COVID-19; 1,988 people were included in the current study, and 1,236 people who reported long-COVID in phase 1 were selected for further analyses. Vaccination status was self-reported: 1,185 people had received at least one dose (1, 2, or 3 doses) and 51 had no vaccination. Data were collected by phone interview in January–February 2022, more than 14 months after hospital admission for COVID-19. The main outcome was long-COVID lasting more than one year after the initial infection. Long long-COVID was reported by 528 of 1,185 vaccinated people (44.6%) and 15 of 51 unvaccinated people (29.4%; p = 0.032); the paper also reports an OR of 1.96 (95% CI 1.06–3.63). By dose, long long-COVID occurred in 11 of 24 after one dose, 181 of 392 after two doses, and 336 of 769 after three doses. Most individual symptom comparisons were not significant, including fatigue (238/1,185 vs 5/51; p = 0.070) and muscle weakness (152/1,185 vs 3/51; p = 0.142). No withdrawals due to harms were reported.

  55. Effectiveness of BNT162b2 BA.4/5 Bivalent COVID-19 Vaccine against Long COVID Symptoms: A US Nationwide Study.2024 · compared with another group · 505 started · 505 with outcome data
    Summary

    This US nationwide survey-based prospective patient-reported outcomes study asked whether pre-infection BNT162b2 BA.4/5 bivalent COVID-19 vaccination was associated with long COVID symptoms among symptomatic adults ≥18 years old with a positive SARS-CoV-2 test at a retail pharmacy testing location. At Week 4, 505 participants completed the first long COVID survey and reported current long COVID symptoms; 260 (51.5%) were in the bivalent cohort and 245 (48.5%) were unvaccinated. Participants were followed at Week 4, Month 3, and Month 6 following infection. The bivalent cohort reported a numerically lower mean number of symptoms at Week 4 (2.4 vs. 2.9, p = 0.076), and long COVID with ≥3 symptoms was 24.2% vs. 35.5% (p = 0.006), with ≥2 symptoms 31.5% vs. 47.8% (p = 0.0002). At Month 3, mean symptoms were 2.1 vs. 2.8 (p = 0.028), while ≥3 symptoms were 21.3% vs. 27.0% (p = 0.150) and ≥2 symptoms 29.1% vs. 36.7% (p = 0.078). At Month 6, ≥3 symptoms were 17.2% vs. 26.5% (p = 0.017) and ≥2 symptoms 25.8% vs. 37.0% (p = 0.011); mean symptoms were 2.0 vs. 2.4 (p = 0.115). The paper reports that 12% discontinued at Month 6, possibly because of survey burden, and does not describe harms. Limitations include observational design, baseline differences, self-report, and lack of a universal long COVID definition.

  56. Evaluation of the Association of Fatigue Syndrome with Levels of Key Inflammatory Markers and Various Medical Interventions in Long-COVID and Post-COVID Patients2024 · compared with another group · 100 in the study
    Summary

    This retrospective observational study examined risk factors for fatigue syndrome after hospitalization for PCR-confirmed COVID-19 with lung lesions. It included 100 patients (60 women and 40 men; age 25 to 84 years; Me 58 (50–64)) from a somatic rehabilitation department in Kazan. Fatigue was assessed with the Fatigue Assessment Scale (FAS); a score of 21 or more was clinically significant. Patients were divided by time after discharge into long-COVID (up to 12 weeks; 65 patients) and post-COVID (more than 12 weeks; 35 patients). Fatigue was detected in 66% overall; significant fatigue was found in 43 (66.2%) long-COVID and 23 (65.7%) post-COVID patients. No study treatment was given; the study examined associations with vaccination, ICU transfer, outpatient etiotropic therapy or anticoagulants, and inflammatory markers. Vaccination was associated with less fatigue (p = 0.002; odds ratio = 0.223; 95% CI 0.081–0.613), significant in post-COVID (p = 0.009) but not long-COVID (p = 0.263). ICU transfer was associated with fatigue (p = 0.044; long-COVID p = 0.006; post-COVID p = 1.000). No association was found for etiotropic therapy (p = 0.459) or anticoagulants (p = 0.358). NLR at admission (p = 0.042), ESR at discharge (p = 0.013), and ferritin at discharge (p = 0.021) were associated with FAS; CRP was not (admission p = 0.775; discharge p = 0.272). The authors note data were not available for all 100 patients because information came from medical records.

  57. Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19.2024 · compared with another group · 1,854 in the study · 1,612 with outcome data
    Summary

    This longitudinal prospective cohort study surveyed adults with a positive SARS-CoV-2 test from a Colorado health system to examine whether monoclonal antibody (mAb) therapy or COVID-19 vaccination was associated with symptom recovery after acute COVID-19. Of 1854 participants who completed at least one survey, 1612 were analysed: 539 received mAb therapy and 1073 were untreated; 486 had received at least 2 vaccinations. The median time of the first survey was 78 (IQR 59 to 99) days after acute infection. The primary outcome was time to symptom resolution; 28-day hospitalization was secondary. Overall time to symptom resolution was not associated with mAb treatment (aHR 0.87, 95% CI 0.73 to 1.03, p=0.09). The neurologic symptom group had a significant difference (aHR 0.84, 95% CI 0.72 to 0.98, p=0.03). Time to resolution was shorter with at least 2 vaccinations versus unvaccinated (aHR 1.56, 95% CI 1.31 to 1.88, p<0.01) and with one vaccination versus unvaccinated (aHR 1.43, 95% CI 1.14 to 1.79, p<0.01). 28-day hospitalization was lower with mAb therapy (5% versus 12%; adjusted OR 0.31, 95% CI 0.19 to 0.50, p<0.01) and with vaccination (2+ vaccines 5%, 1 vaccine 7%, no vaccines 13%; adjusted OR 0.33, 95% CI 0.20 to 0.55, p=0.01 for 2+ vaccines and adjusted OR 0.42, 95% CI 0.21 to 0.79, p<0.01 for 1 vaccine). Harms were not reported.

  58. Association of COVID-19 Vaccination With Risk of Medically Attended Postacute Sequelae of COVID-19 During the Ancestral, Alpha, Delta, and Omicron Variant Eras.2024 · compared with another group · 59 in the study · 41 with outcome data
    Summary

    This retrospective cohort study asked whether COVID-19 mRNA vaccination before infection was associated with medically attended and diagnosed postacute sequelae of COVID-19 (PASC). It included patients with an initial SARS-CoV-2 infection who were continually empaneled for primary care in a large US health system. Of 59 855 individuals identified by PCR, 41 652 met study criteria and were included. At infection, 24 250 were unvaccinated, 9 744 had 2 mRNA doses, and 7 658 had >2 mRNA doses, with vaccination at least 2 weeks before infection. The outcome was a medically attended PASC diagnosis within 6 months of infection (30 days to 6 months). Overall, 2 888 patients (6.9%) received a PASC diagnosis. The study found no difference between unvaccinated patients and those with 2 mRNA doses (adjusted odds ratio [aOR], 0.98; P = .7) or >2 doses (aOR, 1.10; P = .14). It also reported no interaction between vaccination status and variant (P = .79) or hospitalization (P = .16). The text does not report harms or withdrawals for harms. The authors state that >90% of patients were White, limiting generalizability to other races and ethnicities.

  59. The Effectiveness of COVID-19 Vaccination on Post-Acute Sequelae of SARS-CoV-2 Infection Among Geriatric Patients.2024 · compared with another group · 189,059 in the study · 11,230 with outcome data
    Summary

    This retrospective cohort study used the TriNetX database to assess COVID-19 vaccination and post-acute sequelae of SARS-CoV-2 infection (PASC, long COVID) in older patients. It included 189 059 geriatric patients with a first documented SARS-CoV-2 infection: 5615 vaccinated and 183 444 unvaccinated; after propensity score matching, each group contained 5615 patients, and the analysed cohort was 11 230. The vaccinated group had received at least one COVID-19 vaccine dose from 1 day to 1 year before the index date; the control group was unvaccinated. Follow-up was 30-180 days. During follow-up, the composite PASC outcome occurred in 909 vaccinated patients versus 946 control patients (HR 0.852, 95% CI 0.778-0.933, p = 0.0005), and all-cause mortality occurred in 17 versus 66 (HR 0.231, 95% CI 0.136-0.394, p < 0.0001). Anxiety and depression occurred in 154 versus 194 (HR 0.710, 95% CI 0.575-0.878, p = 0.0015). Other symptoms were not statistically significant, including fatigue (139 vs 154; HR 0.809, 95% CI 0.643-1.017, p = 0.0689) and pain (330 vs 283; HR 1.046, 95% CI 0.893-1.227, p = 0.5748). At 90-180 days and 30-365 days, PASC risk was not statistically significant, although a protective trend was observed. Harms and withdrawals were not reported.

  60. Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study.2024 · compared with another group · 1,367 in the study · 1,012 with outcome data
    Summary

    This prospective cohort study enrolled hospitalized adults aged >18 years in two Italian university hospitals from March 1 2020 to April 2022 and compared long COVID outcomes by COVID-19 vaccination status. Of 1367 patients initially included, 355 were excluded because they died during follow-up or did not answer phone calls, leaving 1012 analysed. Follow-up was reported as a median of 19 (IQR: 15–24) months. The paper analysed any long COVID symptomatology and symptom categories using adjusted logistic regression. Vaccination against COVID-19 was associated with reduced odds of reporting any long COVID symptomatology (OR 0.34; 95% CI 0.21–0.58; p<0.0001) and respiratory conditions (OR 0.59; 95% CI 0.42–0.84; p=0.002). Table estimates for other categories were: neurological 1.25 (0.89–1.76), general 0.86 (0.63–1.16), cardiac 0.96 (0.69–1.33), digestive 1.43 (0.95–2.16), dermatological 0.77 (0.47–1.27), and psychiatric 1.36 (0.97–1.90). Harms were not reported, and the paper did not report withdrawals for harms. The authors state that follow-up visits were performed once and not repeated, variants were identified using both molecular methods and aggregated epidemiological data, and outcome data were self-reported by phone without clinical examination.

  61. A prospective cohort study assessing the relationship between long-COVID symptom incidence in COVID-19 patients and COVID-19 vaccination.2023 · compared with another group · 705 in the study · 669 started · 669 with outcome data
    Summary

    This prospective cohort study followed 669 confirmed COVID-19 patients diagnosed between 16 September and 5 October 2021 in the Tulkarm Primary Health Care Directorate, West Bank, Palestine; 705 patients were identified and 36 were excluded. The study compared patients vaccinated against COVID-19 before infection with non-vaccinated patients. Of 669 participants, 274 (41.0%) were vaccinated and 395 (59.0%) were not. Phone interviews on days 10, 30, 60, and 90 asked about persisting symptoms. After 90 days, 278 patients [41.6%; (95% CI 37.8–45.4%)] were categorized as having long-COVID symptoms. In the multivariable analysis, non-vaccinated patients were almost seven times more likely to develop long-COVID symptoms than vaccinated patients [aP value: < 0.001, aOR: 6.9 (95% CI 4.2–11.3)]; the table reports long-COVID symptoms in 57 (20.8%) vaccinated and 221 (55.9%) non-vaccinated patients. The authors conclude that COVID-19 vaccination appears to be protective against developing long-COVID symptoms. They state limitations including self-reported data from telephone interviews rather than physical examinations, possible selection bias, and inability to examine all relevant risk factors; they also note that following patients for more than 90 days would be beneficial.

  62. Effect of vaccination on time till Long COVID, a comparison of two ways to model effect of vaccination and two outcome definitions2023 · compared with another group · 438,431 in the study · preprint
    Summary

    This retrospective analysis of de-identified electronic health record data examined COVID-19 vaccination status and Long COVID. It included 438,431 adults with a positive COVID-19 PCR test between 2021-10-01 and 2022-11-30. The time-independent analysis included 427,703 patients; the time-dependent analysis included 438,431. Outcomes were new Long COVID symptoms or a coded Long COVID diagnosis at least four weeks after infection, with follow-up up to 365 days after time zero (28 days after the positive test). In the time-independent analysis, vaccinated versus unvaccinated hazard ratios were 0.9 [0.87, 0.94] for symptoms and 0.86 [0.74, 0.99] for diagnosis; vaccinated and boosted versus unvaccinated were 0.87 [0.83, 0.91] for symptoms and 0.81 [0.69, 0.95] for diagnosis. For vaccinated and boosted versus vaccinated, the hazard ratios were 0.96 [0.91, 1.01] for symptoms and 0.94 [0.79, 1.13] for diagnosis. Time-dependent estimates were similar: vaccinated versus unvaccinated 0.91 [0.88, 0.95] for symptoms and 0.86 [0.75, 0.99] for diagnosis; vaccinated and boosted versus unvaccinated 0.88 [0.85, 0.91] for symptoms and 0.77 [0.67, 0.9] for diagnosis; vaccinated and boosted versus vaccinated 0.96 [0.92, 1.01] for symptoms and 0.89 [0.76, 1.06] for diagnosis. The abstract prints the diagnosis hazard ratio for boosted versus vaccinated as 0.94-1.13, while Table 4 prints 0.94 [0.79, 1.13]. Harms were not reported.

  63. Efficacy of first dose of covid-19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e-cohort.2023 · compared with another group · 1,296 in the study · 910 started · 910 with outcome data
    Summary

    In a target trial emulation based on the ComPaRe long covid e-cohort in France, adults with long covid were studied. Among 1296 patients included before 1 May 2021 who provided vaccination status, 910 were analysed: 455 in the vaccinated group matched to 455 in the control group. The vaccinated group received a first covid-19 vaccine injection; controls received no vaccination. Outcomes were assessed at 120 days after baseline. The mean long covid symptom tool score was 13.0 (SD 9.4) with vaccination and 14.8 (9.8) without (mean difference −1.8, 95% CI −3.0 to −0.5). Remission occurred in 16.6% (n=57) versus 7.5% (n=27) (risk difference 9.1%, 95% CI 5.0% to 13.2%; hazard ratio 1.93, 95% CI 1.18 to 3.14). The mean impact tool score was 24.3 (SD 16.7) versus 27.6 (16.7) (mean difference −3.3, 95% CI −5.7 to −1.0), and unacceptable symptom state was 38.9% versus 46.4% (risk difference −7.4%, 95% CI −14.5% to −0.3%). For mRNA-1273, symptom score difference was 1.5 (95% CI −2.0 to 5.1) and impact score difference 2.6 (95% CI −4.8 to 10.1). In the vaccinated group, 26/455 (5.7%) self-reported an adverse effect; 4 (0.9%) were serious, including two (0.4%) admissions to hospital and two (0.4%) emergency department visits; relapse of long covid symptoms was reported 13 times (2.8%). Sixty-nine patients were lost to follow-up (32 vaccinated, 37 control). The authors state the intervention was not randomly assigned, the outcome was self-reported and unblinded, and patients were infected before delta and omicron variants.

  64. Association between BNT162b2 vaccination and health-related quality of life up to 18 months post-SARS-CoV-2 infection in Israel.2023 · compared with another group · 6,964 in the study · 951 with outcome data
    Summary

    This non-randomised cross-sectional study asked whether BNT162b2 COVID-19 vaccination was associated with health-related quality of life among adults previously infected with SARS-CoV-2 in Northern Israel. Adults aged 18 years and older with RT-PCR testing at three government hospitals were invited; 6964 individuals responded and provided complete vaccination and testing data, and 951 were included in the final analysis. Quality of life was measured with EQ-5D-5L utility index (UI) 3–18 months post-infection. Participants were grouped by vaccine doses received: 474 were unvaccinated at infection (0 or 1 dose), 227 received 2 doses and 250 received 3 doses. In adjusted analyses, those vaccinated with 2 or 3 doses combined reported a UI 0.05 points higher (CI 0.01–0.10, p=0.024) than those unvaccinated at infection. The double-vaccinated group reported 0.06 points higher (95%CI 0.004–0.11, p=0.036); the triple-vaccinated group’s difference was +0.05 (95%CI -0.01–0.10, p=0.096). Among participants reporting post-COVID symptoms, 2 or 3 doses combined was associated with 0.08 higher UI (CI 0.02–0.14, p=0.013), and three doses with +0.09 (95%CI 0.02–0.16, p=0.024). At 7–12 months among symptomatic participants, 2 or 3 doses combined was associated with 0.15 higher UI (95% CI 0.02–0.29, p=0.024). No association was detected beyond 12 months post-infection (0.05, 95%CI -0.06–0.16, p=0.362). Harms were not reported. The authors state limitations include self-reported outcomes, cross-sectional design, limited generalisability to other vaccines, and small numbers of three-dose participants at later time points.

  65. Prevalence and difference of COVID-19 symptoms, post-COVID conditions and duration of illness among the vaccinated and unvaccinated population: a cross-sectional study in Peshawar.2023 · compared with another group · 250 in the study
    Summary

    This cross-sectional study in Peshawar, Pakistan, compared people who had contracted PCR-confirmed COVID-19 by vaccination status. The study enrolled 250 respondents: 143 had not received the COVID-19 vaccine at the time of contracting the virus, and 107 had been vaccinated, defined as a minimum of two doses of licensed COVID-19 vaccines before contracting COVID-19. The paper reports outcomes for acute COVID-19 symptoms, duration of illness and post-COVID conditions; side effects and withdrawals were not reported. Vaccinated respondents more often recovered within 3–5 days: 62 (57.9%) vaccinated versus 31 (21.7%) unvaccinated. Illness lasting more than 20 days was reported in 9 (6.3%) unvaccinated and 1 (0.9%) vaccinated respondents (P<0.001). Dyspnea occurred in 55 (38.5%) unvaccinated and 25 (23.4%) vaccinated respondents (P=0.011), anosmia/loss of taste in 76 (53.1%) versus 34 (31.8%) (P=0.001), and chest pain in 24 (16.8%) versus 8 (7.5%) (P=0.029). Fever, cough, fatigue, diarrhea, body aches, headache and sore throat did not differ significantly. Post-COVID conditions were reported by 61 (42.7%) unvaccinated and 29 (27.1%) vaccinated respondents (P=0.011; OR=0.5; 95% CI=0.29–0.86). Among post-COVID symptoms, arthralgia, myalgia, anosmia/loss of taste and fatigue were significantly less frequent in vaccinated respondents; chest pain, palpitation, cognitive impairment, headache, mood changes, diarrhea, tremors and vertigo were not. The authors state limitations including small sample size, a lack of consideration for different vaccine types, and a lack of follow-up data for patients.

  66. Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection.2023 · compared with another group · 116,272 started
    Summary

    This prospectively followed Norwegian COVID-19 cohort compared self-reported post-acute symptoms 3-15 months after a positive SARS-CoV-2 test in vaccinated participants with a breakthrough infection and unvaccinated participants. Of 116,272 participants who completed the fourth follow-up questionnaire, 1420 had a positive test: 1060 were unvaccinated and 360 were vaccinated with a breakthrough infection; 104,798 remained untested/negative. Symptoms measured included dyspnea, fatigue, smell/taste changes, concentration problems, memory problems, and the Everyday Memory Questionnaire-13 (EMQ-13). The study reported no differences between vaccinated and unvaccinated participants in dyspnea, fatigue, smell/taste changes, concentration problems, or EMQ-13 score. Memory problems were reported more frequently among unvaccinated participants: 43 of 360 vaccinated and 183 of 1060 unvaccinated, odds ratio 1.91 (95% confidence interval 1.07, 3.43), p=0.03. When participants hospitalized for COVID-19 were excluded, memory problems were no longer significantly different (15.8% and 12.1%, respectively; odds ratio 1.5, 95% confidence interval 0.83, 2.84). Hospitalization for COVID-19 was reported for 4 of 360 vaccinated and 64 of 1060 unvaccinated participants. Withdrawals for harms were not reported. The authors state limitations include self-reported symptoms and vaccination status and uncertainty related to the small sample size.

  67. Vaccination after developing long COVID: Impact on clinical presentation, viral persistence, and immune responses.2023 · compared with another group · 83 in the study
    Summary

    This prospective observational cohort study asked whether COVID-19 vaccination after PCC/long COVID was associated with changes in symptoms, well-being, immune markers, and viral persistence. It included 83 Quebec residents aged 18–100 years, previously infected with SARS-CoV-2 and diagnosed with PCC by the WHO clinical case definition, self-referred or referred by a healthcare provider between February 12 and September 8, 2021. Participants received one or two COVID-19 vaccine doses; 44 were unvaccinated at inclusion. A cross-sectional analysis compared 44 unvaccinated participants with 75 post-one-or-two-dose visits. Vaccinated participants reported fewer PCC symptoms (4.84 ± 3.59 vs 6.64 ± 3.79; p = 0.005), fewer affected organ systems (2.41 ± 1.17 vs 3.18 ± 1.12; p = 0.001), and a lower frequency of WHO-5 scores ≤50 (40.4% vs 68.2%; p = 0.005). In a longitudinal analysis of 36 participants, PCC symptoms fell from 6.56 ± 3.1 to 3.92 ± 4.02 (P < 0.001), affected organ systems from 3.19 ± 1.04 to 1.89 ± 1.12 (P < 0.001), and WHO-5 scores rose from 42.67 ± 22.76 to 56.15 ± 22.83 (P < 0.001). Overall, 77.8% reported improved, 7.4% worsened, and 14.81% unchanged well-being; 86% reported fewer, 8.3% more, and 5.6% the same number of PCC symptoms. The paper reports no significant difference in plasma levels of SARS-CoV-2 spike and nucleocapsid proteins pre- compared to post-vaccination. The paper reports conflicting longitudinal numbers: 39 were evaluated after one and/or two doses, but the longitudinal figure is n = 36. Adverse events were reviewed, but no counts are reported. Follow-up visits were at 12 and 24 months; vaccination administration was not controlled.

  68. Patients' Post-/Long-COVID Symptoms, Vaccination and Functional Status-Findings from a State-Wide Online Screening Study.2023 · compared with another group · 235 in the study · 225 with outcome data
    Summary

    This German survey study looked at whether being vaccinated against COVID-19, and when, was linked to how people with post-/long-COVID fared. 235 people with post-/long-COVID in Bavaria were recruited through doctors, clinics, social media and the press; 225 are included in the analyses. All took part in a programme with a personal pilot who gave coaching on using the health system and coping with symptoms. People filled in online surveys at the start and about three and four weeks later; vaccination history came from telephone interviews. Most had been vaccinated: 118 got their vaccinations more than two weeks before they were infected, and about one in five did not say. People infected before or around the time of vaccination reported more severe symptoms at the first survey than people vaccinated well before infection, but not at the later surveys. Symptoms went down from the first to the second survey in both groups. Across vaccination-dose groups there was no difference in symptom severity or social participation. Life satisfaction and workability differed between dose groups, and people with more doses reported lower life satisfaction and workability; people vaccinated twice had higher life satisfaction than those vaccinated three or more times. Nobody was assigned to a group at random, and side effects were not reported. The authors say the study is limited by having no control group and by not measuring antibody levels.

  69. SARS-CoV-2 infection outcomes associated with the Delta variant: A prospective cohort study.2023 · compared with another group · 142 in the study · 138 with outcome data
    Summary

    This prospective single-centre observational cohort study enrolled adults with SARS-CoV-2 proven infection in the Estrie region of Quebec. Of 142 individuals who agreed to participate, 138 completed questionnaires and were included. Among Delta-variant participants, 66 were vaccinated and 39 were unvaccinated. All vaccinated participants received mRNA-based vaccines (Pfizer or Moderna), with at least two doses; the comparison group was unvaccinated participants. The study measured new or persistent symptoms 30 days or more after acute infection. Vaccinated participants with Delta infection reported persistent symptoms more than 30 days after infection in 61.4% versus 51.4% of unvaccinated participants (p = 0.347). Fatigue after 30 days was present in 40.1% of vaccinated individuals versus 11.4% of unvaccinated individuals (p = 0.003). Total symptoms after 30 days were median 2 (IQR 0–4) in vaccinated versus 1 (IQR 0–2) in unvaccinated participants (p = 0.029). The number of symptoms during acute COVID-19 did not differ overall (RR 1.05, CI 95% 0.88% to 1.25%, p = 0.601). Hospitalization occurred in 5 (7.6%) vaccinated and 3 (7.7%) unvaccinated participants (p = 0.293). During acute infection, palpitation was more frequent in unvaccinated participants (vaccinated 0% versus unvaccinated 7.7%, p = 0.049). No harms are reported, and no withdrawals are reported for harms. The authors state that the sample size was relatively small and the study might have been underpowered to detect small difference.

  70. Profile of COVID-19 breakthrough cases and its comparison with unvaccinated COVID-19 cases among healthcare workers in a tertiary care centre in North Kerala.2023 · compared with another group
    Summary

    This prospective study was conducted among healthcare workers in Government Medical College, Kozhikode, over 78 weeks from 1st of March 2020 through 31st of August 2021. It examined the incidence and profile of COVID-19 breakthrough infections and compared fully vaccinated healthcare workers who had received two doses of COVID vaccination (Covishield or Covaxin) with unvaccinated COVID-19 positive healthcare workers. Real-time data were collected from 401 breakthrough cases and 390 unvaccinated COVID-19 positive healthcare workers through telephonic interviews. The reported incidence of breakthrough infection was 5.62%; 43.3% of breakthrough cases were asymptomatic. None of the breakthrough cases developed severe symptoms of Category C having complications which required intensive care (ICU) admission. The incidence of post-COVID-19 syndrome was 17.45% in the vaccinated group compared with 57.2% in the unvaccinated group. Table 8 reports p=0.18 for post-COVID fatigue. Withdrawals due to harms were not reported. The authors state a limitation: details about vaccination status, date of vaccination, and symptomatology were collected through a telephonic interview, a possible source of information bias.

  71. Vaccination status and long COVID symptoms in patients discharged from hospital.2023 · compared with another group · 412 in the study
    Summary

    This study evaluated long COVID symptoms 90 days after hospital discharge in 412 consecutive patients hospitalised with confirmed COVID-19 at two hospitals in Brazil from May 2021 to February 2022. Patients were grouped by vaccination status: 185 had complete vaccination, defined as two or more doses for all vaccines but ≥ 1 dose for the Janssen™ vaccine, and 227 had no or incomplete vaccination. The study compared the frequency of at least one symptom 90 days after discharge between these groups. It reported that patients with no or incomplete vaccination had a higher frequency of symptoms (≥ 1) than patients with complete vaccination (40 vs. 27%; p = 0.013). In a multivariate logistic regression, no or incomplete vaccination was associated with at least one symptom 90 days after discharge (odds ratio 1.819; 95% confidence interval 1.175–2.815; p = 0.007). The paper did not report harms; withdrawals were not reported for either group. The authors state that the follow-up was short and that the 90-day symptoms relied on patients’ own notification. They also state that the influence of vaccine type on long COVID could not be tested, and that the number of patients hospitalised despite receiving three or four doses was small.

  72. Impact of COVID-19 vaccination in post-COVID cardiac complications.2023 · compared with another group · 1,883 in the study
    Summary

    This observational, analytical and prospective study examined whether a complete COVID-19 vaccination scheme was related to post-COVID cardiac injury and persistent long-COVID cardiac symptoms. It included 1,883 patients (mean age 42±14.5 years, 46% men) seen for post-COVID evaluation at an outpatient cardiology center. The text reports 56.8% (n=1070) unvaccinated and 43.2% (n=813) after a complete scheme, while the tables print 883 vaccinated. Complete vaccination meant at least two doses with 14 days or more since the last dose. The comparison was vaccinated versus unvaccinated patients. Assessment used transthoracic echocardiogram and reports of persistent symptoms at a mean 62 days (range 16–330 days) after COVID-19 diagnosis. Cardiac injury was 1.35% versus 4.11% (p<0.001), with adjusted OR 0.33 (95% CI 0.17–0.65, p=0.01). Persistent long-COVID symptoms were 10.7% versus 18.3% (p<0.001), adjusted OR 0.52 (95% CI 0.40–0.69, p<0.001). Table 2 total injury findings were 4.1% (44) versus 1.35% (11), p<0.001. Pericardial effusion was 0.65% (7) versus 0.86% (7), p=0.605; wall motion abnormalities were 0.93% (10) versus 0.25% (2), p=0.06. LV systolic dysfunction was 2.9% (31) versus 0.37% (3), p<0.001. The paper states no reports of vaccine-related myocarditis in the charts but cannot exclude this issue. Withdrawals for harms were not reported.

  73. Long COVID Prevalence and the Impact of the Third SARS-CoV-2 Vaccine Dose: A Cross-Sectional Analysis from the Third Follow-Up of the Borriana Cohort, Valencia, Spain (2020-2022).2023 · compared with another group · 473 in the study
    Summary

    This cross-sectional follow-up study took place in June 2022 in Borriana, Spain. It included 473 adults aged 18 to 64 who attended the Falles Festival dinners in 2020 and had experienced at least one COVID-19 episode by June 2022. The study compared people who had received a third SARS-CoV-2 vaccine dose (boosted) with people who had received one or two doses (primed). It measured long COVID prevalence and the number of reported symptoms. In the main analysis restricted to people first infected during the Omicron period and on or after 1 January 2022, 90 were boosted and 27 were primed. The unadjusted long COVID prevalence was 13.3% among boosted and 29.6% among primed (SMD = 0.40). The number of symptoms was 1.5 ± 2.6 in boosted compared with 2.4 ± 3.7 in primed (SMD, 0.29). Adjusted analyses reported an absolute reduction in long COVID prevalence of −38.2% (−60.5% to −15.9%), an adjusted RRR of 74.0% (56.4% to 91.7%), a mean reduction of −1.8 (−3.3 to −0.4) symptoms, and an adjusted RRR for symptoms of 55.2% (31.6% to 78.7%). In a sensitivity analysis of 188 boosted and 79 primed people first infected in March 2020, unadjusted long COVID prevalence was 40.5% in boosted and 30.9% in primed (SMD of 0.20); symptom counts were 2.6 ± 3.4 versus 3.1 ± 3.9 (SMD of 0.14), with no evidence of a difference. Adjusted sensitivity confidence intervals were compatible with no significant booster effect or a null booster effect. The authors state adverse vaccination effects were not included. Overall long COVID was found in 133 (28.1%) of the 473 included cohort members.

  74. 15-month post-COVID syndrome in outpatients: Attributes, risk factors, outcomes, and vaccination status - longitudinal, observational, case-control study.2023 · compared with another group · 958 in the study · 222 started · 222 with outcome data
    Summary

    This longitudinal, observational, case-control study asked whether SARS-CoV-2 vaccination after infection affects recovery from post-COVID syndrome (PCS). It followed outpatients who had mostly mild COVID-19 and received care at the University Hospital of Cologne post-COVID outpatient clinic; 958 were in the initial cohort and 222 had 15-month follow-up data and were analysed. Of these, 171 were vaccinated between 10 and 15 months post-infection (vaccinations were given a median of 60 days before the 15-month visit), and 51 were unvaccinated. The study compared PCS recovery and PCS presence between these groups. At T4, PCS was present in 30.4% (52/171) of vaccinated and 33.3% (17/51) of unvaccinated patients (p=.6921); the unadjusted odds ratio for PCS after 15 months was 0.87 (95% CI 0.45-1.75; p=0.6921). Among patients with PCS at T3, 25.8% (16/62) of vaccinated and 26.3% (5/19) of unvaccinated patients recovered until T4 (p=.9646). The paper reports no effect of vaccination on PCS recovery. Harms and withdrawals were not reported. The authors state limitations including limited patient numbers and unadjusted odds ratios for most symptoms being not statistically significant.

  75. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study.2023 · compared with another group · 589,722 in the study
    Summary

    This population based cohort study asked whether covid-19 vaccination before infection was associated with a later clinical diagnosis of post-covid-19 condition (PCC). It included 589 722 adults in the two largest regions of Sweden with covid-19 first registered between 27 December 2020 and 9 February 2022. The study compared 299 692 people who had received at least one covid-19 vaccine dose before the covid-19 index date with 290 030 people who had not been vaccinated at infection. Follow-up began 28 days after the covid-19 index date; median follow-up was 129 (IQR 51-287) days. The primary outcome was a clinical diagnosis of PCC. During follow-up, 1201 (0.4%) vaccinated people and 4118 (1.4%) unvaccinated people had a PCC diagnosis. The adjusted hazard ratio for any dose before infection was 0.42 (95% confidence interval 0.38 to 0.46), with a vaccine effectiveness of 58%. Vaccine effectiveness was 21% for one dose, 59% for two doses, and 73% for three or more doses. The paper did not report side effects or withdrawals. The authors state limitations including that PCC and the ICD-10 code U09.9 are relatively new and the code has not yet been validated in a Swedish setting.

  76. Interruption of viral interference by anti-SARS-CoV-2 vaccination2023 · compared with another group · 305 in the study · 252 with outcome data · preprint
    Summary

    This prospective multicenter study enrolled 305 patients with persistent long-COVID symptoms at a Cardiology Long-COVID Unit in Vienna; after exclusion of 53 patients, 252 patients were included in the analysis. The study compared patients without vaccination (n = 97) with patients already vaccinated before first clinical presentation (n = 155), who had received at least two COVID-19 vaccines. Clinical and laboratory data were collected at the first clinical presentation. The study reports that vaccinated patients had significantly less frequent fatigue (p < 0.001) and significantly less frequent combination of several (≥ 3) multiorgan symptoms (p < 0.001) than non-vaccinated patients. Harms were not reported, and withdrawals were not reported. The authors conclude that anti-SARS-CoV-2 vaccination interrupts viral crosstalk in patients with long-COVID syndrome. The text states that there remains a need for systemic investigations to elucidate the exact mechanisms of viral interference. The text also states that the exact mechanism is only speculative.

  77. Association between post-infection COVID-19 vaccination and symptom severity of post COVID-19 condition among patients on Bonaire, Caribbean Netherlands: a retrospective cohort study2023 · compared with another group · 47 in the study · preprint
    Summary

    This retrospective cohort study on Bonaire, Caribbean Netherlands, examined whether COVID-19 vaccination after SARS-CoV-2 infection was associated with symptom severity change in post COVID-19 condition (PCC). The final sample included 47 PCC patients who were unvaccinated before infection and unrecovered at telephone interview between 15 November and 4 December 2021. After infection, 36 (76%) patients were vaccinated with at least one dose of the Pfizer vaccine and 11 (23%) remained unvaccinated. Vaccination was considered at least one dose at least 8 weeks after infection. The primary outcome was change in severity between the acute and post-acute phase (symptoms persisting more than four weeks after disease onset) for 14 symptoms, rated on a five-point Likert scale from 0 to 4. Among patients reporting heart palpitations, post-infection vaccination was significantly associated with reduced severity after adjusting for acute COVID-19 severity and duration of illness (β=0.60, p=0.01, 95% CI 0.18, 1.02); this involved 10 (28%) vaccinated and 4 (36%) unvaccinated patients. Headache severity change was not significant after adjustment (β 0.60, p = 0.06, 95% CI – 0.04, 1.24). The authors report no statistically significant association for other, more prevalent symptoms. Side effects and withdrawals were not reported.

  78. Do COVID-19 Vaccinations Affect the Most Common Post-COVID Symptoms? Initial Data from the STOP-COVID Register-12-Month Follow-Up.2023 · compared with another group · 1,050 in the study · 900 started · 801 with outcome data
    Summary

    This retrospective STOP-COVID registry study asked whether COVID-19 vaccination relates to post-COVID syndrome in patients in Poland. Of 1050 patients enrolled for the 12th-month follow-up, data were obtained from 900; 99 did not provide or consent to vaccination-status disclosure, and 801 were included in the final analysis. Of these, 665 were vaccinated; vaccination was defined as at least the basic schedule. The vaccinated group was compared with unvaccinated patients. Follow-up visits were in the 3rd and 12th month after the end of the disease. Outcomes included post-COVID syndrome diagnosis and individual symptoms. The paper reports no differences between vaccinated and unvaccinated patients for post-COVID syndrome diagnosis. Headache (p = 0.001), arthralgia (p = 0.032), and dysregulation of hypertension (p = 0.030) were significantly more common in unvaccinated subjects. In analyses by vaccination timing, people vaccinated after the disease manifested headache and arthralgia much less frequently; the paper also states that, considering headache and muscle pain, people vaccinated after the disease manifested these symptoms less frequently, and that people vaccinated after the disease were less likely to present with headache and myalgia. Harms and withdrawals for harms were not reported. The authors state limitations: 150 did not attend the 12th-month visit; the group is not representative of Polish society; and data were lacking on variant, acute treatment, reinfections, acute severity, other infections, and specific vaccine.

  79. Real-world effectiveness of COVID-19 vaccines and anti-SARS-CoV-2 monoclonal antibodies against postacute sequelae of SARS-CoV-2: analysis of a COVID-19 observational registry for a diverse US metropolitan population.2023 · compared with another group · 55,192 in the study · 53,239 started · 53,239 with outcome data
    Summary

    This retrospective cohort study used the Houston Methodist COVID-19 Surveillance and Outcomes Registry, an electronic medical record-based registry from an eight-hospital tertiary hospital system in the Houston metropolitan area, to evaluate COVID-19 vaccination and anti-SARS-CoV-2 monoclonal antibodies (mAbs) against postacute sequelae of SARS-CoV-2 infection (PASC). The primary analysis identified 55,192 adult PCR-positive patients; 1,953 (3.5%) were excluded for missing or unverifiable data, leaving 53,239 analyzed. Among them, 3,781 (7.1%) were breakthrough COVID-19 cases and 4,635 (8.7%) were mAb-treated patients. PASC was defined as constitutional or systemic symptoms beyond the 28-day postinfection period; 5,929 (11.1%, 95% CI 10.9% to 11.4%) met PASC criteria. In fully adjusted models, vaccinated breakthrough cases versus unvaccinated patients had a lower likelihood of PASC, aOR 0.58 (95% CI 0.52 to 0.66), and mAb-treated versus untreated patients had aOR 0.77 (95% CI 0.69 to 0.86). A replication dataset included 631,683 patients; 70,648 (11.2%, 95% CI 11.1 to 11.3) had PASC, with aOR 0.25 (95% CI 0.21 to 0.30) for vaccine and 0.62 (95% CI 0.59 to 0.66) for mAb treatment. Vaccination was reported to confer greater protection across PASC symptoms than mAb treatment. Harms and treatment withdrawals were not reported.

  80. Prevalence of Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status.2023 · compared with another group · 3,507 in the study · 2,689 with outcome data
    Summary

    This longitudinal study at Geneva University Hospitals examined post-COVID condition 12 weeks after Omicron BA.1/BA.2 infection compared with people who tested negative in the same period. Of 11 305 invited, 3507 participated (response rate 31.0%). After excluding 597 with incomplete answers and others with prior or interval positive tests, 2689 were analysed: 1807 tested positive and 882 tested negative. Participants were outpatients tested between December 2021 and February 2022 and followed 12 weeks after their test date. No treatment was assigned; the study compared symptom prevalence and functional impairment between Omicron-positive and negative participants, and by vaccination status. Monoclonal antibody treatment during the acute phase (casirivimab/imdevimab or sotrovimab; n = 15) was included only as an adjustment covariate; the authors state the small number does not allow results to be drawn on its role. No SAMe or Pemgarda data appear. No harms are reported for any treatment, and no treatment withdrawals are described. The authors conclude that the differential prevalence of post-COVID symptoms and functional impairment attributable to Omicron BA.1 and BA.2 infection is low compared with negative controls. They note limitations including potential false-negative RT-PCR tests, a response rate that could limit generalizability, recall bias and subjective self-reported symptoms, and the small monoclonal antibody subgroup (n = 15).

  81. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program.2023 · compared with another group · 198,514 in the study
    Summary

    This EHR-based cohort study asked whether pre-COVID-19 vaccination was associated with later long COVID diagnosis. The study population was drawn from 5,434,528 COVID-19-positive patients in N3C; 198,514 patients at eleven sites met inclusion criteria. A clinic-based cohort comprised 47,404 of these patients. In the model-based cohort, 86,248 were fully vaccinated and 112,266 were unvaccinated; in the clinic-based cohort, 26,354 were fully vaccinated and 21,050 were unvaccinated. Vaccinated patients had completed two doses of BNT162b2 or mRNA-1273 or a single dose of Ad26.COV2.S two weeks prior to the COVID-19 index; unvaccinated patients had no recorded vaccines at index. Outcomes were a clinical long COVID diagnosis in the clinic-based cohort and a computational phenotype score above 0.9 in the model-based cohort. Follow-up ranged from June 10, 2022 to August 1, 2022, and the minimum observed follow-up was 164 days. Adjusted clinic-based estimates were OR 0.70 (0.60, 0.81) and HR 0.67 (0.56, 0.79); adjusted model-based estimates were OR 0.70 (0.65, 0.75) and HR 0.63 (0.57, 0.69). Unadjusted clinic-based estimates were OR 0.79 (0.68, 0.92) and HR 0.79 (0.66, 0.95); unadjusted model-based estimates were OR 1.04 (0.97, 1.11) and HR 1.00 (0.91, 1.10). No harms events were recorded. The authors state that the results are limited by reliance on EHRs and by underdiagnosis of long COVID.

  82. Persistent COVID-19 Symptoms at 6 Months After Onset and the Role of Vaccination Before or After SARS-CoV-2 Infection.2023 · compared with another group · 1,832 in the study
    Summary

    This cohort study used EPICC data from US Military Health System beneficiaries aged 18 years or older who tested positive for SARS-CoV-2. The analysis included 1832 participants; 1413 were unvaccinated at time of infection and 419 had postvaccination infection. The study compared participants unvaccinated before infection with those with postvaccination infection for symptoms lasting ≥28 days and ≥90 days, and, among those unvaccinated at symptom onset, compared survey-reported symptoms around 1, 3, 6, 9, and 12 months for people vaccinated after infection versus not. In the ≥28-day model (n=1807), unvaccinated prior to infection had RR 1.39 (95% CI 1.04-1.85; p=.02); for ≥90 days (n=1726), RR 1.37 (95% CI 0.88-2.13; p=.17). For postinfection vaccination, the 6-month survey (n=836) had RR 0.59 (95% CI 0.40-0.89; p=.01); 1 month (n=537) RR 0.68 (0.34-1.36; p=.27), 3 months (n=602) RR 0.60 (0.35-1.05; p=.08), 9 months (n=848) RR 0.73 (0.46-1.17; p=.19), and 12 months (n=913) RR 0.68 (0.40-1.15; p=.15). Among unvaccinated prior to infection, pulmonary encounters RR 1.72 (1.32-2.27) and neurological encounters RR 1.27 (1.00-1.59). Harms and withdrawals from harms were not reported.

  83. Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome.2023 · compared with another group · 305 in the study · 252 started · 252 with outcome data
    Summary

    This prospective multicenter registry studied patients with PCR-verified past SARS-CoV-2 infection and long-COVID syndrome at a Cardiology Long-COVID Unit. Of 305 consecutive patients entered, 53 were excluded and 252 were included in the analysis: 155 had been vaccinated before the first clinical presentation and 97 were non-vaccinated; 105 healthy, unvaccinated, non-infected controls were also compared. Vaccinated patients had received monovalent COVID-19 vaccines (mean 1.8 ± 0.7 doses); treatment duration was not reported. The study compared vaccinated with non-vaccinated patients at presentation and long-COVID patients with controls, measuring clinical symptoms, inflammatory biomarkers, and DNA virus IgG and IgM titers. Compared with non-vaccinated patients, vaccinated patients had fatigue significantly less frequently (p < 0.001) and less often had a combination of several (≥3) multiorgan symptoms (p < 0.001). A subgroup had a second blood sampling after 106 ± 77 days. Harms, worsening, and stopping were not reported. The authors state the study was exploratory and hypothesis-generating.

  84. Vaccine Effectiveness Against Long COVID in Children: A Report from the RECOVER EHR Cohort.2023 · compared with another group · 1,037,936 in the study · preprint
    Summary

    This retrospective cohort study used RECOVER PCORnet electronic health record data from 17 health systems. It included children aged 5 to <18 years with an in-person visit between vaccine eligibility and October 29, 2022; the cohort was 1,037,936 children. Vaccinated children (N = 692,912) received at least one dose of SARS-CoV-2 vaccine; unvaccinated children (N = 345,024) were the comparator. Main long COVID observations were limited to 12 months following cohort entry, with additional estimates at 6 and 18 months. Outcomes were probable (symptom-based) and diagnosed long COVID. Adjusted vaccine effectiveness within 12 months was 35.4% (95 CI 24.5 – 44.5) against probable long COVID and 41.7% (15.0 – 60.0) against diagnosed long COVID. Estimates were higher for adolescents, 50.3% [36.3 – 61.0], than for children aged 5-11, 23.8% [4.9 – 39.0]. Vaccine effectiveness was 61.4% [51.0 – 69.6] at 6 months and 10.6% (-26.8 – 37.0%) at 18 months. With inverse probability of treatment weighting, the magnitude was 24% (95% CI 20 – 28%) for long COVID up to a year later. One-to-one matching lost 27% of unvaccinated and 64% of vaccinated patients. The text reports no side effects or harms for either arm. The authors state limitations including secondary EHR data, possible misclassification, and changed testing practices.

  85. Post COVID-19 Symptoms Among Infected Vaccinated Individuals: A Cross-Sectional Study in Saudi Arabia.2023 · compared with another group · 484 in the study · 369 with outcome data
    Summary

    This cross-sectional survey in Saudi Arabia (online questionnaire circulated through WhatsApp groups between August and October 2022) examined whether COVID-19 vaccination relates to persistence of post-recovery symptoms. Of 484 participants, 369 were analysed after exclusions: 237 infected after receiving three doses of vaccination, 102 infected prior to vaccination, and 30 unsure of infection timing relative to vaccination. The survey assessed 14 post-COVID-19 symptoms and their persistence, plus hospitalisation, ICU admission, and illness severity; treatment duration and follow-up were not reported. Symptoms ≤3 months after recovery were reported by 24 (10.1%) of 237, 12 (11.8%) of 102, and 23 (76.7%) of 30 (P < 0.001). Symptoms 3–6 months were reported by 123 (51.9%), 76 (74.5%), and 3 (10%) respectively (P < 0.001); symptoms >6 months by 90 (38%), 14 (13.7%), and 4 (13.3%) (P < 0.001). Hospitalisation was reported by 3 (1.3%) of 237 infected after three doses, 8 (7.8%) of 102 infected prior to vaccination, and 1 (3.3%) of 30 unsure (P < 0.001 in the table). In the 237 infected after three doses, none required ICU admission, and 234 (98.7%) described illness as mild to moderate. In logistic regression, vaccination before infection had a β coefficient of 0.45 (95% CI 0.33–0.73; P < 0.05). Harms were not reported.

  86. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study2022 · compared with another group · 3,090 with outcome data · preprint
    Summary

    This community-based, matched cohort study asked whether COVID-19 vaccination before SARS-CoV-2 infection was linked to Long Covid in UK COVID-19 Infection Survey participants randomly selected from the community. It included 3,333 eligible double-vaccinated participants before matching and a pool of 9,854 potential unvaccinated controls; after matching, the study sample comprised 3,090 double-vaccinated participants and matched controls. The vaccination exposure was at least two doses, with vaccination at least 14 days before the first test-confirmed infection; treatment duration was not reported. The comparison group was unvaccinated when infected. The main outcome was Long Covid status at ≥12 weeks after first infection, based on a survey question; activity-limiting symptoms were also assessed. Median follow-up was 96 days in double-vaccinated and 98 days in unvaccinated participants. Long Covid symptoms of any severity were reported by 294 double-vaccinated participants (prevalence 9.5%) and 452 unvaccinated participants (14.6%). Activity-limiting symptoms were reported by 170 (5.5%) and 268 (8.7%) participants, respectively. The adjusted odds ratio was 0.59 (CI 0.50 to 0.69) for Long Covid of any severity and 0.59 (0.48 to 0.73) for activity-limiting symptoms, comparing double-vaccinated with unvaccinated participants. Harms and withdrawals were not reported. The authors state that calendar time of infection could not be matched and that unmeasured confounding may remain.

  87. 1054. Comparison of Post-Acute COVID-19 Symptoms in Infected Individuals Pre- and Post-Vaccination2022 · compared with another group · 369 in the study · 57 with outcome data
  88. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.2022 · compared with another group · 10,024 in the study · 9,479 with outcome data
    Summary

    This retrospective cohort study used the TriNetX electronic health records network, mostly in the USA, to compare COVID-19 sequelae after breakthrough SARS-CoV-2 infection in people vaccinated against COVID-19 at least 2 weeks before infection versus unvaccinated people who had received an influenza vaccine. Among 10,024 vaccinated individuals, 9,479 were matched to 9,479 unvaccinated individuals; the unmatched unvaccinated group numbered 83,957. Outcomes were ICD-10 codes for documented COVID-19 sequelae in the 6 months after confirmed infection. Vaccinated individuals had lower risk of composite outcomes with death for respiratory failure (HR 0.70, 95% CI 0.63–0.78), intubation/ventilation (HR 0.72), hypoxaemia (HR 0.72), seizures (HR 0.73), ICU admission (HR 0.75), psychotic disorder (HR 0.75), hair loss (HR 0.75), hypercoagulopathy or venous thromboembolism (HR 0.81), and oxygen requirement (HR 0.83). There was no significant difference for any long-COVID feature (HR 1.01, 95% CI 0.96–1.05), Type 2 diabetes mellitus (HR 0.97, 95% CI 0.90–1.05), mood disorder (HR 1.05, 95% CI 0.96–1.15), or anxiety disorder (HR 1.06, 95% CI 0.97–1.15). Two vaccine doses were associated with lower risk of myalgia, myocarditis, cerebral haemorrhage, interstitial lung disease, urticaria, anosmia, myoneural junction/muscle disease, and death; one-dose HRs were generally closer to 1. For death or respiratory failure, HR was 0.48 (95% CI 0.39–0.60) in individuals <60 years-old and 0.85 (95% CI 0.76–0.96) in those ≥60 years-old; in those ≥60, none of the HRs were statistically significantly different from 1 after Bonferroni correction.

  89. Symptoms After COVID-19 Vaccination in Patients with Post-Acute Sequelae of SARS-CoV-2.2022 · compared with another group · 6,987 in the study · 2,094 started · 1,596 with outcome data
  90. The Effect of SARS-CoV-2 Vaccination on Post-Acute COVID-19 Syndrome (PACS): A Prospective Cohort Study2022 · compared with another group · 349 in the study · 316 with outcome data
    Summary

    Researchers in Amsterdam, the Netherlands, ran a prospective cohort study (RECoVERED) to test whether SARS-CoV-2 vaccination, given as a treatment, changes symptoms of post-acute COVID-19 syndrome (PACS). Of 349 participants enrolled, 316 had at least 3 months of follow-up. Among participants with PACS, 36 vaccinated cases were exact-matched to 32 unvaccinated controls on age, sex, obesity status and time since illness onset. Follow-up after the matched time-point was censored at 3 months. The study compared the mean total number of symptoms reported over 3 months and the odds of full recovery from PACS. It found no statistically significant difference in the mean total number of symptoms reported between unvaccinated and vaccinated participants during the 3 months following the matched time-point. The odds of recovery from PACS did not differ between vaccinated (6 recovery events) and unvaccinated participants (4 recovery events) (OR 1·57 [95%CI 0·46-5·84], p=0·596) in the follow-up period up to 3 months following the matched time-point. Harms were not reported. The authors state that vaccination was not randomly assigned and that residual confounding may remain, that fewer participants were available for matching, limiting statistical power, and that results may not be generalisable to other SARS-CoV-2 variants.

  91. Association of Vaccination with the Persistence of Post-COVID Symptoms.2022 · compared with another group · 453 in the study
    Summary

    This prospective cohort study asked whether COVID-19 vaccination was associated with change in post-acute sequelae of COVID (PASC) symptoms. Participants were 453 COVID-19 patients with PASC enrolled in an institutional Post-COVID-19 Registry at Mount Sinai Health System in New York City; 11 were excluded due to missing data regarding vaccination status. All were unvaccinated at baseline and completed a baseline and 6-month follow-up interview. The vaccinated group comprised 324 participants (72%) who had received at least one dose of the vaccine at least 2 weeks before the 6-month follow-up; the non-vaccinated group comprised 129 participants. The study compared baseline to 6-month change in anosmia, respiratory symptoms, depression, anxiety, PTSD, and quality-of-life domains. Unadjusted analyses did not show significant differences in these outcomes between vaccinated and unvaccinated patients; propensity-adjusted comparisons and secondary analyses based on number of doses also showed no significant differences. No harms or side-effect data were reported. The authors state that the study was observational and not randomized, and that it may not have sufficient power to identify small differences in some PASC symptoms.

  92. Real World Evidence of Effectiveness of COVID-19 Vaccines and Anti SARS-CoV-2 Monoclonal Antibodies Against Post-Acute Sequelae of SARS-CoV-2 Infection2022 · compared with another group · 55,192 in the study · 53,239 started · 53,239 with outcome data · preprint
    Summary

    This retrospective cohort study used the Houston Methodist COVID-19 Surveillance and Outcomes Registry (CURATOR) to examine COVID-19 vaccination and anti-SARS-CoV-2 monoclonal antibody (mAb) treatment against Post-Acute Sequelae of SARS-CoV-2 infection (PASC) in adults who survived beyond 28 days of index infection. The authors identified 55,192 adult PCR-positive patients; 1,953 (3.5%) were excluded for missing or unverifiable data, leaving 53,239 subjects. The cohort included 3,781 (7.1%) breakthrough COVID-19 cases and 4,635 (8.7%) mAb-treated patients. PASC was defined as new constitutional or systemic symptoms/conditions beyond the 28-day post-infection period, excluding pre-COVID symptoms or symptoms resolving within four weeks. In fully adjusted models, vaccinated breakthrough cases versus unvaccinated cases had a lower likelihood of PASC, aOR 0.58 (CI 0.52 - 0.66), and mAb-treated versus untreated patients had aOR 0.77 (CI 0.69 - 0.86). Overall, 5,929, 11.1% (CI 10.9 - 11.4), met PASC criteria. Vaccination was associated with decreased odds of all constitutional and systemic symptoms except changes in taste and smell; mAb was associated with decreased likelihood of persistent shortness of breath and new onset mood/anxiety disorders. In a replication dataset of 631,683 patients, 70,648, 11.2% (CI 11.1 - 11.3), had PASC; aORs were 0.25 (0.21 - 0.30) for vaccine and 0.62 (0.59 - 0.66) for mAb. Harms and withdrawals were not reported.

  93. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.2022 · compared with another group · 2,090 in the study
    Summary

    This European registry study asked whether SARS-CoV-2 vaccination protects patients with cancer from morbidity, mortality and sequelae of COVID-19. It included 2090 patients with solid or haematologic malignancy and COVID-19: 1930 were unvaccinated, 91 fully vaccinated, and 69 partially vaccinated. Full vaccination meant two doses of BNT162b2, mRNA-1273 or ChAdOx1-S, or a single Ad.26.COV2.S dose at least 28 days before infection. Outcomes included 14-day and 28-day case fatality, COVID-19 symptoms, need of COVID-19-oriented therapy, complications, hospitalization, oxygen therapy, and sequelae assessed after a median of 40 days (interquartile range 25–68). Compared with unvaccinated patients, fully vaccinated patients had lower unadjusted 14-day case fatality (5.5% vs 20.7%), 28-day case fatality (13.2% vs 27.4%), symptomatic COVID-19 (79.1% vs 88.5%), need of COVID-19-oriented therapy (34.9% vs 63.2%), complications (28.6% vs 39.4%), hospitalization (42.2% vs 52.5%), oxygen therapy (35.7% vs 52%), and sequelae (6.7% vs 17.2%). There was no difference in the distribution of individual types of sequelae. Adjusted IPTW analyses showed no statistically significant difference according to vaccination status. Harms, side effects, and withdrawals due to harms were not reported.

  94. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.2022 · compared with another group · 349 in the study · 316 with outcome data
    Summary

    This prospective cohort study (RECoVERED) asked whether SARS-CoV-2 vaccination changes symptoms of post-acute sequelae of COVID-19 (PASC). Adults with mild to critical COVID-19 were enrolled from illness onset in the Amsterdam municipal region; of 349 enrolled participants, 316 had at least 3 months of follow-up and 186 developed PASC. Among participants with PASC, 36 vaccinated cases were exact-matched 1:1 to unvaccinated follow-up periods from 32 unvaccinated controls. Vaccinated participants were invited to receive two doses of BNT162b2 mRNA (Pfizer/BioNTech) vaccine administered 28 days apart; unvaccinated participants remained unvaccinated for at least one month following the matched time-point. Over 3 months following the matched time-point, the monthly mean total number of symptoms did not differ significantly between groups. Odds of full recovery from PASC also did not differ (OR 1.57 [95%CI 0.46–5.84], p = 0.596; 6 recovery events with vaccination vs 4 without). Among all participants with PASC at first vaccination, the vast majority reported their PASC symptoms had not changed within a month after first vaccination. Harms were not reported.

  95. Evidence for positive long- and short-term effects of vaccinations against COVID-19 in wearable sensor metrics -- Insights from the German Corona Data Donation Project2022 · compared with another group · 8,134 with outcome data · preprint
    Summary

    This German study asked whether people vaccinated against COVID-19 before catching it had smaller and shorter changes in smartwatch and fitness-tracker data after infection. Users of the Robert Koch Institute's Corona Data Donation app shared resting heart rate, daily steps and sleep, plus their PCR test results and vaccination dates. Of 8,134 people analysed, 2,272 caught COVID-19 after at least two mRNA vaccine doses and 319 caught it unvaccinated; people with negative tests served as a reference. In the week of the test, resting heart rate rose by about 1.7 beats per minute in unvaccinated people and at most about 1.2 in vaccinated people; it returned to baseline after 11 weeks in unvaccinated people and after about 3–6 weeks in vaccinated people. Daily steps fell by about 3,000 and 2,000, and returned to baseline after 6–11 weeks versus 4 weeks. Sleep rose by about 37 versus 15 minutes a day. Large changes in heart rate, activity and sleep in the first weeks were more common in unvaccinated people. Symptoms and side effects were not recorded. The authors note that the groups were mostly infected with different virus variants, were not representative of Germany, and were not adjusted for other differences such as health conditions, and that changes in activity and sleep may partly reflect self-isolation.

  96. Protective Effects of BNT162b2 Vaccination on Aerobic Capacity Following Mild to Moderate SARS-CoV-2 Infection: A Cross-Sectional Study Israel.2022 · compared with another group · 50 in the study
    Summary

    This prospective cross-sectional study was conducted at the cardiac rehabilitation department of Ziv Medical Centre in Safed, Northern Israel, among people aged 18 to 65 years with laboratory-confirmed mild to moderate COVID-19 and no severe pre-existing cardiac or respiratory condition. Fifty participants were enrolled: 28 were unvaccinated at the time of infection and 22 had breakthrough infection, i.e., were vaccinated at the time of infection. All vaccinated patients had received at least two doses, with the exception of two patients. The study compared the unvaccinated group with the vaccinated group using a symptom-limited cardiopulmonary exercise test (CPET) at a mean of 119 ± 24 days after acute disease. Compared with unvaccinated individuals, vaccinated individuals had higher V’O2/kg at peak exercise and at the anaerobic threshold. The mean peak V’O2/kg was 83% of predicted in the unvaccinated group vs. 100% in the vaccinated group (p < 0.002). In the unvaccinated group, 14/28 subjects (50%) had a V’O2 peak <80% of predicted vs. 2/22 (9%) among the vaccinated group. VE at peak was 74.7 ± 19.5 in the unvaccinated group and 93 ± 18 in the vaccinated group (p < 0.001). There was no significant difference between the two groups in the OUES. Harms and withdrawals were not reported. The authors state limitations including the small cohort size and difference in age at baseline.

  97. EFFECT OF FULL VACCINATION AND POST-COVID OLFACTORY DYSFUNCTION IN RECOVERED COVID-19 PATIENT. A RETROSPECTIVE LONGITUDINAL STUDY WITH PROPENSITY MATCHING2022 · compared with another group · 442 in the study · preprint
    Summary

    This retrospective longitudinal cohort with propensity matching used an Indonesian online Post-COVID survey of recovered COVID-19 patients. A total of 442 participants were extracted from the cohort and equally allocated into two groups of 221: people infected more than 14 days after full vaccination and people infected <14 days after full vaccination or not fully vaccinated. Olfactory dysfunction was measured with the Self-Mini Olfactory Questionnaire two weeks and four weeks after being declared cured. The paper reports no associations between Zinc, Vitamin C, Vitamin D, or plasma convalescent and olfactory dysfunction within two weeks (p>0.05). For azithromycin given <24 hours after diagnosis, the paper reports an OR of 0.311 compared with not receiving therapy at all (95% CI 0.132 to 0.734; p=0.008) for olfactory dysfunction in two weeks. The authors state that after 14 days of full vaccination the protective effect could reduce the chance of post-COVID olfactory dysfunction, while a longer full vaccination-to-diagnosis duration increases the risk. Harms and withdrawals were not reported. The authors note limitations including retrospective self-assessment; they state that missing at random in outcome assessment was likely and that the study did not record interventions affecting olfactory function such as olfactory training and nasal irrigation.

  98. Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.2022 · compared with another group · 923 in the study
    Summary

    This longitudinal survey followed recovered COVID-19 patients from Indonesia who were diagnosed by PCR/antigen testing and had recovered less than 30 days after onset. A total of 923 participants’ data were extracted; 168 people were fully vaccinated more than 14 days after a second dose, 41 had received one dose, and 713 were unvaccinated at diagnosis. Participants reported post-COVID symptoms every 30 days for a total of 90 days after onset or diagnosis. The study compared fully vaccinated participants with those who had one dose or were unvaccinated, and compared timing of Favipiravir, vitamin C, vitamin D, and zinc with early initiation or no treatment. For any post-COVID symptoms in 90 days, there was no difference between fully vaccinated and incomplete or unvaccinated individuals after adjustment (aOR 0.74, 95% CI 0.51–1.08, p = 0.118). Complete vaccination was associated with lower odds of chronic cough (aOR 0.527, 95% CI 0.286–0.971, p = 0.040), chronic headache (aOR 0.317, 95% CI 0.163–0.616, p = 0.001), and chronic arthritis (aOR 0.285, 95% CI 0.116–0.703, p = 0.006). Not taking Favipiravir was associated with lower odds of arthritis than taking it within 24 hours (aOR 0.503, 95% CI 0.287–0.882, p = 0.017). Vitamin C later than 72 hours was associated with lower odds of the overall event than vitamin C within 24 hours (aOR 0.63, 95% CI 0.39–0.99, p = 0.048). The combination of micronutrient supplementations and Favipiravir gave no significant effect in seven outcomes. Harms were not reported for this cohort.

  99. Effect of COVID-19 vaccine on long-COVID: A 2-year follow-up observational study from hospitals in north India2022 · compared with another group · 6,676 in the study · 5,529 with outcome data · preprint
    Summary

    Researchers in India asked whether being vaccinated against COVID-19 before catching it changed the chance of long-lasting symptoms. They sampled 6676 people admitted to hospitals in Delhi with COVID-19 between 2020 and 2022 and phoned them in April 2022; 5529 were analysed: 913 who had both vaccine doses at least 14 days before admission and 4616 who were unvaccinated at admission. Any symptom after discharge was counted as long-COVID, and follow-up ranged from 2 months to 2 years. About 90% in both groups reported at least one symptom; 8.5% of vaccinated and 10.1% of unvaccinated people reported none, not a significant difference. After adjusting for age, sex, severity, stay and other illnesses, the odds of reporting symptoms were 1.27 times as high in the vaccinated group (not significant), and symptom-weeks did not differ. Some symptoms were reported more often by vaccinated people (eyesight problems, fever, weight loss, headache) and others less often (insomnia, cough, myalgia, anxiety). Covishield and Covaxin did not differ in long-COVID. The study did not collect vaccine side effects. The authors note that only hospitalised people were included, symptoms were self-reported, the groups had very different follow-up lengths, and one sentence gives a different odds ratio (0.78).

  100. Are vaccines safe in patients with Long COVID? A prospective observational study2021 · compared with another group · 66 in the study · preprint
    Summary

    Patients originally hospitalised with COVID-19 at a single UK hospital were prospectively followed. Of 66 patients with Long Covid following hospitalisation, 44 vaccinated participants were assessed at a median of 32 days (IQR 20-41) post vaccination and compared with 22 unvaccinated participants matched 2:1 on 8-month symptoms. Vaccinated participants had received at least one dose of Pfizer-BioNTech (BNT162b2) or Oxford-AstraZeneca (ChAdOx1 nCoV-19) between January and February 2021. Outcomes included SF-36 physical and mental composite scores, WEMWBS and ongoing symptoms. There was no significant worsening in quality-of-life or mental wellbeing metrics pre versus post vaccination. Between groups, 9/159 (5.6%) of symptoms worsened in vaccinated patients versus 13/91 (14.3%) in unvaccinated individuals, and improvements occurred in 37/159 (23.2%) versus 14/91 (15.4%) (p=0.035). PCS was median 41 (IQR 27-50) in vaccinated and median 34 (IQR 28-48) in unvaccinated participants (p=0.3); MCS was median 48 (IQR 37-54) versus 38 (IQR 29-48) (p=0.039), not significant after adjustment (p=0.6). WEMWBS was broadly similar in vaccinated participants; a linear model reported a coefficient of -7.6 (95%CI -12.2 ; -2.2, p=0.006) for vaccination, with no significant change in WEMWBS in vaccinated participants themselves. Nearly two-thirds (n=27) reported transient (<72hr duration) systemic effects including fever, myalgia and headache.

  101. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After2021 · compared with another group · 240,648 in the study · preprint
    Summary

    This retrospective analysis used the Arcadia Data Research dataset to identify factors influencing long-COVID in 240,648 COVID-19-infected persons. Patients were grouped by timing of first COVID-19 vaccine dose: prior to diagnosis (2,392), 0-4 weeks after diagnosis (3,560), 4-8 weeks after diagnosis (6,181), 8-12 weeks after diagnosis (8,055), or unvaccinated before 12 weeks (220,460). Long-COVID was classified as one or more COVID-associated symptoms between 12 and 20 weeks after the initial COVID-19 diagnosis. Logistic regression estimated Any Symptom and >1 Symptom; a general linear model estimated Symptom Count. Compared with the unvaccinated group, Any Symptom odds ratios were 0.220 for vaccination prior to diagnosis, 0.382 for 0-4 weeks, 0.535 for 4-8 weeks, and 0.747 for 8-12 weeks. For >1 Symptom, odds ratios were 0.113 prior to diagnosis, 0.189 for 0-4 weeks, and 0.317 for 4-8 weeks. The Symptom Count model reported a vaccination coefficient of -0.85137. The authors state no deleterious effects were detected in vaccinated patients in this study; withdrawals for harms were not reported. No difference, worsening, or stopping was reported. They describe limitations including opportunistic data availability and possible geographic, temporal, contractual, and socioeconomic gaps; vaccination data from payer reports or EHRs without dedicated surveillance sources; and no distinction among the three U.S. vaccines.

  102. Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic.2025 · no comparison group · 123 in the study
    Summary

    This retrospective study asked whether COVID-19 vaccination relates to the course of long COVID in pediatric patients evaluated at a long COVID clinic at Children's Hospital Los Angeles. It included 123 children who reported persistent or new symptoms ≥4 weeks after SARS-CoV-2 infection. The text reports that 26 patients received the COVID-19 vaccine after the onset of long COVID symptoms; vaccine dose, route, schedule and treatment duration were not reported. At subsequent follow-up visits, 7 (41%) of these 26 reported subjective improvement, 10 (59%) reported no change, and 9 had no documentation regarding symptom progression. At initial clinic presentation, COVID-19 vaccination status was not associated with long COVID symptom duration (p = 0.4). The study had no control group for comparative analysis. Symptom counts were summarized at onset, 6-, 12-, 18-, and 18+ months, and harms were not reported. The authors state the study was a single-center, predominantly self-referred retrospective review; they note the absence of a control group, lack of validated questionnaires, and that symptom improvement after vaccination relied on retrospective chart documentation from only 26 children, with possible recall and reporting bias.

  103. How do people with long COVID utilize COVID-19 vaccination and rehabilitation services and what are their experiences with these services? results of a qualitative study with 48 participants from Germany.2024 · no comparison group · 48 in the study
    Summary

    This qualitative study explored how people with long COVID in Germany used and experienced COVID-19 vaccination and outpatient or inpatient rehabilitation. Forty-eight adults with long COVID participated: 25 in one-on-one interviews and 23 in four focus groups. Participants were recruited through university hospital websites, social media, and respondents’ networks. No treatment duration and no comparison group were reported; the study analysed interview and focus-group accounts. Thirty-five participants reported receiving a COVID-19 vaccination, and 16 reported using rehabilitation. Nine participants stated they developed long COVID despite vaccination before COVID-19. Ten participants reported vaccination reactions, and two reported severe side effects. Three participants experienced symptoms comparable to the acute phase of COVID-19; two reported externally visible symptoms; two reported very poor health and heart problems; one reported extrasystoles; and one interviewee was hospitalized with myocarditis. Two participants reported persistent deterioration of their long COVID symptoms after vaccination. Among rehabilitation users, four reported rehabilitation helped to improve their health situation and alleviate long COVID complaints, while four experienced rehabilitation as unhelpful or counterproductive. Two persons found the combination of inpatient rehabilitation and rehabilitation sport helpful, and two participants reported inpatient psychosomatic rehabilitation in which long COVID was not considered. The authors note heterogeneous experiences and high willingness to be vaccinated and to participate in rehabilitation.

  104. Post-COVID-19 Vaccination and Long COVID: Insights from Patient-Reported Data.2024 · no comparison group
    Summary

    This retrospective cohort study used patient-reported data from two independent groups with Long COVID (PASC): 128 patients seen at the Stanford PASC Clinic and 484 respondents to a multinational survey. It examined COVID-19 vaccinations received after PASC onset and asked whether PASC symptoms improved, showed no change, or worsened. In the clinic cohort, 77 patients reported no change, 22 reported improvement, and 29 reported worsening. In the survey cohort, 293 reported no effect, 93 reported improvement, and 98 reported worsening. The clinic cohort recorded acute adverse events after vaccination in 58 of 128 patients; acute vaccine adverse events were reported in 4 of 22 whose PASC symptoms improved, 29 of 77 with no change, and 25 of 29 whose symptoms worsened. In the survey, a significant difference was observed across symptom outcomes when comparing booster vaccination groups (p < 0.001); no significant difference was found by vaccination brand (p = 0.121). The authors state limitations including retrospective design and recall bias.

  105. Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID.2024 · no comparison group · 16 in the study · 14 with outcome data
    Summary

    This prospective, unblinded, observational pre-post study assessed changes in symptoms and immune responses after COVID-19 vaccination in vaccine-naïve people with Long COVID. Sixteen individuals completed the baseline survey and received a first dose of any approved COVID-19 vaccine; 14 completed all four surveys. Participants were recruited through social media advertisements and patient support groups and traveled to New Haven, Connecticut for biospecimen collection. Surveys were administered before vaccination and at 2, 6, and 12 weeks after the first dose; nine of 13 participants recommended a second dose reported receiving it. There was no comparison group. Outcomes included self-reported overall health, symptom number, physical and social effect scores, and immune assays. At 2 weeks, 6 out of 14 reported better health, 3 same, 1 worse, and 4 not sure; at 6 weeks, 11 out of 14 better, 2 same, 1 worse; at 12 weeks, 10 out of 16 better, 3 same, and 3 worse. Median symptom number was 23 before vaccination and 19.5, 17.5, and 15.5 at 2, 6, and 12 weeks. Median physical effect score was 68.5 before and 46.5, 36.5, and 38.5; social score was 36.5 before and 27.5, 23, and 19. Anti-S1 and anti-RBD IgG increased significantly at 6 and 12 weeks, while non-spike TCR classifier scores did not differ significantly. One participant was hospitalized for chest pain three days after the first dose and again after the second. Withdrawals were not reported, and harms as a reason for withdrawal were not reported. The abstract reports 1 had worse health and 2 marginal changes at 12 weeks; the Results report 3 (19%) worse at 12 weeks.

  106. Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections2022 · no comparison group · 20 in the study · preprint
    Summary

    This observational study enrolled 20 participants in Dhaka, Bangladesh, who had long COVID after breakthrough infections following two doses of ChAdOx1-nCoV-19. All 20 received a third dose of BNT162b2. The study had no comparison group. Serum CRP and quantitative anti S1-RBD IgG were measured before and 14 days after the third dose. A Wilcoxon matched paired signed rank test showed a significant (P value <0.05) reduction in CRP after the third dose. Pre- and post-third-dose anti S1-RBD IgG showed a significant boosting effect. Harms were not reported in the text. The authors state that the short sample size cannot produce generalizability and call for larger clinical studies.

  107. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID.2022 · no comparison group · 42 in the study
    Summary

    This single-centre study enrolled 42 patients with Long COVID who visited an outpatient department specializing in Long COVID and requested vaccination. The median age was 45 years, and 17 (40.5%) were men. Patients received a single vaccination (first dose). Symptoms and antibody titers were assessed before and 14–21 days after the first vaccination. Postvaccination symptoms were relieved in 7 (16.7%), worsened in 9 (21.4%), and unchanged in 26 (61.9%) patients. The authors report that the worsened group had a significantly higher antibody titer ratio than the nonworsened group. There were 12 (29%) patients who did not receive the second vaccination. The authors state that patients refused the second vaccination because of worsening Long COVID symptoms, concerns about strong side effects, and satisfaction with the antibody titers after the first vaccination. The study had no comparison group; the authors note that antibody titers after the first and second vaccinations were not compared because of the small number of patients who underwent the second vaccination. The authors state limitations: a single-centre study with a small sample size, and changes in sequelae symptoms could not be evaluated. They also note possible outpatient treatment for symptoms and that self-assessment may not accurately reflect the relationship of the vaccine with sequelae status.

  108. Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study.2021 · no comparison group · 620 in the study · 567 with outcome data
    Summary

    VAXILONG was an online survey of French-speaking adults with post-acute sequelae of COVID-19 (PASC) recruited through social media and patient associations. Of 620 respondents, 567 met inclusion criteria and were analysed. A total of 396 patients had received at least one SARS-CoV-2 vaccine injection; 380 reported persistent symptoms at vaccination. There was no control group. Among the 380, 201 (52.8%) reported an impact on symptoms after injection: 117 (31% of vaccinated PASC patients) reported global worsening and 83 (21.8%) global improvement. Worsening was mostly fever/chills (74%), gastro-intestinal symptoms (70%), paresthesia (64%) and arthralgia (63%); improvement was mainly anosmia (62%) and brain fog (51%). The impact did not differ by vaccine used (p = 0.60). Improvement was similar in virologically confirmed vs non-virologically confirmed patients (20.2% (48/238) vs 24.3% (34/140), p = 0.35), while worsening was more frequent in non-virologically confirmed patients (41.4% (58/140) vs 24.8% (59/238), p < 0.001). The impact lasted more than 2 weeks in 72.6% of patients reporting improvement and 63.7% reporting worsening. After a complete scheme, 93.3% (28/30) of initially seronegative patients reported positive anti-SARS-CoV-2 IgG. Withdrawals for harms were not reported.

  109. Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.2025 · case report · 13 in the study
    Summary

    This patient-led case series documented the impact of extended-course oral nirmatrelvir/ritonavir in 13 individuals with established Long COVID. Participants came from public forums led by and for people with Long COVID or heard about the project by word-of-mouth. They took courses >5 days (range: 7.5–30 days): 11 outside the context of an acute infection (Cases 1–11) and 2 within an acute reinfection (Cases 12–13). There was no comparison group; participants reported symptoms and health experiences before, during, and after treatment. Some outside-acute participants experienced a meaningful reduction in symptoms, although not all benefits persist; others experienced no effect. The discussion states only 5 of the 13 cases experienced sustained improvement. Individual reports included no change, temporary improvement, return to pre-treatment baseline, and recurrence after stopping. One participant stopped early due to intense stomach pain. Reported harms included severe constipation and a severe MCAS flare, a severe “crash,” insomnia and taste-related side effects, dysgeusia, severe stomach pain with discontinuation, itchiness and tingling, dizziness and shakiness, and a PEM crash. For the two participants treated during acute reinfection, both report eventually returning to their pre-re-infection baseline. The authors list limitations: only 13 individuals who may or may not be representative; patient-reported experiences subject to recall or fatigue bias; and substantial heterogeneity in ages, symptoms, and treatment lengths.

  110. Corona With Lyme: A Long COVID Case Study.2023 · case report · 1 in the study
    Summary

    This case report describes a previously healthy 26-year-old female medical student living in New York, NY, who developed long COVID after a presumed acute SARS-CoV-2 infection in March 2020, with a concurrent perceived early-disseminated Lyme disease infection. The three-year arc covers numerous trial-and-error treatments: a two-week regimen of doxycycline 100 mg twice a day, metformin escalation alongside diet modifications, graded compression stockings, breathing exercises, increases in caffeine and salt consumption with increased fluid intake, a horizontal cardio exercise program with rest periods, osteopathic manipulative treatment, cognitive behavioral therapy, sleep hygiene improvements, supplements (vitamin C, vitamin D, vitamin B12, B-complex, n-acetyl cysteine, turmeric extract), a two-dose Moderna mRNA COVID-19 vaccination course, and abortive headache therapies (Excedrin or Fioricet and prochlorperazine). The authors report a moderate reduction in cycle length and morning hypoglycemic symptoms with metformin, a moderate reduction in myalgias, headaches and scalp allodynia with osteopathic manipulative treatment, some relief of post-COVID headache, help with headache pain, orthostatic palpitations, fatigue and brain fog from abortive therapies plus caffeine, salt and fluid intake, moderate improvements in fatigue and brain fog in the first 24 hours after the first vaccine dose, moderate symptom alleviation from digital interventions, and small but recognizable differences in fatigue and cognition from sleep hygiene. No improvement in symptoms other than mild reduction in right shoulder pain followed the doxycycline regimen. Supplements provided no discernable benefit. The patient reports full recovery from long COVID with residual blurred vision and oligomenorrhea. Reported harms include worsening blurred vision, palpitations, heat intolerance and near-syncopal events; a moderate increase in fatigue and brain fog with a CGRP antagonist; fatigue exacerbation with traditional exercise rehabilitation; symptom re-exacerbations with compression stockings; and increased headache frequency and duration with n-acetyl cysteine. The abstract describes near-total remission.

  111. Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2.2023 · case report · 1 in the study
    Summary

    This case report described one 25-year-old female with delayed and prolonged post-COVID parosmia and dysgeusia; the authors presented their treatment experience. There was no comparison group. Treatments included prednisone 0.5 mg/kg for 8 days, nasal irrigation with saline solution three times a day for 10 days plus Mupirocin for 10 days, Gabapentin 300 mg orally every 8 hours for 1 month, Escitalopram 5 mg daily, multivitamins, and olfactory rehabilitation. A transfusion of 50 million mesenchymal stem cells of endometrial origin showed no evidence of improvement even 8 weeks after it. The first COVID-19 vaccine dose was followed by an improvement of 25% of the parosmia and dysgeusia in the 7 days after application. After the second dose, an olfactory test found 40%, compared with 2 of 16 odors (12%) identified earlier. The report described mild improvement with prednisone, gabapentin, nasal irrigations and olfactory rehabilitation, greater after the second vaccine dose; improvement in depression but minimal improvement in parosmia and dysgeusia. Harms and withdrawals were not reported. Follow-up was 12 months after suffering the condition, when parosmia and dysgeusia still persisted.

  112. The Protective Effect of Coronavirus Disease 2019 (COVID-19) Vaccination on Postacute Sequelae of COVID-19: A Multicenter Study From a Large National Health Research Network.2022 · case report · 1 in the study · 50 with outcome data
    Summary

    This retrospective study used the TriNetX Research Network, US electronic medical records, to examine adult patients aged ≥18 years with SARS-CoV-2 infection confirmed by polymerase chain reaction who sought care from 21 September 2020 to 14 December 2021. At baseline, 1 578 719 patients with confirmed COVID-19 were identified, and 1.6% (n = 25 225) had documented COVID-19 vaccination. The analysis compared a Vaccine + COVID-19 group (n = 25 225) with a No-Vaccine + COVID-19 group; after 1:1 propensity matching, each matched group had 25 225 patients. The paper defined PASC as new, continuing, or recurrent symptoms occurring 4 or more weeks after the initial SARS-CoV-2 infection. Outcomes included new-onset or persistent symptoms, new-onset diagnoses, and death, assessed at 28 days and 90 days following COVID-19 diagnosis. At 28 days, the vaccine cohort had lower risk than the no-vaccine cohort for each outcome; for mortality, the relative risk was 0.33 (95% CI, .28–.39). At 90 days, the relative risk for mortality was 0.21 (95% CI, .16–.27); relative risks for hypertension, diabetes, heart disease, fatigue, and other listed outcomes were also below 1.0. The paper reports differences in both 28- and 90-day risk between cohorts for each outcome and reports P < .05. Harms and withdrawals were not reported. The authors state limitations including EHR data limitations and that causation cannot be inferred.

  113. Long COVID-associated Brain Fog and Therapeutic Intervention Using Repetitive Transcranial Magnetic Stimulation(rTMS)2022 · case report · 1 in the study
    Summary

    This is a single case report (症例提示) of one patient with long COVID-associated brain fog seen at the author's post-COVID outpatient clinic in Japan. The patient was given high-frequency rTMS at 10 Hz, 1,200 pulses to each target site (bilateral occipital lobes and the right dlPFC), at an intensity of 90% of the minimum motor threshold required for upper-limb motor area stimulation, once weekly for 10 consecutive sessions. There was no comparison group and no randomisation. Brain fog improved markedly immediately after the first rTMS session. At the end of the 10th session, memory-related failures slightly remained while visuospatial failures were absent; the patient could read without difficulty and join conversations without stagnation, the planned demotion was withdrawn and he returned to full work. At follow-up 1 month after the end of rTMS there was no re-exacerbation of symptoms; fatigue was not entirely absent but recovered with one night's sleep, and clock drawing was correct. No adverse events occurred during the rTMS period. The authors state that many questions remain about the specific method — frequency, stimulation intensity, number of sessions and especially the stimulation site — and that their method is not considered optimal.

  114. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies.2022 · case report · 4 in the study
    Summary

    This case series reports 4 sequential volunteers from the UCSF LIINC study (NCT04362150) with Long COVID symptoms and a history of nirmatrelvir/ritonavir use. Oral nirmatrelvir/ritonavir was given as a 5-day course at various stages after infection; there was no comparison group. In Case 1, treatment began within 24 hours of symptom onset and the participant experienced rapid improvement in systemic symptoms. Approximately 4 days following completion of the 5-day course, he experienced rebound symptoms with recurrence of fever, fatigue, rhinorrhea, cough, chest pain, rash, and trouble concentrating (“brain fog”). Approximately 3 weeks following the positive test, he experienced worsening of fatigue, chest soreness, palpitations, brain fog, and post-exertional malaise, which persisted beyond 30 days after symptom onset. In Case 2, he continued to experience improvement in his symptoms during the course; as of 2 weeks later they had not resolved entirely and he reported gradually approaching baseline health. In Case 3, she experienced improvement in fatigue symptoms one day following completion of therapy, with residual shortness of breath and myalgias but re-engagement with usual activities. In Case 4, she reported relief from chronic Long COVID symptoms within two days of initiating therapy, with substantial improvement in myalgia, diarrhea, and chest pain. Withdrawals were not reported, and the text does not report whether any were linked to harms. The authors state the case series was limited by a lack of intensive physiologic and laboratory measurements throughout the disease course.

  115. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series.2021 · case report · 36 in the study
    Summary

    This case series described changes in symptoms and quality of life after COVID-19 vaccination in people with persistent symptoms after acute infection. The 36 participants were identified from 163 patients admitted to a single U.K. hospital with COVID-19 and had persistent symptoms 8 months after admission. They received one dose of Pfizer-BioNTech (n = 18) or Oxford-AstraZeneca (n = 18) vaccine. Participants were reassessed approximately 1 month after vaccination, at a median of 30 days (IQR, 26 to 36 days). Symptoms, SF-36 quality-of-life metrics, and WEMWBS mental well-being were assessed before and after vaccination. Among 159 symptoms reported before vaccination, 37 (23.2%) improved, 9 (5.6%) worsened, and 113 (71.1%) were unchanged. There was no significant worsening in SF-36 quality-of-life metrics before versus after vaccination (t test P > 0.1 for all comparisons). WEMWBS mental well-being was stable (median, 49 [IQR, 42 to 54] vs. 50 [IQR, 40 to 59]). A total of 26 of 36 (72%) reported transient (<72 hours' duration) systemic effects, including fever (44%), myalgia (22%), and headache (19%). No difference in any outcome measure was identified between the Pfizer-BioNTech (n = 18) and Oxford-AstraZeneca (n = 18) vaccines (t test P > 0.1 for all comparisons). Withdrawals were not reported, and reasons for withdrawal were not reported. The authors state limitations including the small sample size, inability to blind participants, and inability to suitably match vaccinated and unvaccinated persons; data were available only after the first vaccine dose.

  116. Understanding the role of COVID-19 vaccination in all-cause healthcare resource utilisation among adults with long COVID in the UK primary care setting: data from the 2022-2023 respiratory virus season.2025 · how it is prescribed, safety only · 8,507 in the study
    Summary

    This population-based retrospective cohort study used UK primary care electronic healthcare record data from The Health Improvement Network (THIN). Adults aged ≥18 years with confirmed or suspected COVID-19 during the 2022–2023 respiratory virus season who were eligible for seasonal COVID-19 vaccination were included; the All COVID-19 Patients cohort was n = 8,507. Exposure was COVID-19 vaccination status, defined as time since vaccination (14–90 days, 91–180 days, >180 days) or seasonal vaccination versus no seasonal vaccination. Outcomes were long COVID incidence, healthcare resource utilisation (primary care consultations, outpatient specialist referrals, hospital admissions) and primary care consultation costs, with follow-up to one year. In the adjusted and weighted models, the paper reports no significant associations between long COVID incidence rate and vaccination status across the cohorts. In the High Risk Cohort, outpatient specialist referrals were lower in the 3–6 months subgroup than the >6 months subgroup (weighted and adjusted IRR: 0.28; 95% CI: 0.10–0.79; p < 0.05); in the All COVID-19 Patients Cohort the corresponding estimate was 0.46 (95% CI: 0.27–0.79; p ≤ 0.01). In the All COVID-19 Patients Cohort, primary care consultation costs were lower with seasonal vaccination than without (weighted and adjusted IRR: 0.86; 95% CI: 0.78–0.95; p ≤ 0.01). Side effects and withdrawals were not reported. The authors note that the dataset captured primary care data only; they were unable to determine whether a patient had been hospitalized for their COVID-19 during their episode.

  117. The impact of COVID vaccination on incidence of long COVID and healthcare resource utilisation in a primary care cohort in England, 2021-2022.2025 · how it is prescribed, safety only · 111,235 in the study
    Summary

    This population-based retrospective cohort study used primary care electronic health record data from England (CPRD Aurum) to examine long COVID after COVID-19 diagnosis. It included 111,235 adults with COVID-19: 75,522 unvaccinated patients and 35,713 who had completed primary series vaccination (two doses for immunocompetent and three doses for immunocompromised patients, with doses separated by at least 21 days). Vaccination status was assessed at diagnosis; follow-up was up to a maximum of 9-months post index. The study measured incident long COVID and, among patients with long COVID, primary care consultation rates and costs. After weighting and adjustment, long COVID incidence was lower in the primary series group than the unvaccinated group: adjusted IRR 0.81 (95% CI 0.77–0.86) overall, 0.83 (0.78–0.88) in the immunocompetent cohort, and 0.28 (0.13–0.58) in the immunocompromised cohort. The crude IRR was 1.10 (1.06–1.14). Among high-risk patients, adjusted IRR was 0.82 (0.70–0.95) overall and 0.82 (0.70–0.96) in the immunocompetent cohort. Primary care consultation rate showed no significant association overall/immunocompetent (adjusted IRR 1.02, 0.97–1.06). Costs showed no significant association; mean costs were £55.6 (SD 59.7) in unvaccinated and £43.1 (SD 45.5) in primary series patients. In a sensitivity analysis restricted to visits with a long COVID clinical code, consultation rates were greater in the primary series group: IRR 1.15 (1.11–1.21) overall and 1.16 (1.11–1.21) immunocompetent. Harms and withdrawals were not reported. The authors state limitations including short follow-up and a small immunocompromised sample.

  118. The impact of COVID-19 vaccination on long COVID prevention in the Omicron era: An updated systematic review and meta-analysis2026 · systematic review · preprint
    Summary

    This updated systematic review and meta-analysis examined whether COVID-19 vaccination prevents long COVID (LC) in the Omicron era. Databases (Embase, MEDLINE, PubMed, Europe PMC, LILACS, Cochrane COVID-19 Study Register) were searched for studies published between 1 March 2024 and 13 July 2026. Nineteen new studies were identified, of which ten were included in the updated meta-analyses alongside eight studies from the original review. Vaccinated adults (any dose) were compared with unvaccinated adults, booster vaccination with unvaccinated people, and booster vaccination with primary course vaccination only. The pooled OR of LC in vaccinated adults (any dose) versus unvaccinated was 0.75 (95% confidence interval [CI] 0.67–0.84; 13 studies); for booster vaccination versus unvaccinated 0.73 (95% CI 0.65–0.82; 6 studies); and for booster vaccination versus primary course vaccination 0.63 (95% CI 0.53–0.75; 6 studies). Between-study heterogeneity was considerable (I2=87.3%) in the vaccinated-versus-unvaccinated analysis. Certainty of evidence was very low for all meta-analyses. Harms were not reported. The authors state that limitations include observational designs, variable LC definitions and vaccination status classifications, residual confounding, and collider bias.

  119. Effectiveness of COVID-19 vaccines against post-COVID-19 condition/long COVID: systematic review and meta-analysis.2025 · systematic review
    Summary

    This systematic review and meta-analysis asked whether COVID-19 vaccination given before SARS-CoV-2 infection prevents post-COVID-19 condition (PCC) or long COVID (LC). The search ran to 01 August 2024 and included 89 nonrandomized studies of interventions; no RCTs fulfilled the inclusion criteria. The studies included >5.7 million participants, and most included adults from the general population. Vaccination was compared with no vaccination. The primary outcome was PCC, defined as symptoms 3 months or later after infection; LC was a secondary outcome. For PCC, vaccine effectiveness with at least one dose versus no vaccination was 41.0% (95% CI 27.8%; 51.7%; 22 NRSI; CoE low). By dose, VE was 19.1% for one dose, 43.2% for two doses, and 70.0% for three doses in one study; 3 versus 2 doses was 12.7%. VE was 26% in children/adolescents, 41% in persons over 75 years, 32.1% after pre-Omicron infection, 20.9% after Omicron infection, and 72% in immunocompromised persons after three doses. For LC, VE with at least one dose versus no vaccination was 34.1% (42 NRSI; CoE low). Sensitivity analyses gave 37.7% for PCC and 35.8% for LC. Side effects, worsening, and stopping were not reported. The authors state limitations including a small chance the search missed relevant studies and subjectivity in risk-of-bias assessment.

  120. Protective effects of booster dose of SARS-COV-2 vaccination against post-acute COVID-19 syndrome: A systematic review.2025 · systematic review
    Summary

    This umbrella review asked whether COVID-19 vaccination lowers long-COVID (post-acute COVID-19 syndrome) risk. It included five meta-analyses of observational studies identified in PubMed, Scopus, and Web of Science. Vaccination (any platform, primary series or booster) was compared with no vaccination or different dose schedules. Outcomes were long-COVID incidence/prevalence and symptom duration/severity. In adults, vaccination was associated with lower risk. Gao et al. (15 observational studies; 945k participants) reported a 29% relative risk reduction (RR = 0.71, 95% CI 0.58-0.87). Marra et al. reported VE = 29.2% (DOR = 0.708, 95% CI 0.692-0.725) and, in fully vaccinated cohorts (24 studies; 620,221 participants), VE ~ 32.0% (DOR = 0.680, 95% CI 0.523-0.885). Peine et al. (>2 million participants) estimated VE = 41.0% (95% CI 27.8-51.7) against post-COVID-19 condition at 23 months and VE = 34.1% (95% CI 25.0-42.2) against long COVID at 24 weeks. One dose was not significant (VE 19.1%), two doses were 43.2%, and three doses 70.0%; first-booster VE was ~68.7% (DOR = 0.313, 95% CI 0.278-0.353). The pediatric meta-analysis (5 studies; 20,325 children/adolescents) found no significant protective effect (pooled DOR = 1.07, 95% CI 0.77-1.49), and a two-dose before-infection analysis was also not significant (DOR = 0.82, 95% CI 0.63-1.08). One dose in Gao was not protective (RR = 0.83, 95% CI 0.65-1.07). Side effects and withdrawals were not reported. Authors state limits: observational data with confounding/bias, varied long-COVID definitions, moderate primary-study overlap, and sparse pediatric evidence.

  121. Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review.2025 · systematic review
    Summary

    This systematic literature review asked whether COVID-19 vaccination affects post-COVID-19 condition (PCC). It summarizes evidence across 56 publications and pre-prints published or posted between January 1, 2020 and July 18, 2023, and included 97 studies; findings are summarized from 56 studies reporting adjusted estimates. Searches used the OVID platform across EMBASE, MEDLINE® and Evidence-Based Medicine reviews, supplemented with WHO COVID library and Google Scholar® searches. The review examined vaccination before infection, after infection, after PCC-onset, and mixed or unspecified timing, compared with unvaccinated groups where reported, and measured ≥1 PCC. The authors report consistent evidence suggesting that pre-infection COVID-19 vaccination reduces the risk of ≥1 PCC; they state evidence was limited for vaccination at other timepoints relative to infection or PCC-onset, and report a trend that mRNA vaccines offer greater protection. Named study findings include: Strain and colleagues reported greater symptom improvement with mRNA vs non-mRNA vaccines given after PCC-onset; Tran and colleagues reported vaccinated-after-infection people were less likely to report an unacceptable symptom state, more likely to achieve full remission, and had less severe long COVID; Nehme and colleagues reported higher PCC symptom prevalence among those who received ≥1 dose before infection vs unvaccinated; Taquet and colleagues reported significant differences in risk of some specific PCC as composite endpoints with death for 1 dose vs unvaccinated and 2 doses vs unvaccinated. No harms or withdrawals were recorded.

  122. Long COVID: A Systematic Review of Preventive Strategies.2025 · systematic review
    Summary

    This systematic review asked whether treatments can prevent long COVID, defined as symptoms lasting three or more months after SARS-CoV-2 infection. The authors searched PubMed/MEDLINE for articles published between December 2019 and September 2024 and included 28 studies: fifteen on COVID-19 vaccination, seven on antivirals, and six on other treatments. Findings are reported study by study rather than pooled. For vaccination, ten out of fifteen studies demonstrated a protective effect against long COVID; Ayoubkhani et al. reported odds decreased by 12.8% after a first dose and by an additional 8.8% after a second dose compared with unvaccinated individuals, while Antonelli et al. found a booster did not reduce risk when long COVID was defined as symptoms lasting 12 weeks or longer. For antivirals, a randomized trial of remdesivir found no significant differences between treated and untreated groups, whereas Boglione et al. reported a 36% reduction in odds with remdesivir and Wang et al. reported nirmatrelvir/ritonavir reduced odds by 65%. Convalescent plasma showed no statistically significant reduction; metformin showed a 42% reduction in long COVID incidence; multiple micronutrient supplements for 2 weeks showed no differences. Luo et al. reported vaccination after infection increased risk of reporting long COVID symptoms, which may be due to side effects. No stopping data were recorded. The authors state that COVID-19 vaccines likely reduce the risk of developing long COVID, while evidence for antivirals and other drugs is still in its infancy.

  123. The effect of pre-COVID and post-COVID vaccination on long COVID: A systematic review and meta-analysis.2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether COVID vaccination before or after infection is linked to long COVID, defined as symptoms persisting 3 months since infection. It included 25 observational studies with a total sample of 14,128,260 people infected by COVID; no randomised controlled trials were included. Data came from 13 databases searched up to 18 February 2024, including peer reviewed and preprint studies. Vaccinated groups were compared with people who remained unvaccinated throughout the study; the follow-up length was not reported. The review measured long COVID and 10 individual symptoms. One-dose pre-COVID vaccination did not have an effect on long COVID (10 studies; summary OR 1.01, 95% CI 0.88–1.15, p=0.896). Two-dose pre-COVID vaccination (15 studies) gave a summary OR of 0.76 (95% CI 0.65–0.89, p=0.001) and was associated with 4 symptoms out of 10 analysed: fatigue, headache, loss of smell, muscle pain. Three-dose pre-COVID vaccination (3 studies) was statistically insignificant, OR 0.31 (95% CI 0.05–1.84, p=0.198). One-dose post-COVID vaccination (5 studies) gave OR 0.85 (95% CI 0.73–0.98, p=0.024). Two-dose post-COVID vaccination (3 studies) was statistically insignificant, OR 0.63 (95% CI 0.38–1.03, p=0.066). No side effects were recorded, and people who worsened or stopped were not reported. The authors state high heterogeneity between each study as a limitation.

  124. Impact of Pre-Infection COVID-19 Vaccination on the Incidence and Severity of Post-COVID Syndrome: A Systematic Review and Meta-Analysis.2024 · systematic review
    Summary

    This systematic review and meta-analysis asked whether COVID-19 vaccination before SARS-CoV-2 infection is associated with the incidence and severity of post-COVID-19 syndrome. The authors searched PubMed, Embase, and Scopus in October 2023 and included 13 articles. The review compared findings from included studies of vaccinated and unvaccinated people with breakthrough infection; the review itself reports no comparison group. Vaccination was COVID-19 vaccination before infection, with vaccine types and doses varying across studies. Outcomes included post-COVID-19 syndrome, ICU admissions, mortality, long COVID symptoms, activity-limiting symptoms, hospitalization, mechanical ventilation, and frailty. The pooled odds ratio was 0.77 (95% CI 0.75–0.79), which the authors describe as a 23% reduction in the risk of developing post-COVID-19 syndrome. In included studies, Al-Aly et al. reported ICU admissions at 2.4% and a post-COVID-19 syndrome risk OR of 0.82 (0.80–0.85); Ayoubkhani et al. reported long COVID symptoms in 9.5% of double-vaccinated versus 14.6% of unvaccinated people and an adjusted OR of 0.59 (95% CI 0.48–0.73) for activity-limiting symptoms. Antonelli et al. reported an increased risk of frailty in older adults post-first dose (OR 1.93, 95% CI 1.50–2.48). The review does not report discontinuations. The authors state that the definitive impact of vaccines in preventing or treating long COVID remains unclear; they describe variability in study methodologies and definitions of post-COVID-19 syndrome.

  125. The effectiveness of the COVID-19 vaccines in the prevention of post-COVID conditions in children and adolescents: a systematic literature review and meta-analysis.2024 · systematic review
    Summary

    This systematic literature review and meta-analysis asked whether COVID-19 vaccination prevents post-COVID conditions (long COVID) in children and adolescents. Eight studies with 23,995 individuals evaluated vaccination and post-COVID conditions; 5 observational studies comprising 20,325 children and adolescents were included in the meta-analysis. Vaccinated groups received at least 1 dose of COVID-19 vaccine, or 2 doses in some analyses, and were compared with unvaccinated individuals. The included studies were conducted in the United Kingdom, Thailand, Israel, Italy, Norway, and the United States. The prevalence of children who did not receive COVID-19 vaccines ranged from 65% to 97%. The pooled prevalence of post-COVID conditions was 21.3% among unvaccinated individuals and 20.3% among those vaccinated at least once. The pooled DOR for post-COVID conditions among individuals vaccinated with at least 1 dose was 1.07 (95% CI, 0.77–1.49); for those vaccinated with 2 doses it was 0.82 (95% CI, 0.63–1.08). The authors report that vaccination did not appear protective. Side-effect counts were not reported in the recorded data. The authors state that conclusions were limited by the lack of randomized trials and selection bias inherent in observational studies.

  126. Effect of covid-19 vaccination on long covid: systematic review.2023 · systematic review
    Summary

    This systematic review asked whether covid-19 vaccination, given before or after SARS-CoV-2 infection or after a diagnosis of long covid, affects long covid. Searches covered 1 January 2020 to 3 August 2022; no randomised controlled trials were found. The review included 16 observational studies from five countries (USA, UK, France, Italy, and the Netherlands) reporting on 614 392 patients. Vaccines were compared with no vaccination, an active non-covid-19 vaccine control, or placebo. Outcomes were long covid diagnosis and individual symptoms. The review did not report a single treatment duration; included studies assessed outcomes at different follow-up times. The authors report that current studies suggest covid-19 vaccines might have protective and therapeutic effects on long covid, and that vaccination after infection was reassuringly consistent in being protective. For harms, three of the five studies of vaccination after infection showed significant reductions in patients with long covid, but none showed any harm of vaccination. Worsening and stopping were not reported. The authors state that all 16 studies were non-randomised, most had moderate to critical risk of bias, and evidence certainty was low.

  127. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis searched PubMed and EMBASE on September 16, 2022 and included 12 studies involving 629,093 patients. Six observational studies compared people vaccinated before SARS-CoV-2 infection with unvaccinated people: 536,291 unvaccinated and 84,603 vaccinated patients. Two-dose COVID-19 vaccination was associated with a lower frequency of long COVID than no vaccination (OR, 0.64; 95 % CI, 0.45–0.92) and than one-dose vaccination (OR, 0.60; 95 % CI, 0.43–0.83). One-dose vaccination compared with no vaccination was not significantly associated with a lower frequency of long COVID (OR, 0.90; 95 % CI, 0.80–1.01). Two-dose vaccination compared with no vaccination was associated with a lower incidence of persistent fatigue (OR, 0.62; 95 % CI, 0.41–0.93) and pulmonary disorder (OR, 0.50; 95 % CI, 0.47–0.52); trends for other disorders were not statistically significant. Six observational studies involving 8,199 long COVID patients examined vaccination after infection: 20.3 % reported symptomatic improvement, 20.5 % symptomatic worsening, and 54.4 % no symptomatic change. One study showed more than half of symptomatic worsening after vaccination resolved within 3–7 days. The authors state limitations including observational designs, non-universal long COVID definitions, and one-group meta-analyses.

  128. A systematic review of the evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition.2023 · systematic review
    Summary

    This systematic review asked whether COVID-19 vaccination before or after COVID-19 is associated with the risk of post COVID-19 condition (PCC), and whether vaccination is associated with symptom changes or reported adverse events in people who already have PCC. The search was updated on 13 December 2022 and included 31 observational studies; most were conducted in Europe (n = 18) or North America (n = 7), and two had a multi-national sampling frame. For vaccination before COVID-19, two doses were associated with lower odds of developing PCC (pOR 0.67, 95% CI 0.60–0.74, I2 = 59.9%, five studies), while one dose may not reduce the odds (pOR 0.64, 95% CI 0.31 – 1.31, four studies). Evidence for three doses was very uncertain (pOR 0.45, 95% CI 0.10–1.99). One study reported that one dose after COVID-19 was associated with lower odds of PCC when given earlier post-infection (aOR 0–4 weeks 0.38, 95% CI 0.35–0.41; 4–8 weeks 0.54, 0.51–0.57; 8–12 weeks 0.75, 0.71–0.78). Among people with PCC, studies reported symptom changes and adverse events: one large cohort reported adverse events in 5.7% (n = 26/455), and a survey of 67 healthcare workers reported immediate, but self-limiting side effects in 72% (n = 48). One study found no significant difference in the number or type of side effects following one dose (BNT162b2) among those with PCC compared to controls. The authors state the topic is rapidly evolving and findings may change with emerging evidence.

  129. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis.2023 · systematic review
    Summary

    This systematic review and meta-analysis examined SARS-CoV-2 vaccination for prevention and treatment of long COVID. The search covered PubMed/MEDLINE, PsycInfo, EMBASE, Web of Science, and Scopus from database inception to January 27, 2022. The review included 17 studies and meta-analyzed 6; component study sample sizes included n = 36 and n = 240 648. Vaccination was compared with no vaccination, fewer doses, or an unvaccinated reference group across studies; outcomes were long COVID symptoms or post-acute sequelae after infection and changes in pre-existing long COVID after vaccination. No single overall treatment duration was reported. In prevention studies, Al-Aly et al. (n = 64 571) reported a lower risk of post-acute sequelae and burden (-30.60; 95% CI −42.25, −18.49) with breakthrough COVID-19 compared with no prior vaccination. Ayoubkhani et al. (n = 6 180) reported aOR 0.589, 95% CI 0.501–0.691 for self-reported long COVID. Taquet et al. (n = 18 958) reported HR 1.01, 95% CI 0.96–1.05, p = 0.83. For pre-existing long COVID, Gaber et al. (n = 67) reported 45/67 with no changes, 14/67 improvement, and 8/67 worsening; Strain et al. (n = 812) reported 470/812 improvement, 145/812 deterioration, and 197/812 no change. The North Bristol NHS Trust case series (n = 36) reported 37/159 symptoms improved, 9/159 worsened, and 113/159 unchanged. Limitations included not considering prevention of infection, heterogeneity precluding quantitative summary of post-vaccination data, cross-sectional designs limiting temporality, natural improvement over time, and no data on booster doses.

  130. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.2022 · systematic review
    Summary

    This systematic review asked whether COVID-19 vaccination affects the risk of long-COVID or existing long-COVID symptoms. The authors searched MEDLINE, CINAHL, PubMed, EMBASE, Web of Science, medRxiv and bioRxiv up to June 20, 2022 and included 11 peer-reviewed studies and six preprints. Studies compared vaccinated with unvaccinated people or followed long-COVID patients before and after vaccination; vaccines included BNT162b2, mRNA 1273, Ad26.COV2.S and ChAdOx1 nCoV-19. For vaccination before infection, the review reports reduced risks or odds of long-COVID. Examples include Simon et al. (n = 2392) any symptom OR 0.22 (0.196–0.245) and >1 symptom OR 0.113 (0.09–0.143); Antonelli et al. (n = 9462) symptoms lasting ≥28 days D2: 0.51(0.006); Ayoubkhani et al. (n = 6180) long-COVID of any severity aOR 0.59 (0.50 to 0.69); and Al-Aly et al. (n = 13,369,073) post-acute sequelae HR = 0.85 (0.82, 0.89). For people with existing long-COVID, findings were mixed: Arnold et al. (n = 66) reported improvement in 37/159 vaccinated versus 14/91 unvaccinated (p value = 0.035) and worsening in 9/159 versus 13/91; Gaber et al. (n = 67) reported improvement in 14/67 (21%) and worsening in 8/67 (12%); Scherlinger et al. (n = 567) reported improvement in 83 (21.8%) and worsening in 117 (31%).

  131. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: A systematic literature review and meta-analysis.2022 · systematic review
    Summary

    This systematic literature review and meta-analysis asked whether COVID-19 vaccination prevents post–COVID-19 conditions (long COVID). The authors searched PubMed, CINAHL, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science. They included 10 studies with 1,600,830 individuals; 6 studies with 251,123 individuals entered the meta-analysis. Vaccinated people received at least 1 dose of Pfizer/BioNTech, Moderna, AstraZeneca, or Janssen vaccine and were compared with unvaccinated people. The review did not report a single treatment duration. The main measure was pooled diagnostic odds ratio for post–COVID-19 conditions, with an estimated value derived from it. The pooled DOR was 0.708 (95% CI, 0.692–0.725), and the estimated value was 29.2% (95% CI, 27.5%–30.8%). It was 35.3% (95% CI, 32.3%–38.1%) when vaccination was before COVID-19 and 27.4% (95% CI, 25.4%–29.3%) when after. Pooled prevalence was 39.1% in unvaccinated and 37.6% in vaccinated people. Included studies were mixed: some reported benefit, others no association. For harms, only 1 included study reported possible adverse events after vaccination. Worsening of post–COVID-19 symptoms was 22.7% vs 15.8%; P = .209 between vaccinated and unvaccinated individuals, reported as no significant difference. The authors state limitations including observational designs subject to biases, inability to analyse adverse events further, few studies, and varying definitions.

  132. Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis.2022 · systematic review
    Summary

    This systematic review and meta-analysis asked whether COVID-19 vaccines reduce long COVID after SARS-CoV-2 infection/COVID-19. The authors searched PubMed, Embase, Web of Science and ScienceDirect from inception to 19 September 2022 and included 18 eligible studies for quantitative synthesis. The included studies were observational and compared vaccinated and unvaccinated people diagnosed with COVID-19; the recorded data do not report total participant numbers, follow-up duration, or setting by country. Vaccination was with COVID-19 vaccines, with analyses by two doses versus one dose and by vaccination before or after SARS-CoV-2 infection/COVID-19. Outcomes were occurrence of long COVID and various long COVID symptoms. The authors conclude that COVID-19 vaccines were found to have an effect on reducing the risk of long COVID; the protective effect was found in participants vaccinated with two doses, but not one dose, and regardless of whether vaccination was before or after SARS-CoV-2 infection/COVID. For symptoms, vaccination reduced the risk of cognitive dysfunction/symptoms, kidney diseases/problems, myalgia, and sleeping disorders/problems sleeping. Side effects and withdrawals were not reported in the recorded data. The authors state high heterogeneity, different long COVID definitions, insufficient symptom data, few pooled studies, and limited data on inactivated vaccines as limitations.

  133. Impact of COVID-19 vaccination on long COVID: a systematic review and meta-analysis2022 · systematic review · preprint
    Summary

    This systematic review asked whether COVID-19 vaccination before or after SARS-CoV-2 infection, or after long COVID diagnosis, affects long COVID. The authors searched from 1 January 2020 to 16 Feb 2022 and included six observational studies from three countries (USA, UK, France) covering 442,601 patients; no randomised trials were found. Vaccines studied included Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson, given as one or two doses before infection, after infection, or after long COVID diagnosis. Outcomes were long COVID cases and individual symptoms such as fatigue, cough, loss of smell, shortness of breath, loss of taste, headache, muscle ache, trouble sleeping, difficulty concentrating, worry or anxiety, and memory loss or confusion. The extracted study-level findings were not reported in the recorded data, and high heterogeneity precluded a meaningful meta-analysis. The authors state that current studies suggest vaccination may have protective and therapeutic effects on long COVID, but the evidence is of low certainty. They call for more robust comparative observational studies and trials.

  134. Prior COVID-19 vaccination and cognitive outcomes after SARS-CoV-2 infection: a mini-review.2026 · review
    Summary

    This mini-review asked whether COVID-19 vaccination before SARS-CoV-2 infection is associated with cognitive outcomes after infection. Five studies met inclusion criteria; cognition was assessed with objective measures and vaccinated individuals were compared with unvaccinated individuals at the time of infection. Across the included studies, samples were 1,638 participants with PASC and neuropsychiatric symptoms (Alaa Elmazny et al.), 93 participants with cognitive impairment and 117 with preserved cognition (Bonner-Jackson et al.), 112,964 participants (Hampshire et al.), 200 hospitalized and 1,100 non-hospitalized participants (Mukherjee et al.), and 91 participants infected with the Delta variant (Zhang et al.). Most comparisons found no statistically significant difference. Alaa Elmazny et al. reported no significant difference in severity of cognitive dysfunction on a visual analog scale (median 4 [IQR: 1–4] vs. 3 [IQR: 3–4], p=0.698). Bonner-Jackson et al. found no significant differences (p=0.74; p=0.72). Hampshire et al. found one dose did not differ from no vaccination (standardized difference=0.08 standard deviations), more than one dose showed a small cognitive advantage (standardized difference=0.15 standard deviations), and Pfizer versus AstraZeneca was non-significant (standardized difference=–0.07 standard deviations). Mukherjee et al. found no significant differences in processing speed, attention, executive functions, or working memory in hospitalized or non-hospitalized groups. Zhang et al. reported 5.6% of vaccinated versus 26.5% of unvaccinated participants scored below 25 on the MMSE; the difference was reduced after adjustment for age (p=0.013) and lost significance after adjustment for sex, age, and education (p=0.076). No side effects were recorded.

  135. Pediatric post-acute sequelae of SARS-CoV-2 infection in Taiwan: Insights from the DISCOVER cohort.2026 · review
    Summary

    This review summarizes the DISCOVER cohort in Taiwan, which was set up to study pediatric post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. Within the cohort, the authors describe a double-blind randomized controlled trial in 33 children with PASC. Children received either oral vitamin D 2000 IU/day or placebo for six months. The main outcome recorded here was overall symptom burden measured with CSSI-24. The review reports that vitamin D supplementation led to a significant reduction in overall CSSI-24 symptom burden compared with placebo. It also reports that improvements were observed across several neuropsychiatric, respiratory, and cardiovascular symptoms, whereas no symptom reached statistical significance in the placebo group. The text provided did not report side effects, withdrawals, or worsening. The authors describe the trial findings as preliminary and early randomized evidence that vitamin D supplementation may improve certain post-acute symptoms in children. They conclude that vitamin D supplementation has emerged as a promising therapeutic candidate that may help reduce symptom burden and systemic inflammation, particularly in genetically susceptible children, but state that larger studies are required to confirm these findings.

  136. Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment.2026 · review
    Summary

    This REVIEW ARTICLE summarizes current understanding of Long COVID, including epidemiology, pathophysiology, organ-specific manifestations, and potential therapeutic approaches. It enrolled no patients and gave no treatment: there was no comparison group, no randomisation, no crossover, no follow-up, and no trial registration. The review reports no results of its own. It discusses cited studies separately: an RCT evaluating a 15-day course of Nirmatrelvir/Ritonavir did not demonstrate clear efficacy for established Long COVID; a randomized trial of plasmapheresis failed to demonstrate significant efficacy; an RCT reported greater improvements in Long COVID symptoms with a synbiotic formulation than with placebo; a non-randomized, open-label study involving 60 patients reported FMT recipients had significant improvements in insomnia and reductions in cortisol levels at 12 weeks; open-label studies reported aspirin, clopidogrel, and apixaban may reduce microclot burden and improve fatigue and dyspnea; a retrospective cohort study found pre-existing oral anticoagulant use did not prevent Long COVID and was associated with a higher risk of post-acute sequelae. The authors state no specific therapeutic agents have been approved; rehabilitation efficacy remains largely based on expert opinion, as RCT evidence is still limited; and few pharmacological treatments have been evaluated in randomized controlled trials.

  137. Effect of Complete COVID-19 Vaccination on Long COVID among the Nepalese Population2025 · review
    Summary

    This narrative literature review examined whether complete COVID-19 vaccination (two or more doses) is associated with long COVID in Nepal. It integrated Nepalese national datasets, tertiary hospital reports, WHO publications, and peer-reviewed international studies. No primary cohort size or follow-up was reported. The review described findings from named studies: Ayoubkhani et al. (2022) reported that individuals with two vaccine doses were 41% less likely to report long COVID symptoms. Yang et al. (2025) reported long COVID symptom incidence of 7% to 9% among vaccinated individuals compared with 12% to 18% in unvaccinated or partially vaccinated patients. Fatima et al. (2023) reported average symptom duration of 4–6 weeks among vaccinated patients compared with 8–12 weeks in unvaccinated counterparts. Al-Aly et al. (2022) reported a reduced risk of organ damage and persistent symptoms among vaccinated individuals. The review did not report harms. The authors concluded that available data suggest complete COVID-19 vaccination significantly reduces the risk and severity of long COVID among Nepalese individuals. They stated limitations including inadequate long-term follow-up systems, underreporting and lack of awareness, diagnostic limitations in rural areas, and variations in vaccine efficacy by type and timing of doses.

  138. Cardiovascular damage and comorbidities related to long COVID: pathomechanisms, prevention, and therapy.2025 · review
    Summary

    This is a review, not a primary trial; it reports no enrolled patients or comparison group of its own and summarizes cited studies in long COVID with cardiovascular involvement. Kucharska, Sumbalova (29) reported that ubiquinol supplementation 2 × 100 mg daily with mountain spa rehabilitation alleviated clinical, including CV symptoms, and improved antioxidant protection; Hansen, Mogensen (218) observed only a slight trend toward CoQ10 having potentially beneficial effects. A randomized controlled trial (151 adult patients, duration of 24 weeks) reported that vitamin D3 (2,000 IU/day) plus K2 reduced the number of LC symptoms, inflammatory markers, and OS. A single-blind randomized, placebo-controlled study reported that vitamin C plus L-arginine improved endothelial function, fatigue, muscle strength, and walking performance. A double-blind, placebo-controlled randomized trial reported beneficial effects of an oral food supplement (2 cps/day, for two months) on inflammatory state, fatigue, and quality of life. Metformin initiated within 7 days of SARS-CoV-2 infection reduced the risk of LC by 41%; nirmatrelvir-ritonavir during acute infection decreased the incidence of LC. Vaccination was followed by relief in 16.7%, worsening in 21.4%, and unchanged symptoms in 61.9%. Harms included that many nutrients and natural substances in exceedingly high doses can be dangerous, that vaccination rarely may cause myocarditis or pericarditis, especially in young males, and ACEI/ARB adverse effects. The authors state that incomplete understanding of LC pathomechanisms has hampered targeted therapies.

  139. Interventions for Long COVID: A Narrative Review.2025 · review
    Summary

    This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).

  140. Immunization as Protection Against Long COVID in the Americas: A Scoping Review.2025 · review
    Summary

    This scoping review asked whether SARS-CoV-2 immunization protects against long COVID in the Americas. The authors included studies of vaccinated adults with long COVID from Central and South America and the Caribbean, with Mexico also considered; the review reports eight included articles and states it had no primary participants. Vaccination was described in different ways across the included studies, including immunization with two or more doses, multiple booster doses, complete vaccination status, and vaccination generally. Comparisons also varied, including vaccinated versus less-vaccinated or unvaccinated groups and different dose numbers. Outcomes concerned the risk, persistence, severity, and duration of long COVID or post-COVID conditions. Fuller et al. recruited a cohort of 276 adults and reported that immunization with two or more doses reduced the persistence of symptoms and that multiple booster doses were associated with a significantly reduced risk of developing PCCs. Marra et al. reported that vaccinated cases were less likely to develop PCCs than those infected before immunization. Batista et al. reported that complete vaccination status decreases the risk of long COVID. Del Carpio-Orantes et al. identified 138 adults and did not identify a significant decrease in vaccinated participants’ neurologic, cardiac, pulmonary, gastrointestinal, and musculoskeletal symptoms. Berry et al. reported an increase in the severity of heart palpitations following immunization, without counts. The authors state limitations of small sample sizes, varied methodologies, inconsistent definitions, absent data on specific populations, and restricted observational designs.

  141. Effects of Prior Vaccination on the Reduction of Cognitive Deficits Associated with COVID-19 Infection: A Mini-Review2025 · review
    Summary

    This mini-review asked whether prior COVID-19 vaccination is associated with cognitive deficits after infection. Searches in PubMed/MEDLINE and Scopus on January 25, 2025 identified records, and five studies met inclusion criteria. The included studies enrolled adults with COVID-19 or post-COVID condition/PASC: 1,638 participants; 210 participants with PASC plus 369 controls; 112,964 participants; 200 hospitalized and 1,100 non-hospitalized participants; and 91 participants. The comparison was vaccinated versus unvaccinated at the time of infection, not a fixed treatment course. Cognition was measured with objective tests, including MoCA, neuropsychological tests, Cognitron, NIH Toolbox, and MMSE. Alaa Elmazny et al. found no statistically significant difference in cognitive dysfunction severity (median 4 [IQR: 1–4] vs. 3 [IQR: 3–4], p=0.698). Bonner-Jackson et al. found no statistically significant differences (p=0.74; p=0.72). Hampshire et al. reported one dose did not differ (standardized difference=0.08 standard deviations), more than one dose showed a small cognitive advantage (standardized difference=0.15 standard deviations), and Pfizer versus AstraZeneca was non-significant (standardized difference=–0.07 standard deviations). Mukherjee et al. found no significant differences in hospitalized or non-hospitalized groups across four domains. Zhang et al. reported 5.6% versus 26.5% scoring below 25; the difference was reduced after age adjustment (p=0.013) and lost significance after sex, age, and education adjustment (p=0.076). Side effects, worsening, and stopping were not reported. The authors state the evidence remains limited and inconclusive.

  142. The knowns and unknowns of long COVID-19: from mechanisms to therapeutical approaches.2024 · review
    Summary

    This review describes predictors, symptoms and therapeutic approaches for long COVID-19 (L-C19); it reports no enrolled participants, no comparison group, and no randomised design. It summarises named studies rather than presenting its own cohort. In Strain et al., 812 L-C19 vaccinated participants had average symptom improvement scores of 22.6% after Astra Zeneca/Oxford vaccine, 24.4% after Pfizer/BioNTech vaccine, and 31% after Moderna vaccine. Notarte et al.’s meta-analysis reported that two doses of vaccine were more effective than a single dose for reducing L-C19 risk, and Ayoubkhani et al. reported that L-C19 symptoms decreased after a second vaccine dose regardless of vaccine type or timing. For probiotics and short-chain fatty acids, the review reports restored gut microbiota and decreased GI disorders, improved mental health, maintained blood-brain barrier, downregulated microglial activation and reduced inflammation. L-Arginine 1.66 g with 500 mg liposomal vitamin C for 28 days improved endothelial function, walking performance, reduced fatigue and normalized pulmonary arterial hypertension. Vitamins and minerals were reported to have a preventive effect on autoimmunity, alveolar damage, endothelial dysfunction, infection fervency reduction, gut microbiota balance and coagulation. Harms noted include increased fatigue in Wright et al. and the possibility of symptom worsening with graded exercise. The authors conclude that immunized patients showed overall improvement in L-C19 symptoms irrespective of vaccine type or doses; they also state antidepressants have no effect, graded-exercise-related therapies showed inconsistent results, and valacyclovir, valganciclovir and famciclovir may help prevent neurological manifestations.

  143. Gaps in Long COVID treatments research: A scoping review2024 · review
    Summary

    This scoping review set out to find gaps in research on long COVID treatments, so that future research could be prioritised. The authors searched four databases (MEDLINE, Embase, the Cochrane trial register and Epistemonikos) and grey literature up to April 2023. Two reviewers screened the articles and extracted data, which were analysed by theme. Of 3675 records found, 26 studies were included. Most of the studies were done in high-income countries and only two in upper-middle-income countries. None reported including children or pregnant women, and few reported the ethnicity of their participants. The treatments studied were grouped as nutritional supplements, conventional medicines, hyperbaric medicine, COVID vaccination, and complementary and alternative medicine. The text available here is the abstract followed by a reference list: it does not say which of the listed papers were the included studies or what any of them found, so no result for any treatment is recorded from it. The review reports no side effects.

  144. Long COVID-19 syndrome: An overview2023 · review
    Summary

    This narrative review discusses possible pathophysiology, risk factors, and treatments for Long COVID-19 syndrome, with particular reference to the cardiovascular system. It reports no enrollment, setting, or follow-up for a study of its own. For prevention, it summarizes a cohort study of over 180 000 patients with COVID-19 infection and at least one risk factor for progression to severe COVID-19 illness: treatment with nirmatrelvir during the acute phase resulted in a 26% reduced risk for development of Long COVID-19 syndrome. It also states that studies with ensitrelvir and molnupiravir showed a reduction of risk, without a number. A sub-analysis of one randomized controlled study reported outpatient metformin reduced the incidence of Long COVID-19 syndrome with an absolute risk reduction of 4.1% compared to placebo, a result the authors say needs confirmation. For vaccination, research by the Office for National Statistics in the United Kingdom including one million individuals showed a 41% reduction of Long COVID-19 symptoms, with no statistical difference in incidence between adenovirus vector (Oxford/AstraZeneca) and mRNA (Pfizer/BioNTech or Moderna) vaccines. Another community-based cohort study including over 6700 patients showed a reduction of risk by 13% after one dose and an additional 9% after two vaccine doses. No harms, worsening, or discontinuations are recorded. The authors state evidence-based specific pharmacological treatments are lacking.

  145. Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review.2022 · review
    Summary

    This narrative review discusses evidence on SARS-CoV-2 vaccination and long COVID-19; no single enrolled or analysed count is reported. It discusses studies from Israel, the US, and the UK in long COVID-19/post-COVID-19 condition, including 951 infected and 2437 uninfected individuals, 16,091 adults, 2560 patients with mild COVID-19, over 97,000 vaccinated individuals, and 6030 participants. COVID-19 vaccination (two or three doses, primary and booster doses, BNT162b2, ChAdOx1 nCoV-19/AZD1222, mRNA-1273) was compared with unvaccinated status or fewer doses; duration is not reported. Outcomes included long COVID-19 symptoms, persistent symptoms, post-acute sequelae, and symptom improvement/worsening. Two vaccine doses were associated with being less likely than unvaccinated to mention symptoms by 64%, 54%, 57%, and 68%, respectively. Complete but not partial vaccination was associated with diminished risk for long COVID-19 (OR: 0.72; 95% CI: 0.60–0.86). A prospective cohort of 2560 patients reported symptoms in 16% with three doses, 17.4% with two, 30% with one, and 42.8% in unvaccinated individuals. Persistent symptoms were 4.5% after Omicron versus 10.8% after Delta in over 97,000 vaccinated individuals. Fully vaccinated participants were about half as likely as unvaccinated to have symptoms lasting ≥28 days (OR: 0.51, 95% CI: 0.32–0.82) in 6030 participants. Kuodi et al. reported 2 or 3 doses were 54% to 83% less likely than unvaccinated to report seven of ten symptoms. In one study of 163 patients, only 5% reported worsening one month after vaccination. Listed harms include a small risk of myocarditis associated with mRNA vaccines, a very rare syndrome of thrombosis with thrombocytopenia, and Guillain-Barre Syndrome (GBS).

  146. Are there clinically significant interactions between COVID-19 vaccination and post-COVID-19 condition (long COVID)?2022 · review
  147. COVID-19 Vaccine and Long COVID: A Scoping Review.2022 · review
    Summary

    This scoping review asked how COVID-19 vaccination affects long COVID and compared vaccine types. It searched Ovid Medline, Embase, medRxiv and NIH COVID-19 portfolios for articles published between 1 January 2020 to 20 April 2022 and included 16 studies. The included vaccine studies involved people with long COVID; examples enrolled 28,356 participants followed for an 8-month period and 910 participants followed for 120 days. Vaccination was compared with no vaccination or with vaccination before versus after infection; follow-up in some studies was one month. Outcomes included long COVID symptomatology, symptom severity, remission, hospitalization and symptoms lasting ≥ 28 days. Findings were mixed. Ayoubkhani et al. reported improvement after first and second doses (OR = 0.87 and OR = 0.91); Tran et al. reported lower severity (mean difference in COVID ST score = −1.8) and more remission (HR = 1.97); Arnold et al. reported symptomatic improvement (23.2% vs. 15.4%, p = 0.035). Wisnivesky et al. and Peghin et al. found no significant association (p > 0.05), and Taquet et al. found no association (HR = 1). Worsening symptoms were reported in Strain et al. (19%), Scherlinger et al. (31%), and Gaber et al. (8 (12%)). No side-effect counts or stopping/dose changes were recorded. The authors state the evidence strength is limited.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime